Trans B
- I
3 I
( I
10 I
) I
- I
caren I
- I
4 I
- I
ol I
( O
22 O
. O
3 O
% O
) O
, O
artemisia B
ketone I
( O
18 O
. O
6 O
% O
) O
, O
1 B
, I
8 I
- I
cineole I
( O
14 O
. O
9 O
% O
) O
, O
delta B
- I
selinene I
( O
13 O
. O
0 O
% O
) O
and O
alpha B
- I
pinene I
( O
8 O
. O
2 O
% O
) O
were O
the O
major O
compounds O
. O

In O
particular O
, O
we O
have O
isolated O
and O
identified O
harpagide B
, O
7 B
- I
beta I
- I
hydroxy I
- I
harpagide I
, O
ajugol B
, O
5 B
- I
allosyloxy I
- I
aucubin I
, O
verbascoside B
and O
, O
for O
the O
first O
time O
in O
this O
genus O
, O
arbutin B
. O

Therefore O
, O
electrophysiological O
responses O
and O
changes O
in O
levels O
of O
intracellular O
Ca B
( I
2 I
+ I
) I
in O
mouse O
cholinergic O
LDT O
neurons O
following O
application O
of O
specific O
mGluR O
agonists O
and O
antagonists O
were O
examined O
. O

Concurrent O
Ca B
( I
2 I
+ I
) I
imaging O
revealed O
that O
while O
CHPG B
actions O
did O
include O
release O
of O
Ca B
( I
2 I
+ I
) I
from O
CPA B
/ O
thapsigargin B
- O
sensitive O
intracellular O
stores O
, O
actions O
of O
LY O
did O
not O
. O

Concurrent O
Ca B
( I
2 I
+ I
) I
imaging O
revealed O
that O
while O
CHPG B
actions O
did O
include O
release O
of O
Ca B
( I
2 I
+ I
) I
from O
CPA B
/ O
thapsigargin B
- O
sensitive O
intracellular O
stores O
, O
actions O
of O
LY O
did O
not O
. O

The O
large O
- O
conductance O
, O
Ca B
( I
2 I
+ I
) I
- O
dependent O
potassium B
( O
BK O
) O
channel O
blocker O
, O
iberiotoxin O
, O
attenuated O
CHPG B
actions O
. O

Monoterpene B
( O
25 O
. O
2 O
- O
84 O
. O
9 O
% O
) O
and O
sesquiterpene B
hydrocarbons I
( O
12 O
. O
2 O
- O
46 O
. O
8 O
% O
) O
were O
the O
principal O
subclasses O
of O
compounds O
, O
with O
alpha B
- I
pinene I
( O
15 O
- O
65 O
. O
4 O
% O
) O
, O
germacrene B
D I
( O
5 O
. O
9 O
- O
30 O
. O
5 O
% O
) O
, O
delta B
- I
3 I
- I
carene I
( O
2 O
- O
16 O
. O
6 O
% O
) O
and O
gamma B
- I
cadinene I
( O
1 O
. O
3 O
- O
9 O
. O
8 O
% O
) O
as O
the O
main O
constituents O
. O

These O
oils O
were O
differentiated O
by O
the O
content O
of O
the O
major O
constituents O
( O
alpha B
- I
pinene I
, O
germacrene B
D I
, O
delta B
- I
3 I
- I
carene I
and O
gamma B
- I
cadinene I
) O
, O
geographical O
location O
and O
climatic O
characteristics O
. O

A O
new O
pentacyclic B
triterpenoid I
and O
three O
new O
derivatives O
based O
on O
the O
taraxer B
- I
14 I
- I
ene I
skeleton O
with O
a O
C O
- O
28 O
attached O
a O
carboxylic B
acid I
group O
have O
been O
isolated O
from O
the O
stem O
bark O
of O
Hypodaphnis O
zenkeri O
, O
together O
with O
six O
known O
compounds O
. O

A O
new O
xanthone B
, O
calothorexanthone B
, O
together O
with O
five O
known O
compounds O
, O
garbogiol B
, O
1 B
, I
4 I
, I
8 I
- I
trihydroxyxanthone I
, O
delta B
- I
tocotrienol I
, O
1 B
, I
7 I
- I
dihydroxyxanthone I
and O
globuxanthone B
, O
was O
isolated O
from O
a O
petroleum O
ether O
extract O
of O
the O
bark O
of O
Calophyllum O
thorelii O
. O

To O
further O
improve O
dissolution O
characteristics O
, O
the O
physical O
mixtures O
of O
ITR B
and O
ITRDNT B
with O
two O
cyclodextrins O
, O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
and O
HP B
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
were O
prepared O
and O
their O
molar O
ratios O
were O
optimized O
. O

To O
further O
improve O
dissolution O
characteristics O
, O
the O
physical O
mixtures O
of O
ITR B
and O
ITRDNT B
with O
two O
cyclodextrins O
, O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
and O
HP B
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
were O
prepared O
and O
their O
molar O
ratios O
were O
optimized O
. O

It O
was O
observed O
that O
about O
75 O
% O
of O
drug O
was O
released O
in O
30 O
min O
from O
1 O
: O
3 O
molar O
ratio O
of O
ITRDNT B
and O
HP B
- I
beta I
- I
CD I
physical O
mixture O
, O
which O
was O
distinctly O
higher O
than O
ITR B
commercial O
capsules O
( O
70 O
% O
) O
. O

The O
K B
( I
+ I
) I
- O
evoked O
[ B
( I
3 I
) I
H I
] I
GABA I
release O
was O
inhibited O
by O
the O
mGlu7 O
allosteric O
agonist O
N B
, I
N I
' I
- I
dibenzyhydryl I
- I
ethane I
- I
1 I
, I
2 I
- I
diamine I
dihydrochloride I
( O
AMN082 B
, O
0 O
. O
001 O
- O
10 O
mu O
M O
) O
, O
as O
well O
as O
by O
the O
group O
III O
mGlu O
receptor O
agonist O
l B
- I
( I
+ I
) I
- I
2 I
- I
amino I
- I
4 I
- I
phosphonobutyric I
acid I
[ O
( B
l I
) I
- I
AP4 I
, O
0 O
. O
01 O
- O
1 O
mM O
] O
. O

AMN082 B
and O
( B
l I
) I
- I
AP4 I
- O
induced O
effects O
were O
recovered O
by O
the O
mGlu7 O
negative O
allosteric O
modulator O
( O
NAM O
) O
6 B
- I
( I
4 I
- I
methoxyphenyl I
) I
- I
5 I
- I
methyl I
- I
3 I
- I
( I
4 I
- I
pyridinyl I
) I
- I
isoxazolo I
[ I
4 I
, I
5 I
- I
c I
] I
pyridin I
- I
4 I
( I
5H I
) I
- I
one I
hydrochloride I
( O
MMPIP B
) O
. O

AMN082 B
and O
the O
adenylyl O
cyclase O
( O
AC O
) O
inhibitor O
MDL B
- I
12 I
, I
330A I
reduced O
[ B
( I
3 I
) I
H I
] I
GABA I
exocytosis O
in O
a O
8 B
- I
Br I
- I
cAMP I
- O
sensitive O
. O

AMN082 B
and O
the O
adenylyl O
cyclase O
( O
AC O
) O
inhibitor O
MDL B
- I
12 I
, I
330A I
reduced O
[ B
( I
3 I
) I
H I
] I
GABA I
exocytosis O
in O
a O
8 B
- I
Br I
- I
cAMP I
- O
sensitive O
. O

The O
interplay O
between O
cardiac O
sarcoplasmic O
Ca B
( I
2 I
+ I
) I
ATPase O
and O
phospholamban O
is O
a O
key O
regulating O
factor O
of O
contraction O
and O
relaxation O
in O
the O
cardiac O
muscle O
. O

In O
heart O
failure O
, O
aberrations O
in O
the O
inhibition O
of O
sarcoplasmic O
Ca B
( I
2 I
+ I
) I
ATPase O
by O
phospholamban O
are O
associated O
with O
anomalies O
in O
cardiac O
functions O
. O

The O
aim O
of O
our O
research O
was O
to O
find O
molecules O
able O
to O
interfere O
with O
the O
inhibitory O
activity O
of O
phospholamban O
on O
sarcoplasmic O
Ca B
( I
2 I
+ I
) I
ATPase O
. O

Its O
functional O
activity O
was O
tested O
in O
Ca B
( I
2 I
+ I
) I
uptake O
assays O
utilizing O
preparations O
from O
cardiac O
sarcoplasmic O
reticulum O
. O

Sm O
. O
: O
alpha B
- I
pinene I
, O
p B
- I
cymene I
, O
1 B
, I
8 I
- I
cineole I
, O
and O
limonene B
. O

In O
a O
comparison O
of O
the O
components O
of O
the O
mixed O
inhalation O
, O
the O
ratio O
of O
alpha B
- I
pinene I
increased O
to O
about O
three O
times O
that O
of O
1 B
, I
8 I
- I
cineole I
. O

Thioxodipeptides B
Gly B
- I
thio I
- I
Lys I
( O
GtK B
) O
, O
Ala B
- I
thio I
- I
Lys I
( O
AtK B
) O
, O
and O
Ala B
- I
thio I
- I
Arg I
( O
AtR B
) O
in O
which O
the O
amide B
group O
has O
been O
modified O
to O
a O
thioxoamide B
were O
made O
into O
dications O
by O
electrospray O
ionization O
and O
converted O
to O
cation O
- O
radicals O
, O
( O
GtK B
+ O
2H B
) O
( O
+ O
* O
) O
, O
( O
AtK B
+ O
2H B
) O
( O
+ O
* O
) O
, O
and O
( O
AtR B
+ O
2H B
) O
( O
+ O
* O
) O
, O
by O
electron O
transfer O

Thioxodipeptides B
Gly B
- I
thio I
- I
Lys I
( O
GtK B
) O
, O
Ala B
- I
thio I
- I
Lys I
( O
AtK B
) O
, O
and O
Ala B
- I
thio I
- I
Arg I
( O
AtR B
) O
in O
which O
the O
amide B
group O
has O
been O
modified O
to O
a O
thioxoamide B
were O
made O
into O
dications O
by O
electrospray O
ionization O
and O
converted O
to O
cation O
- O
radicals O
, O
( O
GtK B
+ O
2H B
) O
( O
+ O
* O
) O
, O
( O
AtK B
+ O
2H B
) O
( O
+ O
* O
) O
, O
and O
( O
AtR B
+ O
2H B
) O
( O
+ O
* O
) O
, O
by O
electron O
transfer O

Thioxodipeptides B
Gly B
- I
thio I
- I
Lys I
( O
GtK B
) O
, O
Ala B
- I
thio I
- I
Lys I
( O
AtK B
) O
, O
and O
Ala B
- I
thio I
- I
Arg I
( O
AtR B
) O
in O
which O
the O
amide B
group O
has O
been O
modified O
to O
a O
thioxoamide B
were O
made O
into O
dications O
by O
electrospray O
ionization O
and O
converted O
to O
cation O
- O
radicals O
, O
( O
GtK B
+ O
2H B
) O
( O
+ O
* O
) O
, O
( O
AtK B
+ O
2H B
) O
( O
+ O
* O
) O
, O
and O
( O
AtR B
+ O
2H B
) O
( O
+ O
* O
) O
, O
by O
electron O
transfer O

One O
- O
NH B
group O
of O
dimethylethylenediam B
( O
DMEDA B
) O
first O
attacks O
the O
carbon B
atom O
of O
urea B
, O
eliminating O
one O
- O
NH3 B
group O
and O
forming O
an O
intermediate O
state O
CH3NHC2H4N B
( I
CH3 I
) I
CONH2 I
( O
IMI O
) O
. O

The O
ameliorating O
action O
of O
nicotine B
on O
PPI O
deficits O
in O
DAT O
KO O
mice O
was O
blocked O
by O
mecamylamine B
, O
the O
alpha O
7 O
nACh O
receptor O
antagonist O
methyllycaconitine B
or O
WAY100635 B
, O
while O
the O
alpha O
4 O
beta O
2 O
nACh O
receptor O
antagonist O
dihydro B
- I
beta I
- I
erythroidinehydrobro I
( O
DH B
beta I
E I
) O
produced O
only O
a O
non O
- O
significant O
trend O
toward O
attenuation O
of O
nicotine B
effects O
. O

Finally O
, O
we O
observed O
that O
administration O
of O
the O
5 O
- O
HT1A O
receptor O
agonist O
8 B
- I
OH I
- I
DPAT I
also O
ameliorated O
the O
deficit O
in O
PPI O
observed O
in O
DAT O
KO O
mice O
. O

Specifically O
, O
the O
sirtuin O
- O
catalyzed O
AcK O
side O
chain O
deacetylation O
is O
not O
merely O
an O
amide B
hydrolysis O
reaction O
, O
instead O
is O
coupled O
to O
the O
nicotinamide B
cleavage O
from O
beta B
- I
nicotinamide I
adenine I
dinucleotide I
( O
beta B
- I
NAD I
+ O
or O
NAD B
+ O
) O
with O
the O
generation O
of O
three O
enzymatic O
products O
, O
i O
. O
e O
. O
the O
deacetylated O
protein O
species O
, O
nicotinamide O
, O
and O
2 B
' I
- I
O I
- I
acetyl I
- I
ADP I
- I
ribose I
( O
2 B
' I
- I
O I
- I
AADPR I
) O
. O

Multidrug O
resistance O
- O
associated O
proteins O
are O
involved O
in O
the O
transport O
of O
the O
glutathione B
conjugates O
of O
the O
ultimate O
carcinogen O
of O
benzo B
[ I
a I
] I
pyrene I
in O
human O
Caco O
- O
2 O
cells O
. O

A O
wide O
variety O
of O
contaminants O
are O
ingested O
through O
food O
, O
among O
them O
the O
pro O
- O
carcinogenic O
polycyclic O
aromatic O
hydrocarbon O
benzo B
[ I
a I
] I
pyrene I
( O
BP O
) O
that O
is O
resorbed O
and O
partially O
metabolized O
in O
the O
enterocytes O
of O
the O
small O
intestine O
. O

The O
objective O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
mercuric B
( O
Hg B
( I
2 I
+ I
) I
) O
and O
lead O
( O
Pb B
( I
2 I
+ I
) I
) O
ions O
on O
T O
cells O
. O

The O
objective O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
mercuric B
( O
Hg B
( I
2 I
+ I
) I
) O
and O
lead O
( O
Pb B
( I
2 I
+ I
) I
) O
ions O
on O
T O
cells O
. O

Additionally O
, O
Hg B
( I
2 I
+ I
) I
induced O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
accompanied O
by O
the O
loss O
of O
mitochondrial O
transmembrane O
potential O
, O
measured O
by O
Dihydrorhodamine B
and O
Rhodamine B
- I
123 I
, O
respectively O
. O

The O
antioxidant O
N B
- I
acetylcysteine I
partially O
reversed O
the O
toxic O
effects O
of O
Hg B
( I
2 I
+ I
) I
, O
pointing O
to O
an O
involvement O
of O
ROS O
. O

Hg B
( I
2 I
+ I
) I
had O
no O
effect O
on O
the O
secretion O
of O
IL O
- O
2 O
, O
but O
on O
IL O
- O
2 O
mediated O
signal O
transduction O
pathways O
, O
reducing O
phosphorylation O
of O
the O
downstream O
kinases O
ERK1 O
/ O
2 O
and O
AKT O
. O

Moreover O
, O
Hg B
( I
2 I
+ I
) I
led O
to O
an O
arrest O
of O
the O
cells O
in O
the O
S O
phase O
of O
the O
cell O
cycle O
. O

Taken O
together O
, O
these O
data O
fit O
a O
model O
in O
which O
Hg B
( I
2 I
+ I
) I
disrupts O
mitochondria O
, O
and O
the O
resulting O
release O
of O
ROS O
inhibits O
IL O
- O
2 O
- O
dependent O
signal O
transduction O
, O
reducing O
proliferation O
and O
survival O
of O
T O
cells O
. O

In O
this O
work O
, O
the O
molecular O
effects O
of O
N B
, I
N I
- I
diethyldithiocarbama I
( O
DEDTC B
) O
were O
studied O
in O
human O
SH O
- O
SY5Y O
neuroblastoma O
cells O
to O
determine O
the O
role O
of O
copper B
in O
the O
DEDTC B
toxicity O
and O
the O
pathway O
trigged O
in O
cell O
by O
the O
complex O
Cu B
- I
DEDTC I
. O

The O
growth O
of O
sphere O
- O
like O
trimanganese B
tetraoxide I
( O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
) O
nanoparticles O
on O
silk O
fiber O
was O
achieved O
by O
sequential O
dipping O
in O
an O
alternating O
bath O
of O
potassium B
hydroxide I
and O
manganese B
( I
II I
) I
nitrate I
under O
ultrasound O
irradiation O
. O

Twenty B
five I
- I
hydroxyvitamin I
D I
[ O
25 B
( I
OH I
) I
D I
] O
increased O
by O
115 O
% O
( O
19 O
. O
8 O
ng O
/ O
mL O
to O
40 O
. O
5 O
ng O
/ O
mL O
, O
p O
< O
0 O
. O
001 O
) O
after O
4 O
weeks O
of O
UVB O
exposure O
. O

Twenty B
five I
- I
hydroxyvitamin I
D I
[ O
25 B
( I
OH I
) I
D I
] O
increased O
by O
115 O
% O
( O
19 O
. O
8 O
ng O
/ O
mL O
to O
40 O
. O
5 O
ng O
/ O
mL O
, O
p O
< O
0 O
. O
001 O
) O
after O
4 O
weeks O
of O
UVB O
exposure O
. O

Triggers O
of O
eryptosis O
include O
increase O
of O
cytosolic O
Ca B
( I
2 I
+ I
) I
- O
activity O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
following O
activation O
of O
oxidant O
- O
sensitive O
Ca B
( I
2 I
+ I
) I
- O
permeable O
cation O
channels O
, O
ceramide B
formation O
and O
/ O
or O
ATP B
- O
depletion O
. O

Triggers O
of O
eryptosis O
include O
increase O
of O
cytosolic O
Ca B
( I
2 I
+ I
) I
- O
activity O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
following O
activation O
of O
oxidant O
- O
sensitive O
Ca B
( I
2 I
+ I
) I
- O
permeable O
cation O
channels O
, O
ceramide B
formation O
and O
/ O
or O
ATP B
- O
depletion O
. O

Triggers O
of O
eryptosis O
include O
increase O
of O
cytosolic O
Ca B
( I
2 I
+ I
) I
- O
activity O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
following O
activation O
of O
oxidant O
- O
sensitive O
Ca B
( I
2 I
+ I
) I
- O
permeable O
cation O
channels O
, O
ceramide B
formation O
and O
/ O
or O
ATP B
- O
depletion O
. O

To O
this O
end O
, O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
was O
estimated O
from O
Fluo3 B
- O
fluorescence O
, O
cell O
volume O
from O
forward O
scatter O
, O
phosphatidylserine B
exposure O
from O
annexin O
- O
V O
- O
binding O
, O
hemolysis O
from O
hemoglobin O
release O
, O
oxidative O
stress O
from O
DCFDA B
- O
fluorescence O
and O
ceramide B
abundance O
utilizing O
antibodies O
. O

A O
48 O
h O
exposure O
to O
withaferin B
A I
significantly O
decreased O
forward O
scatter O
( O
at O
> O
= O
10 O
mu O
M O
withaferin B
concentration O
) O
and O
increased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
( O
> O
= O
5 O
mu O
M O
) O
, O
ROS O
- O
formation O
( O
> O
= O
10 O
mu O
M O
) O
ceramide B
- O
formation O
( O
> O
= O
10 O
mu O
M O
) O
as O
well O
as O
annexin O
- O
V O
- O
binding O
( O
> O
= O
5 O
mu O
M O
) O
. O

Extracellular O
Ca B
( I
2 I
+ I
) I
removal O
, O
amiloride B
, O
and O
the O
antioxidant O
N B
- I
acetyl I
- I
l I
- I
cysteine I
significantly O
blunted O
withaferin B
A I
- O
triggered O
annexin O
- O
V O
- O
binding O
. O

The O
formation O
of O
supramolecular O
inclusion O
complexes O
between O
rutin B
and O
four O
cyclodextrins O
, O
namely O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
alpha I
- I
cyclodextrin I
( O
HP B
- I
alpha I
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
and O
( B
2 I
- I
hydroxypropyl I
) I
- I
gamma I
- I
cyclodextrin I
( O
HP B
- I
gamma I
- I

The O
formation O
of O
supramolecular O
inclusion O
complexes O
between O
rutin B
and O
four O
cyclodextrins O
, O
namely O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
alpha I
- I
cyclodextrin I
( O
HP B
- I
alpha I
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
and O
( B
2 I
- I
hydroxypropyl I
) I
- I
gamma I
- I
cyclodextrin I
( O
HP B
- I
gamma I
- I

CD I
) O
, O
and O
the O
effects O
of O
the O
complexation O
on O
the O
stability O
and O
antioxidant O
activity O
of O
rutin B
were O
investigated O
. O

Results O
from O
phase O
- O
solubility O
studies O
showed O
that O
rutin B
formed O
1 O
: O
1 O
stoichiometric O
inclusion O
complexes O
with O
HP B
- I
alpha I
- I
CD I
, O
beta B
- I
CD I
, O
HP B
- I
beta I
- I
CD I
and O
HP B
- I
gamma I
- I
CD I
; O
the O
complexes O
formed O
with O
HP B
- I
gamma I
- I
CD I
and O
HP B
- I
beta I
- I
CD I
had O
the O
greatest O
stability O
constants O
, O
followed O
by O
beta B
- I
CD I
and O
HP B
- I
alpha I
- I
CD I
. O

Results O
from O
phase O
- O
solubility O
studies O
showed O
that O
rutin B
formed O
1 O
: O
1 O
stoichiometric O
inclusion O
complexes O
with O
HP B
- I
alpha I
- I
CD I
, O
beta B
- I
CD I
, O
HP B
- I
beta I
- I
CD I
and O
HP B
- I
gamma I
- I
CD I
; O
the O
complexes O
formed O
with O
HP B
- I
gamma I
- I
CD I
and O
HP B
- I
beta I
- I
CD I
had O
the O
greatest O
stability O
constants O
, O
followed O
by O
beta B
- I
CD I
and O
HP B
- I
alpha I
- I
CD I
. O

Results O
from O
phase O
- O
solubility O
studies O
showed O
that O
rutin B
formed O
1 O
: O
1 O
stoichiometric O
inclusion O
complexes O
with O
HP B
- I
alpha I
- I
CD I
, O
beta B
- I
CD I
, O
HP B
- I
beta I
- I
CD I
and O
HP B
- I
gamma I
- I
CD I
; O
the O
complexes O
formed O
with O
HP B
- I
gamma I
- I
CD I
and O
HP B
- I
beta I
- I
CD I
had O
the O
greatest O
stability O
constants O
, O
followed O
by O
beta B
- I
CD I
and O
HP B
- I
alpha I
- I
CD I
. O

Results O
from O
phase O
- O
solubility O
studies O
showed O
that O
rutin B
formed O
1 O
: O
1 O
stoichiometric O
inclusion O
complexes O
with O
HP B
- I
alpha I
- I
CD I
, O
beta B
- I
CD I
, O
HP B
- I
beta I
- I
CD I
and O
HP B
- I
gamma I
- I
CD I
; O
the O
complexes O
formed O
with O
HP B
- I
gamma I
- I
CD I
and O
HP B
- I
beta I
- I
CD I
had O
the O
greatest O
stability O
constants O
, O
followed O
by O
beta B
- I
CD I
and O
HP B
- I
alpha I
- I
CD I
. O

Results O
from O
phase O
- O
solubility O
studies O
showed O
that O
rutin B
formed O
1 O
: O
1 O
stoichiometric O
inclusion O
complexes O
with O
HP B
- I
alpha I
- I
CD I
, O
beta B
- I
CD I
, O
HP B
- I
beta I
- I
CD I
and O
HP B
- I
gamma I
- I
CD I
; O
the O
complexes O
formed O
with O
HP B
- I
gamma I
- I
CD I
and O
HP B
- I
beta I
- I
CD I
had O
the O
greatest O
stability O
constants O
, O
followed O
by O
beta B
- I
CD I
and O
HP B
- I
alpha I
- I
CD I
. O

Results O
from O
phase O
- O
solubility O
studies O
showed O
that O
rutin B
formed O
1 O
: O
1 O
stoichiometric O
inclusion O
complexes O
with O
HP B
- I
alpha I
- I
CD I
, O
beta B
- I
CD I
, O
HP B
- I
beta I
- I
CD I
and O
HP B
- I
gamma I
- I
CD I
; O
the O
complexes O
formed O
with O
HP B
- I
gamma I
- I
CD I
and O
HP B
- I
beta I
- I
CD I
had O
the O
greatest O
stability O
constants O
, O
followed O
by O
beta B
- I
CD I
and O
HP B
- I
alpha I
- I
CD I
. O

Thermodynamic O
studies O
demonstrate O
that O
the O
inclusion O
of O
rutin B
into O
HP B
- I
beta I
- I
CD I
was O
an O
exothermic O
process O
which O
occurred O
spontaneously O
. O

Two O
- O
dimensional O
rotating O
- O
frame O
nuclear O
Overhauser O
effect O
spectroscopy O
( O
2D O
ROESY O
) O
( B
1 I
) I
H I
NMR O
analyses O
show O
that O
the O
A O
ring O
of O
rutin B
was O
the O
part O
of O
the O
molecule O
that O
most O
likely O
inserted O
into O
the O
cavity O
of O
HP B
- I
beta I
- I
CD I
, O
thus O
forming O
a O
supramolecular O
inclusion O
complex O
. O

A O
phase O
I O
, O
open O
- O
label O
, O
single O
- O
dose O
, O
mass O
balance O
study O
of O
14C B
- I
labeled I
abiraterone I
acetate I
in O
healthy O
male O
subjects O
. O

3 O
. O
Main O
circulating O
metabolites O
were O
abiraterone B
sulfate I
and O
N B
- I
oxide I
abiraterone I
sulfate I
. O

The O
main O
metabolite O
excreted O
in O
urine O
was O
N B
- I
oxide I
abiraterone I
sulfate I
( O
4 O
. O
22 O
% O
of O
TR O
) O
. O

CYT B
significantly O
inhibited O
the O
neuronal O
apoptosis O
induced O
by O
NMDA B
exposure O
by O
reversing O
intracellular O
Ca B
( I
2 I
+ I
) I
overload O
and O
balancing O
Bcl O
- O
2 O
and O
Bax O
expression O
levels O
. O

In O
this O
study O
, O
we O
compared O
the O
effects O
of O
RSV B
and O
two O
glycosyl B
RSVs I
, O
resveratrol B
- I
3 I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
3G B
- I
RSV I
; O
polydatin B
/ O
piceid B
) O
and O
resveratrol B
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
4 B
' I
G I
- I
RSV I
) O
, O
at O
the O
cellular O
level O
. O

In O
oxygen O
radical O
absorbance O
capacity O
and O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
radical O
scavenging O
assays O
, O
the O
antioxidant O
activity O
of O
3G B
- I
RSV I
was O
comparable O
to O
that O
of O
RSV B
, O
whereas O
the O
radical O
- O
scavenging O
efficiency O
of O
4 B
' I
G I
- I
RSV I
was O
less O
than O
50 O
% O
of O
that O
of O
RSV B
. O

However O
, O
4 B
' I
G I
- I
RSV I
, O
but O
not O
3G B
- I
RSV I
, O
induced O
SIRT1 O
- O
dependent O
histone O
H3 O
deacetylation O
and O
SOD2 O
expression O
in O
mouse O
C2C12 O
skeletal O
myoblasts O
; O
as O
with O
RSV B
, O
SIRT1 O
knockdown O
blunted O
these O
effects O
. O

RSV B
and O
4 B
' I
G I
- I
RSV I
, O
but O
not O
3G B
- I
RSV I
, O
mitigated O
oxidative O
stress O
- O
induced O
cell O
death O
in O
C2C12 O
cells O
and O
primary O
neonatal O
rat O
cardiomyocytes O
. O

RSV B
and O
4 B
' I
G I
- I
RSV I
inhibited O
C2C12 O
cell O
proliferation O
, O
but O
3G B
- I
RSV I
did O
not O
. O

RSV B
was O
found O
in O
both O
the O
intracellular O
and O
extracellular O
fractions O
of O
C2C12 O
cells O
that O
had O
been O
incubated O
with O
4 B
' I
G I
- I
RSV I
, O
indicating O
that O
4 B
' I
G I
- I
RSV I
was O
extracellularly O
deglycosylated O
to O
RSV B
, O
which O
was O
then O
taken O
up O
by O
the O
cells O
. O

RSV B
was O
found O
in O
both O
the O
intracellular O
and O
extracellular O
fractions O
of O
C2C12 O
cells O
that O
had O
been O
incubated O
with O
4 B
' I
G I
- I
RSV I
, O
indicating O
that O
4 B
' I
G I
- I
RSV I
was O
extracellularly O
deglycosylated O
to O
RSV B
, O
which O
was O
then O
taken O
up O
by O
the O
cells O
. O

Our O
results O
point O
to O
4 B
' I
G I
- I
RSV I
as O
a O
useful O
RSV B
prodrug O
with O
high O
water O
solubility O
. O

Immunohistochemical O
analysis O
also O
revealed O
that O
LPS O
- O
induced O
lipocalin O
- O
2 O
is O
expressed O
by O
brain O
endothelial O
cells O
and O
is O
partly O
co O
- O
localised O
with O
cyclooxygenase O
- O
2 O
( O
Cox O
- O
2 O
) O
, O
the O
rate O
- O
limiting O
enzyme O
for O
the O
production O
of O
inflammatory O
induced O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
, O
which O
is O
the O
key O
mediator O
of O
fever O
. O

Complex O
yet O
appealing O
rutile O
TiO B
( I
2 I
) I
flower O
films O
are O
, O
for O
the O
first O
time O
, O
directly O
hydrothermally O
grown O
on O
a O
transparent O
conducting O
fluorine B
- I
doped I
tin I
oxide I
( O
FTO B
) O
substrate O
. O

Recent O
studies O
have O
demonstrated O
a O
similar O
acute O
effect O
of O
3 B
, I
4 I
- I
methylenedioxymetham I
( O
MDMA B
) O
in O
blood O
platelets O
and O
brain O
tissue O
via O
action O
on O
the O
serotonin B
transporter O
. O

Exposures O
to O
1 B
, I
3 I
- I
dimethylamylamine I
- O
containing O
products O
reported O
to O
Texas O
poison O
centers O
. O

1 B
, I
3 I
- I
Dimethylamylamine I
( O
DMAA B
) O
is O
an O
ingredient O
in O
a O
number O
of O
weight O
loss O
and O
exercise O
performance O
enhancing O
products O
. O

The O
toxicity O
of O
the O
N B
- I
hydroxy I
and O
6 B
- I
hydroxy I
metabolites O
of O
3 B
, I
4 I
- I
dichloropropionanili I
does O
not O
depend O
on O
calcium B
release O
- O
activated O
calcium B
channel O
inhibition O
. O

( O
Kiely O
, O
T O
. O
, O
Donaldson O
, O
D O
. O
, O
and O
Grube O
, O
A O
. O
[ O
2004 O
] O
. O
Pesticide O
Industry O
Sales O
and O
Usage O
. O
2000 O
and O
2001 O
Market O
Estimates O
. O
Available O
at O
: O
http O
: O
/ O
/ O
www O
. O
epa O
. O
gov O
/ O
pesticides O
/ O
pestsales O
/ O
01pestsales O
/ O
market O
_ O
estimates2001 O
. O
pdf O
. O
Accessed O
October O
25 O
, O
2012 O
. O
) O
Propanil B
( O
3 B
, I
4 I
- I
dichloropropionanili I
[ O
DCPA B
] O
) O
is O
a O
commonly O
used O
herbicide O
in O
the O
United O
States O
, O
with O
2 O
- O
4 O
million O

( O
Salazar O
, O
K O
. O
D O
. O
, O
Ustyugova O
, O
I O
. O
V O
. O
, O
Brundage O
, O
K O
. O
M O
. O
, O
Barnett O
, O
J O
. O
B O
. O
, O
and O
Schafer O
, O
R O
. O
[ O
2008 O
] O
. O
A O
review O
of O
the O
immunotoxicity O
of O
the O
pesticide O
3 B
, I
4 I
- I
dichloropropionanali I
. O
J O
. O
Toxicol O
. O
Environ O
. O
Health O
B O
Crit O
. O
Rev O
. O
11 O
, O
630 O
- O
645 O
. O
) O
In O
mammals O
, O
hepatic O
enzymes O
metabolize O
DCPA B
, O
resulting O
in O
the O
production O
of O
3 B
, I
4 I
- I

dichloroaniline I
( O
DCA B
) O
. O

Fingolimod B
( O
FTY720 B
) O
, O
a O
novel O
drug O
approved O
for O
the O
treatment O
of O
relapsing O
- O
remitting O
multiple O
sclerosis O
, O
activates O
different O
sphingosine B
- I
1 I
- I
phosphate I
receptor O
( O
S1PR O
) O
subtypes O
. O

Here O
, O
we O
examined O
the O
effect O
of O
FTY720 B
, O
its O
active O
metabolite O
, O
FTY720 B
- I
P I
, O
and O
sphingosine B
- I
1 I
- I
phosphate I
( O
S1P B
) O
on O
neuronal O
viability O
using O
a O
classical O
in O
vitro O
model O
of O
excitotoxic O
neuronal O
death O
. O

The O
theoretical O
calculation O
successfully O
predicted O
the O
experimental O
observation O
that O
the O
monomodal O
- O
poly B
( I
dimethyl I
siloxane I
) I
( O
PDMS B
) O
- O
brush O
- O
grafted O
TiO B
( I
2 I
) I
nanoparticles O
can O
only O
be O
well O
dispersed O
within O
a O
small O
molecular O
weight O
silicone B
matrix O
. O

Ethanol B
levels O
reached O
in O
circulation O
during O
moderate O
- O
to O
- O
heavy O
alcohol B
intoxication O
( O
50 O
- O
100 O
mM O
) O
modify O
Ca B
( I
2 I
+ I
) I
- O
and O
voltage O
- O
gated O
K B
( I
+ I
) I
( O
BK O
) O
channel O
steady O
- O
state O
activity O
, O
eventually O
altering O
both O
physiology O
and O
behavior O
. O

Ethanol B
( O
50 O
mM O
) O
increased O
the O
steady O
- O
state O
activities O
of O
mslo1 O
and O
Ca B
( I
2 I
+ I
) I
- O
gated O
MthK O
, O
the O
latter O
after O
channel O
reconstitution O
into O
phospholipid O
bilayers O
. O

Rather O
, O
a O
CTD O
containing O
Ca B
( I
2 I
+ I
) I
- O
sensing O
regulator O
of O
conductance O
for O
K B
( I
+ I
) I
domains O
seems O
to O
be O
critical O
to O
bestow O
K B
( O
V O
) O
structures O
, O
whether O
of O
TM2 O
( O
MthK O
) O
or O
TM6 O
( O
slo1 O
) O
, O
with O
sensitivity O
to O
intoxicating O
ethanol B
levels O
. O

N B
- I
Methyl I
- I
anthraniloyl I
modification O
at O
the O
3 B
' I
- I
OH I
of O
the O
2 B
' I
- I
deoxyribose I
leads O
to O
ligands O
( O
mant O
- O
deoxy O
- O
ATP B
[ O
dATP O
] O
, O
mant O
- O
deoxy O
- O
ADP B
) O
with O
inverse O
agonist O
activity O
. O

Although O
high B
- I
fructose I
corn I
syrup I
( O
HFCS B
- I
55 I
) O
is O
the O
major O
sweetener O
in O
foods O
and O
soft O
- O
drinks O
, O
its O
potential O
role O
in O
the O
pathophysiology O
of O
diabetes O
and O
obesity O
( O
" O
diabesity O
" O
) O
remains O
unclear O
. O

Synthesis O
and O
chiral O
recognition O
of O
nickel B
( I
II I
) I
macrocyclic O
complex O
with O
( B
R I
) I
- I
naphthylethyleneamin I
pendant O
groups O
and O
its O
self O
- O
assembled O
framework O
. O

A O
novel O
nickel B
( I
II I
) I
hexaaza I
macrocyclic O
complex O
, O
[ B
Ni I
( I
L I
( I
R I
, I
R I
) I
) I
] I
( I
ClO I
( I
4 I
) I
) I
( I
2 I
) I
( O
1 O
) O
, O
containing O
chiral O
pendant O
groups O
was O
synthesized O
by O
an O
efficient O
one O
- O
pot O
template O
condensation O
and O
characterized O
( O
L O
( O
R O
, O
R O
) O
= O
1 B
, I
8 I
- I
di I
( I
( I
R I
) I
- I
alpha I
- I
methylnaphthyl I
) I
- I
1 I
, I
3 I
, I
6 I
, I
8 I
, I
10 I
, I
13 I
- I
hexaazacyclotetradec I
) O
. O

Open O
framework O
[ B
Ni I
( I
L I
( I
R I
, I
R I
) I
) I
] I
( I
3 I
) I
[ I
C I
( I
6 I
) I
H I
( I
3 I
) I
( I
COO I
) I
( I
3 I
) I
] I
( I
2 I
) I
( O
2 O
) O
was O
constructed O
from O
the O
self O
- O
assembly O
of O
compound O
1 O
with O
deprotonated O
1 B
, I
3 I
, I
5 I
- I
benzenetricarboxylic I
acid I
, O
BTC B
( I
3 I
- I
) I
. O

Room O
- O
temperature O
electron O
spin O
amplifier O
based O
on O
Ga B
( I
In I
) I
NAs I
alloys O
. O

An O
efficient O
, O
defect O
- O
enabled O
spin O
amplifier O
based O
on O
a O
non O
- O
magnetic O
semiconductor O
, O
Ga B
( I
In I
) I
NAs I
, O
is O
proposed O
and O
demonstrated O
, O
with O
a O
large O
spin O
gain O
( O
up O
to O
2700 O
% O
at O
zero O
field O
) O
for O
conduction O
electrons O
and O
a O
high O
cut O
- O
off O
frequency O
of O
up O
to O
1 O
GHz O
. O

The O
extract O
inhibited O
elevation O
of O
the O
intracellular O
Ca B
( I
2 I
+ I
) I
concentration O
caused O
by O
stimulation O
by O
antigen O
, O
while O
not O
suppressing O
degranulation O
induced O
by O
a O
calcium B
ionophore O
A23187 B
. O

The O
principal O
constituents O
of O
the O
oils O
were O
similar O
except O
for O
the O
minor O
compounds O
, O
including O
linalool B
, O
terpinen B
- I
4 I
- I
ol I
and O
alpha B
- I
terpineol I
, O
the O
levels O
of O
which O
increased O
after O
steam O
distillation O
. O

We O
evaluated O
its O
anticancer O
potential O
by O
studying O
its O
effect O
on O
mitochondrial O
membrane O
potential O
, O
intracellular O
calcium B
levels O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
, O
cell O
membrane O
integrity O
, O
apoptotic O
body O
formation O
and O
DNA O
fragmentation O
in O
cultured O
HepG2 O
cells O
. O

Our O
data O
further O
indicate O
reduction O
of O
Delta O
psi O
M O
and O
increased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
during O
apoptosis O
induction O
by O
neferine B
with O
increased O
expression O
of O
apoptotic O
proteins O
such O
as O
Bax O
, O
Bad O
, O
cleaved O
forms O
of O
caspase O
3 O
, O
caspase O
9 O
and O
PARP O
, O
with O
the O
downregulation O
of O
anti O
- O
apoptotic O
protein O
Bcl2 O
in O
HepG2 O
cells O
. O

This O
approach O
allowed O
the O
identification O
of O
four O
endocrine O
compounds O
( O
tetrahydroaldosteron B
- I
3 I
- I
glucuronide I
, O
cortolone B
- I
3 I
- I
glucuronide I
, O
testosterone B
- I
glucuronide I
and O
17 B
- I
hydroxyprogesterone I
) O
, O
which O
belonged O
to O
the O
steroid B
biosynthesis O
pathway O
as O
significant O
metabolites O
upregulated O
by O
citrus O
juice O
intake O
. O

This O
approach O
allowed O
the O
identification O
of O
four O
endocrine O
compounds O
( O
tetrahydroaldosteron B
- I
3 I
- I
glucuronide I
, O
cortolone B
- I
3 I
- I
glucuronide I
, O
testosterone B
- I
glucuronide I
and O
17 B
- I
hydroxyprogesterone I
) O
, O
which O
belonged O
to O
the O
steroid B
biosynthesis O
pathway O
as O
significant O
metabolites O
upregulated O
by O
citrus O
juice O
intake O
. O

Therefore O
, O
in O
this O
study O
, O
the O
effects O
of O
rosemary O
on O
the O
activation O
of O
nuclear O
factor O
kappa O
beta O
( O
NF O
- O
kB O
) O
and O
mitogen O
- O
activated O
protein O
kinases O
( O
MAPKs O
) O
, O
the O
expression O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
and O
the O
production O
of O
nitric B
oxide I
( O
NO B
) O
, O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
, O
and O
cytokine O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O

We O
investigated O
the O
effects O
of O
Cd B
and O
17 B
- I
alpha I
- I
ethinylestradiol I
( O
EE B
2 I
) O
on O
AhR O
- O
associated O
gene O
expression O
after O
oral O
exposure O
of O
ovariectomized O
female O
Wistar O
rats O
, O
and O
metallothionein O
( O
Mt1a O
) O
expression O
as O
a O
typical O
metal O
- O
response O
marker O
. O

To O
assess O
the O
influence O
of O
Zn B
( I
2 I
+ I
) I
, O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Ti B
( I
IV I
) I
, O
and O
Sn B
( I
IV I
) I
on O
incorporation O
of O
( B
68 I
) I
Ga I
( I
3 I
+ I
) I
into O
pendant O
- O
arm O
macrocyclic O
chelators O
, O
the O
( B
68 I
) I
Ga I
labeling O
of O
1 B
, I
4 I
, I
7 I
- I
triazacyclononane I
- I
1 I
, I
4 I
, I
7 I
- I
triacetic I
acid I
( O
NOTA B
) O
, O
1 B
, I
4 I
, I
7 I
, I
10 I
- I
tetraazacyclododecan I
- I

To O
assess O
the O
influence O
of O
Zn B
( I
2 I
+ I
) I
, O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Ti B
( I
IV I
) I
, O
and O
Sn B
( I
IV I
) I
on O
incorporation O
of O
( B
68 I
) I
Ga I
( I
3 I
+ I
) I
into O
pendant O
- O
arm O
macrocyclic O
chelators O
, O
the O
( B
68 I
) I
Ga I
labeling O
of O
1 B
, I
4 I
, I
7 I
- I
triazacyclononane I
- I
1 I
, I
4 I
, I
7 I
- I
triacetic I
acid I
( O
NOTA B
) O
, O
1 B
, I
4 I
, I
7 I
, I
10 I
- I
tetraazacyclododecan I
- I

To O
assess O
the O
influence O
of O
Zn B
( I
2 I
+ I
) I
, O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Ti B
( I
IV I
) I
, O
and O
Sn B
( I
IV I
) I
on O
incorporation O
of O
( B
68 I
) I
Ga I
( I
3 I
+ I
) I
into O
pendant O
- O
arm O
macrocyclic O
chelators O
, O
the O
( B
68 I
) I
Ga I
labeling O
of O
1 B
, I
4 I
, I
7 I
- I
triazacyclononane I
- I
1 I
, I
4 I
, I
7 I
- I
triacetic I
acid I
( O
NOTA B
) O
, O
1 B
, I
4 I
, I
7 I
, I
10 I
- I
tetraazacyclododecan I
- I

To O
assess O
the O
influence O
of O
Zn B
( I
2 I
+ I
) I
, O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Ti B
( I
IV I
) I
, O
and O
Sn B
( I
IV I
) I
on O
incorporation O
of O
( B
68 I
) I
Ga I
( I
3 I
+ I
) I
into O
pendant O
- O
arm O
macrocyclic O
chelators O
, O
the O
( B
68 I
) I
Ga I
labeling O
of O
1 B
, I
4 I
, I
7 I
- I
triazacyclononane I
- I
1 I
, I
4 I
, I
7 I
- I
triacetic I
acid I
( O
NOTA B
) O
, O
1 B
, I
4 I
, I
7 I
, I
10 I
- I
tetraazacyclododecan I
- I

This O
behavior O
results O
in O
substantially O
improved O
selectivity O
for O
Ga B
( I
3 I
+ I
) I
and O
, O
therefore O
, O
in O
more O
robust O
and O
reliable O
( B
68 I
) I
Ga I
labeling O
procedures O
. O

High O
- O
dose O
sodium B
selenite I
toxicity O
cannot O
be O
prevented O
by O
the O
co O
- O
administration O
of O
pharmacological O
levels O
of O
epigallocatechin B
- I
3 I
- I
gallate I
which O
in O
turn O
aggravates O
the O
toxicity O
. O

Several O
lines O
of O
evidence O
show O
epigallocatechin B
- I
3 I
- I
gallate I
( O
EGCG B
) O
, O
a O
predominant O
component O
of O
green O
tea O
catechins B
with O
numerous O
health O
benefits O
, O
can O
ameliorate O
the O
toxicity O
of O
many O
agents O
. O

Carvacrol B
is O
one O
of O
the O
main O
substances O
of O
essential O
oil O
which O
triggers O
intracellular O
Ca B
( I
2 I
+ I
) I
mobilization O
and O
causes O
cytotoxicity O
in O
diverse O
cell O
models O
. O

However O
, O
the O
mechanism O
of O
carvacrol B
- O
induced O
Ca B
( I
2 I
+ I
) I
movement O
and O
cytotoxicity O
is O
not O
fully O
understood O
. O

This O
study O
examined O
the O
effect O
of O
carvacrol B
on O
cytosolic O
free O
Ca B
( I
2 I
+ I
) I
concentrations O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
) O
, O
cell O
viability O
and O
apoptosis O
in O
OC2 O
human O
oral O
cancer O
cells O
. O

This O
study O
examined O
the O
effect O
of O
carvacrol B
on O
cytosolic O
free O
Ca B
( I
2 I
+ I
) I
concentrations O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
) O
, O
cell O
viability O
and O
apoptosis O
in O
OC2 O
human O
oral O
cancer O
cells O
. O

Carvacrol B
induced O
a O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
and O
the O
signal O
was O
reduced O
by O
removal O
of O
extracellular O
Ca B
( I
2 I
+ I
) I
. O

Carvacrol B
induced O
a O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
and O
the O
signal O
was O
reduced O
by O
removal O
of O
extracellular O
Ca B
( I
2 I
+ I
) I
. O

Carvacrol B
- O
induced O
Ca B
( I
2 I
+ I
) I
entry O
was O
not O
altered O
by O
store O
- O
operated O
Ca B
( I
2 I
+ I
) I
channel O
inhibitors O
and O
protein O
kinase O
C O
( O
PKC O
) O
activator O
, O
but O
was O
inhibited O
by O
a O
PKC O
inhibitor O
. O

Carvacrol B
- O
induced O
Ca B
( I
2 I
+ I
) I
entry O
was O
not O
altered O
by O
store O
- O
operated O
Ca B
( I
2 I
+ I
) I
channel O
inhibitors O
and O
protein O
kinase O
C O
( O
PKC O
) O
activator O
, O
but O
was O
inhibited O
by O
a O
PKC O
inhibitor O
. O

In O
Ca B
( I
2 I
+ I
) I
- O
free O
medium O
, O
treatment O
with O
the O
endoplasmic O
reticulum O
Ca B
( I
2 I
+ I
) I
pump O
inhibitor O
thapsigargin B
( O
TG O
) O
or O
2 B
, I
5 I
- I
di I
- I
tert I
- I
butylhydroquinone I
( O
BHQ B
) O
inhibited O
carvacrol B
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
. O

In O
Ca B
( I
2 I
+ I
) I
- O
free O
medium O
, O
treatment O
with O
the O
endoplasmic O
reticulum O
Ca B
( I
2 I
+ I
) I
pump O
inhibitor O
thapsigargin B
( O
TG O
) O
or O
2 B
, I
5 I
- I
di I
- I
tert I
- I
butylhydroquinone I
( O
BHQ B
) O
inhibited O
carvacrol B
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
. O

In O
Ca B
( I
2 I
+ I
) I
- O
free O
medium O
, O
treatment O
with O
the O
endoplasmic O
reticulum O
Ca B
( I
2 I
+ I
) I
pump O
inhibitor O
thapsigargin B
( O
TG O
) O
or O
2 B
, I
5 I
- I
di I
- I
tert I
- I
butylhydroquinone I
( O
BHQ B
) O
inhibited O
carvacrol B
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
. O

Conversely O
, O
incubation O
with O
carvacrol B
inhibited O
TG O
or O
BHQ B
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
. O

Inhibition O
of O
phospholipase O
C O
( O
PLC O
) O
with O
U73122 B
abolished O
carvacrol B
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
. O

Carvacrol B
decreased O
cell O
viability O
, O
which O
was O
not O
reversed O
when O
cytosolic O
Ca B
( I
2 I
+ I
) I
was O
chelated O
with O
BAPTA B
- I
AM I
( O
1 B
, I
2 I
- I
bis I
( I
2 I
- I
aminophenoxy I
) I
ethane I
- I
N I
, I
N I
, I
N I
' I
, I
N I
' I
- I
tetraacetic I
acid I
- I
acetoxymethyl I
ester I
) O
. O

Together O
, O
carvacrol B
induced O
a O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
by O
inducing O
PLC O
- O
dependent O
Ca B
( I
2 I
+ I
) I
release O
from O
the O
endoplasmic O
reticulum O
and O
Ca B
( I
2 I
+ I
) I
entry O
via O
PKC O
- O
sensitive O
, O
non O
store O
- O
operated O
Ca B
( I
2 I
+ I
) I
channels O
. O

Together O
, O
carvacrol B
induced O
a O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
by O
inducing O
PLC O
- O
dependent O
Ca B
( I
2 I
+ I
) I
release O
from O
the O
endoplasmic O
reticulum O
and O
Ca B
( I
2 I
+ I
) I
entry O
via O
PKC O
- O
sensitive O
, O
non O
store O
- O
operated O
Ca B
( I
2 I
+ I
) I
channels O
. O

Together O
, O
carvacrol B
induced O
a O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
by O
inducing O
PLC O
- O
dependent O
Ca B
( I
2 I
+ I
) I
release O
from O
the O
endoplasmic O
reticulum O
and O
Ca B
( I
2 I
+ I
) I
entry O
via O
PKC O
- O
sensitive O
, O
non O
store O
- O
operated O
Ca B
( I
2 I
+ I
) I
channels O
. O

Together O
, O
carvacrol B
induced O
a O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
by O
inducing O
PLC O
- O
dependent O
Ca B
( I
2 I
+ I
) I
release O
from O
the O
endoplasmic O
reticulum O
and O
Ca B
( I
2 I
+ I
) I
entry O
via O
PKC O
- O
sensitive O
, O
non O
store O
- O
operated O
Ca B
( I
2 I
+ I
) I
channels O
. O

Anti O
- O
proliferative O
effect O
of O
( B
19Z I
) I
- I
halichondramide I
, O
a O
novel O
marine O
macrolide O
isolated O
from O
the O
sponge O
Chondrosia O
corticata O
, O
is O
associated O
with O
G2 O
/ O
M O
cell O
cycle O
arrest O
and O
suppression O
of O
mTOR O
signaling O
in O
human O
lung O
cancer O
cells O
. O

( B
19Z I
) I
- I
Halichondramide I
( O
( B
19Z I
) I
- I
HCA I
) O
, O
a O
novel O
trisoxazole B
- O
containing O
macrolide O
, O
exhibited O
the O
highest O
potency O
among O
the O
macrolides O
, O
with O
IC50 O
values O
in O
the O
submicro O
- O
molar O
ranges O
. O

( B
19Z I
) I
- I
Halichondramide I
( O
( B
19Z I
) I
- I
HCA I
) O
, O
a O
novel O
trisoxazole B
- O
containing O
macrolide O
, O
exhibited O
the O
highest O
potency O
among O
the O
macrolides O
, O
with O
IC50 O
values O
in O
the O
submicro O
- O
molar O
ranges O
. O

Prompted O
by O
the O
high O
potency O
of O
growth O
inhibition O
of O
cancer O
cells O
, O
we O
investigated O
the O
mechanism O
of O
action O
of O
the O
anti O
- O
proliferative O
activity O
of O
( B
19Z I
) I
- I
HCA I
in O
human O
A549 O
lung O
cancer O
cells O
. O

( B
19Z I
) I
- I
HCA I
induced O
cell O
cycle O
arrest O
in O
the O
G2 O
/ O
M O
phase O
, O
and O
this O
event O
was O
highly O
correlated O
with O
the O
expression O
of O
checkpoint O
proteins O
, O
including O
the O
up O
- O
regulation O
of O
p53 O
and O
GADD45 O
alpha O
and O
the O
down O
- O
regulation O
of O
cyclin O
B1 O
, O
cyclin O
A O
, O
CDC2 O
, O
and O
CDC25C O
. O

In O
addition O
, O
the O
growth O
inhibition O
by O
( B
19Z I
) I
- I
HCA I
was O
associated O
with O
the O
suppression O
of O
mTOR O
and O
its O
downstream O
effector O
molecules O
4EBP1 O
and O
p70S6K O
. O

The O
modulation O
of O
mTOR O
signaling O
by O
( B
19Z I
) I
- I
HCA I
was O
found O
to O
be O
mediated O
by O
the O
regulation O
of O
upstream O
proteins O
, O
including O
the O
down O
- O
regulation O
of O
Akt O
and O
p38 O
MAPK O
and O
the O
up O
- O
regulation O
of O
AMPK O
. O

These O
data O
suggest O
the O
potential O
of O
( B
19Z I
) I
- I
HCA I
to O
serve O
as O
a O
candidate O
for O
cancer O
chemotherapeutic O
agents O
derived O
from O
marine O
organisms O
by O
virtue O
of O
arresting O
the O
cell O
cycle O
in O
the O
G2 O
/ O
M O
phase O
and O
the O
modulation O
of O
mTOR O
/ O
AMPK O
signaling O
pathways O
. O

Metabolically O
competent O
human O
skin O
models O
: O
activation O
and O
genotoxicity O
of O
benzo B
[ I
a I
] I
pyrene I
. O

The O
polycyclic B
aromatic I
hydrocarbon I
( O
PAH B
) O
benzo B
[ I
a I
] I
pyrene I
( O
BP O
) O
is O
metabolized O
into O
a O
complex O
pattern O
of O
BP O
derivatives O
, O
among O
which O
the O
ultimate O
carcinogen O
( B
+ I
) I
- I
anti I
- I
BP I
- I
7 I
, I
8 I
- I
diol I
- I
9 I
, I
10 I
- I
epoxide I
( O
BPDE B
) O
is O
formed O
to O
certain O
extents O
. O

Retinal O
drug O
delivery O
using O
eyedrop O
preparations O
of O
poly B
- I
L I
- I
lysine I
- O
modified O
liposomes O
. O

Various O
molecular O
weights O
and O
concentrations O
of O
the O
water O
- O
soluble O
cationic O
polymer O
poly B
- I
L I
- I
lysine I
( O
PLL B
) O
were O
used O
to O
modify O
the O
surface O
of O
submicronized O
( O
100 O
nm O
) O
liposomes O
. O

Pre O
- O
training O
peripheral O
injections O
of O
methyllycaconitine B
( O
MLA B
) O
or O
dihydro B
- I
beta I
- I
erythroidine I
( O
DH B
beta I
E I
) O
, O
which O
are O
specific O
alpha O
7 O
and O
alpha O
4 O
beta O
2 O
nicotinic O
receptor O
antagonists O
, O
respectively O
, O
dose O
- O
dependently O
impaired O
retention O
latencies O
in O
an O
inhibitory O
avoidance O
task O
when O
tested O
7 O
- O
days O
but O
not O
1 O
h O
after O
training O
. O

Using O
an O
exemplar O
poly B
( I
ethylene I
glycol I
) I
- O
based O
resin O
, O
the O
control O
of O
features O
in O
the O
X O
, O
Y O
, O
and O
Z O
planes O
is O
demonstrated O
such O
that O
complex O
structures O
can O
be O
manufactured O
. O

8 B
, I
8 I
- I
dialkyldihydroberber I
with O
potent O
antiprotozoal O
activity O
. O

Semisynthetic O
8 B
, I
8 I
- I
dialkyldihydroberber I
( O
8 B
, I
8 I
- I
DDBs I
) O
were O
found O
to O
possess O
mid O
- O
to O
low O
- O
nanomolar O
potency O
against O
Plasmodium O
falciparum O
blood O
- O
stage O
parasites O
, O
Leishmania O
donovani O
intracellular O
amastigotes O
, O
and O
Trypanosoma O
brucei O
brucei O
bloodstream O
forms O
. O

Semisynthetic O
8 B
, I
8 I
- I
dialkyldihydroberber I
( O
8 B
, I
8 I
- I
DDBs I
) O
were O
found O
to O
possess O
mid O
- O
to O
low O
- O
nanomolar O
potency O
against O
Plasmodium O
falciparum O
blood O
- O
stage O
parasites O
, O
Leishmania O
donovani O
intracellular O
amastigotes O
, O
and O
Trypanosoma O
brucei O
brucei O
bloodstream O
forms O
. O

In O
turn O
, O
two O
8 B
, I
8 I
- I
dialkylcanadines I
, O
obtained O
by O
reduction O
of O
the O
corresponding O
8 B
, I
8 I
- I
DDBs I
, O
were O
much O
less O
potent O
against O
these O
parasites O
in O
vitro O
. O

In O
turn O
, O
two O
8 B
, I
8 I
- I
dialkylcanadines I
, O
obtained O
by O
reduction O
of O
the O
corresponding O
8 B
, I
8 I
- I
DDBs I
, O
were O
much O
less O
potent O
against O
these O
parasites O
in O
vitro O
. O

While O
the O
natural O
product O
berberine O
is O
a O
weak O
DNA O
binder O
, O
the O
8 B
, I
8 I
- I
DDBs I
displayed O
no O
affinity O
for O
DNA O
, O
as O
assessed O
by O
changes O
in O
the O
melting O
temperature O
of O
poly B
( I
dA I
. I
dT I
) I
DNA O
. O

Selected O
8 B
, I
8 I
- I
DDBs I
showed O
efficacy O
in O
mouse O
models O
of O
visceral O
leishmaniasis O
and O
African O
trypanosomiasis O
, O
with O
8 B
, I
8 I
- I
dimethyldihydroberbe I
chloride I
( O
5a O
) O
reducing O
liver O
parasitemia O
by O
46 O
% O
in O
L O
. O
donovani O
- O
infected O
BALB O
/ O
c O
mice O
when O
given O
at O
an O
intraperitoneal O
dose O
of O
10 O
mg O
/ O
kg O
/ O
day O
for O
five O
days O
. O

Further O
, O
5 O
- O
HT1A O
autoreceptor O
desensitization O
was O
evidenced O
by O
electrophysiological O
studies O
, O
GTP B
- I
gamma I
- I
S I
coupling O
to O
5 O
- O
HT1A O
autoreceptor O
and O
a O
lower O
hypothermic O
response O
to O
5 O
- O
HT1A O
activation O
. O

Metabolism O
and O
pharmacokinetics O
of O
3 B
- I
n I
- I
butylphthalide I
( O
NBP B
) O
in O
humans O
: O
the O
role O
of O
cytochrome O
P450s O
and O
alcohol B
dehydrogenase O
in O
biotransformation O
. O

3 B
- I
n I
- I
Butylphthalide I
( O
NBP B
) O
is O
a O
cardiovascular O
drug O
currently O
used O
for O
the O
treatment O
of O
cerebral O
ischemia O
. O

10 B
- I
Keto I
- I
NBP I
( O
M2 O
) O
, O
3 B
- I
hydroxy I
- I
NBP I
( O
M3 O
- O
1 O
) O
, O
10 B
- I
hydroxy I
- I
NBP I
( O
M3 O
- O
2 O
) O
, O
and O
M5 O
- O
2 O
were O
the O
major O
circulating O
metabolites O
, O
wherein O
the O
areas O
under O
the O
curve O
values O
were O
1 O
. O
6 O
- O
, O
2 O
. O
9 O
- O
, O
10 O
. O
3 O
- O
, O
and O
4 O
. O
1 O
- O
fold O
higher O
than O
that O
of O
NBP B
. O

10 B
- I
Keto I
- I
NBP I
( O
M2 O
) O
, O
3 B
- I
hydroxy I
- I
NBP I
( O
M3 O
- O
1 O
) O
, O
10 B
- I
hydroxy I
- I
NBP I
( O
M3 O
- O
2 O
) O
, O
and O
M5 O
- O
2 O
were O
the O
major O
circulating O
metabolites O
, O
wherein O
the O
areas O
under O
the O
curve O
values O
were O
1 O
. O
6 O
- O
, O
2 O
. O
9 O
- O
, O
10 O
. O
3 O
- O
, O
and O
4 O
. O
1 O
- O
fold O
higher O
than O
that O
of O
NBP B
. O

10 B
- I
Keto I
- I
NBP I
( O
M2 O
) O
, O
3 B
- I
hydroxy I
- I
NBP I
( O
M3 O
- O
1 O
) O
, O
10 B
- I
hydroxy I
- I
NBP I
( O
M3 O
- O
2 O
) O
, O
and O
M5 O
- O
2 O
were O
the O
major O
circulating O
metabolites O
, O
wherein O
the O
areas O
under O
the O
curve O
values O
were O
1 O
. O
6 O
- O
, O
2 O
. O
9 O
- O
, O
10 O
. O
3 O
- O
, O
and O
4 O
. O
1 O
- O
fold O
higher O
than O
that O
of O
NBP B
. O

In O
vitro O
phenotyping O
studies O
demonstrated O
that O
multiple O
cytochrome O
P450 O
( O
P450 O
) O
isoforms O
, O
especially O
CYP3A4 O
, O
2E1 O
, O
and O
1A2 O
, O
were O
involved O
in O
the O
formation O
of O
M3 O
- O
1 O
, O
M3 O
- O
2 O
, O
and O
11 B
- I
hydroxy I
- I
NBP I
. O

Using O
M3 O
- O
2 O
and O
11 B
- I
hydroxy I
- I
NBP I
as O
substrates O
, O
human O
subcellular O
fractions O
experiments O
revealed O
that O
P450 O
, O
alcohol B
dehydrogenase O
, O
and O
aldehyde B
dehydrogenase O
catalyzed O
the O
generation O
of O
M2 O
and O
M5 O
- O
2 O
. O

Furthermore O
, O
the O
level O
of O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
was O
determined O
in O
LPS O
- O
induced O
RAW264 O
. O
7 O
macrophages O
. O

( I
3 I
) I
O I
( I
4 I
) I
( O
110 O
) O
- O
B O
( O
0 O
. O
41 O
eV O
) O
, O
that O
is O
, O
the O
( O
110 O
) O
surface O
shows O
higher O
reactivity O
for O
CO B
oxidation O
than O
the O
( O
111 O
) O
surface O
; O
5 O
) O
in O
addition O
to O
the O
O B
( O
2f O
) O
, O
it O
was O
also O
found O
that O
Co B
( I
3 I
+ I
) I
is O
more O
active O
than O
Co B
( I
2 I
+ I
) I
, O
so O
both O
O B
( O
2f O
) O
and O
Co B
( I
3 I
+ I
) I
control O
the O
catalytic O
activity O
of O
CO B
oxidation O
on O
Co B
( I
3 I
) I
O I
( I
4 I
) I
, O
as O
opposed O
to O
a O
previous O
DFT O
study O
which O
concluded O
that O
either O
Co B
( I
3 I
+ I
) I
or O
O B
( O

( I
3 I
) I
O I
( I
4 I
) I
( O
110 O
) O
- O
B O
( O
0 O
. O
41 O
eV O
) O
, O
that O
is O
, O
the O
( O
110 O
) O
surface O
shows O
higher O
reactivity O
for O
CO B
oxidation O
than O
the O
( O
111 O
) O
surface O
; O
5 O
) O
in O
addition O
to O
the O
O B
( O
2f O
) O
, O
it O
was O
also O
found O
that O
Co B
( I
3 I
+ I
) I
is O
more O
active O
than O
Co B
( I
2 I
+ I
) I
, O
so O
both O
O B
( O
2f O
) O
and O
Co B
( I
3 I
+ I
) I
control O
the O
catalytic O
activity O
of O
CO B
oxidation O
on O
Co B
( I
3 I
) I
O I
( I
4 I
) I
, O
as O
opposed O
to O
a O
previous O
DFT O
study O
which O
concluded O
that O
either O
Co B
( I
3 I
+ I
) I
or O
O B
( O

( I
3 I
) I
O I
( I
4 I
) I
( O
110 O
) O
- O
B O
( O
0 O
. O
41 O
eV O
) O
, O
that O
is O
, O
the O
( O
110 O
) O
surface O
shows O
higher O
reactivity O
for O
CO B
oxidation O
than O
the O
( O
111 O
) O
surface O
; O
5 O
) O
in O
addition O
to O
the O
O B
( O
2f O
) O
, O
it O
was O
also O
found O
that O
Co B
( I
3 I
+ I
) I
is O
more O
active O
than O
Co B
( I
2 I
+ I
) I
, O
so O
both O
O B
( O
2f O
) O
and O
Co B
( I
3 I
+ I
) I
control O
the O
catalytic O
activity O
of O
CO B
oxidation O
on O
Co B
( I
3 I
) I
O I
( I
4 I
) I
, O
as O
opposed O
to O
a O
previous O
DFT O
study O
which O
concluded O
that O
either O
Co B
( I
3 I
+ I
) I
or O
O B
( O

( I
3 I
) I
O I
( I
4 I
) I
( O
110 O
) O
- O
B O
( O
0 O
. O
41 O
eV O
) O
, O
that O
is O
, O
the O
( O
110 O
) O
surface O
shows O
higher O
reactivity O
for O
CO B
oxidation O
than O
the O
( O
111 O
) O
surface O
; O
5 O
) O
in O
addition O
to O
the O
O B
( O
2f O
) O
, O
it O
was O
also O
found O
that O
Co B
( I
3 I
+ I
) I
is O
more O
active O
than O
Co B
( I
2 I
+ I
) I
, O
so O
both O
O B
( O
2f O
) O
and O
Co B
( I
3 I
+ I
) I
control O
the O
catalytic O
activity O
of O
CO B
oxidation O
on O
Co B
( I
3 I
) I
O I
( I
4 I
) I
, O
as O
opposed O
to O
a O
previous O
DFT O
study O
which O
concluded O
that O
either O
Co B
( I
3 I
+ I
) I
or O
O B
( O

The O
microsomal O
enzyme O
17 B
beta I
- I
hydroxysteroid I
dehydrogenase O
3 O
faces O
the O
cytoplasm O
and O
uses O
NADPH B
generated O
by O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase O
. O

To O
test O
this O
hypothesis O
, O
we O
used O
human O
embryonic O
kidney O
- O
293 O
cells O
transfected O
with O
17 O
beta O
- O
HSD3 O
and O
/ O
or O
11 O
beta O
- O
HSD1 O
, O
in O
the O
absence O
or O
presence O
of O
hexose B
- I
6 I
- I
phosphate I
dehydrogenase O
that O
generates O
reduced O
nicotinamide B
adenine I
dinucleotide I
phosphate I
( O
NADPH B
) O
in O
the O
endoplasmic O
reticulum O
and O
determined O
enzyme O
activities O
. O

17 O
beta O
- O
HSD3 O
- O
dependent O
reduction O
of O
Delta B
4 I
- I
androstene I
- I
3 I
, I
17 I
- I
dione I
was O
affected O
by O
neither O
coexpression O
with O
11 O
beta O
- O
HSD1 O
nor O
overexpression O
or O
knockdown O
of O
hexose B
- I
6 I
- I
phosphate I
dehydrogenase O
. O

In O
contrast O
, O
knockdown O
of O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase O
decreased O
17 O
beta O
- O
HSD3 O
activity O
, O
indicating O
dependence O
on O
cytoplasmic O
NADPH B
. O

In O
conclusion O
, O
the O
results O
demonstrate O
a O
cytoplasmic O
orientation O
of O
17 O
beta O
- O
HSD3 O
and O
dependence O
on O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase O
- O
generated O
NADPH B
, O
explaining O
the O
lack O
of O
a O
direct O
functional O
coupling O
with O
the O
luminal O
11 O
beta O
- O
HSD1 O
- O
mediated O
glucocorticoid O
metabolism O
. O

Annotation O
clustering O
revealed O
enrichment O
of O
genes O
related O
to O
vesicular O
transport O
, O
dopamine B
metabolism O
, O
synapse O
function O
, O
Ca B
( I
2 I
+ I
) I
metabolism O
and O
oxidative O
stress O
. O

Disturbance O
of O
dopamine O
function O
and O
of O
Ca B
( I
2 I
+ I
) I
metabolism O
can O
explain O
abnormal O
movement O
; O
loss O
of O
protection O
against O
reactive O
oxygen B
species O
may O
account O
for O
the O
neurodegenerative O
changes O
in O
XDP O
. O

We O
have O
demonstrated O
that O
the O
activation O
of O
P2X3 O
receptor O
on O
peripheral O
afferent O
neurons O
is O
critical O
to O
development O
of O
inflammatory O
hyperalgesia O
in O
peripheral O
tissue O
, O
although O
pharmacological O
administration O
of O
prostaglandin B
E I
( I
2 I
) I
or O
sympathomimetic O
amines B
is O
enough O
to O
sensitize O
primary O
afferent O
neurons O
by O
acting O
directly O
in O
neuronal O
receptors O
. O

Therefore O
, O
to O
clarify O
this O
ambiguity O
this O
study O
verifies O
whether O
P2X3 O
receptor O
activation O
on O
primary O
afferent O
neurons O
enables O
the O
sensitization O
induced O
by O
prostaglandin B
E I
( I
2 I
) I
or O
sympathomimetic O
amine B
. O

It O
catalyzes O
the O
hydration O
of O
carbon B
dioxide I
( O
CO B
( I
2 I
) I
) O
to O
bicarbonate B
( O
HCO B
( I
3 I
) I
- I
) O
and O
the O
corresponding O
dehydration O
of O
HCO B
( I
3 I
) I
- I
in O
acidic O
medium O
with O
regeneration O
of O
CO B
( I
2 I
) I
. O

It O
catalyzes O
the O
hydration O
of O
carbon B
dioxide I
( O
CO B
( I
2 I
) I
) O
to O
bicarbonate B
( O
HCO B
( I
3 I
) I
- I
) O
and O
the O
corresponding O
dehydration O
of O
HCO B
( I
3 I
) I
- I
in O
acidic O
medium O
with O
regeneration O
of O
CO B
( I
2 I
) I
. O

Novel O
block O
copolymers O
comprising O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
and O
an O
oligo B
( I
tyrosine I
) I
block O
were O
synthesized O
in O
different O
compositions O
by O
N B
- I
carboxyanhydride I
( O
NCA B
) O
polymerization O
. O

The O
4 O
- O
desmethylated O
metabolite O
, O
2 B
, I
4 I
- I
dihydroxybenzophenon I
( O
2 B
, I
4 I
- I
diOH I
- I
BP I
) O
, O
previously O
reported O
as O
the O
major O
in O
vivo O
metabolite O
of O
BP B
- I
3 I
, O
was O
also O
detected O
. O

The O
ability O
of O
chiral B
beta I
- I
amino I
alcohols I
to O
catalyze O
the O
direct O
asymmetric O
aldol B
reaction O
was O
evaluated O
for O
the O
first O
time O
in O
aqueous O
micellar O
media O
. O

Water O
- O
soluble O
star O
- O
like O
poly B
( I
vinyl I
alcohol I
) I
/ O
C B
( I
60 I
) I
and O
poly B
{ I
[ I
poly I
( I
ethylene I
glycol I
) I
acrylate I
] I
- I
co I
- I
( I
vinyl I
acetate I
) I
} I
/ O
C B
( I
60 I
) I
nanohybrids O
are O
prepared O
by O
grafting O
macroradicals O
onto O
C B
( I
60 I
) I
and O
are O
assessed O
as O
photosensitizers O
for O
photodynamic O
therapy O
. O

Dose O
- O
response O
re O
- O
determinations O
during O
chronic O
treatment O
revealed O
the O
following O
: O
1 O
) O
> O
250 O
- O
fold O
( O
AM411 B
, O
methanandamide B
) O
and O
> O
45 O
- O
fold O
( O
AM4054 B
, O
WIN55 B
, I
212 I
. I
2 I
, O
Delta B
( I
9 I
) I
- I
THC I
) O
rightward O
shifts O
in O
the O
ED O
( O
50 O
) O
values O
for O
CB O
( O
1 O
) O
agonists O
; O
2 O
) O
> O
100 O
- O
fold O
and O
> O
20 O
- O
fold O
leftward O
shifts O
in O
the O
ED O
( O
50 O
) O
values O
for O
SR141716A B
and O
AM4113 B
, O
respectively O
; O
and O
3 O
) O
approximately O
4 O
. O
8 O
- O
fold O
and O
10 O
- O

Both O
dihydropyridazinone B
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4 B
, I
4 I
- I
dimethylpyrazolone I
subunits O
and O
the O
core O
pyrazolopyridine B
by O
isosteric O
bicyclic O
heteroaromatics O
. O

The O
self O
- O
assembling O
co O
- O
polymer O
stearoyl B
- I
PEG I
- I
poly I
- I
sulfadimethoxine I
methacrylate I
( O
stearoyl B
- I
PEG I
- I
polySDM I
) O
was O
prepared O
to O
obtain O
micelles O
with O
responsive O
behaviour O
in O
the O
physiopathologic O
pH O
range O
. O

Stearoyl B
- I
PEG I
- I
polySDM I
was O
synthesised O
using O
a O
multi O
- O
step O
procedure O
that O
includes O
pH O
- O
sensitive O
sulfadimethoxine B
methacrylate I
polymerisation O
by O
AGET O
- O
ATRP O
at O
the O
amino B
terminal O
side O
of O
stearoyl B
- I
PEG I
- I
NH2 I
. O

Stearoyl B
- I
PEG I
- I
polySDM I
was O
synthesised O
using O
a O
multi O
- O
step O
procedure O
that O
includes O
pH O
- O
sensitive O
sulfadimethoxine B
methacrylate I
polymerisation O
by O
AGET O
- O
ATRP O
at O
the O
amino B
terminal O
side O
of O
stearoyl B
- I
PEG I
- I
NH2 I
. O

Chemical O
analysis O
showed O
that O
the O
stearoyl B
- I
PEG I
- I
polySDM I
co O
- O
polymer O
contained O
a O
mean O
of O
seven O
methacryloyl B
sulfadimethoxines I
per O
molecule O
. O

Potentiometric O
and O
turbidimetric O
analyses O
showed O
that O
stearoyl B
- I
PEG I
- I
polySDM I
has O
an O
apparent O
pKa O
of O
7 O
. O
2 O
and O
a O
cloud O
point O
at O
pH O
7 O
. O
0 O
. O

Fluorescence O
spectroscopic O
and O
cytofluorimetric O
studies O
showed O
that O
the O
incubation O
of O
MCF O
- O
7 O
tumour O
cells O
with O
fluorescein B
- O
labelled O
stearoyl B
- I
PEG I
- I
polySDM I
at O
pH O
6 O
. O
5 O
resulted O
in O
massive O
time O
- O
dependent O
cell O
association O
, O
while O
the O
incubation O
at O
pH O
7 O
. O
4 O
showed O
significantly O
lower O
cell O
interaction O
. O

Confocal O
microscopy O
confirmed O
that O
at O
pH O
6 O
. O
5 O
, O
the O
micelles O
are O
taken O
up O
by O
cells O
and O
that O
the O
fluorescein B
- O
labelled O
stearoyl B
- I
PEG I
- I
polySDM I
is O
distributed O
into O
the O
cytosol O
. O

At O
pH O
6 O
. O
5 O
, O
paclitaxel B
- O
loaded O
stearoyl B
- I
PEG I
- I
polySDM I
micelles O
had O
a O
higher O
cytotoxic O
effect O
than O
the O
micelles O
incubated O
at O
pH O
7 O
. O
4 O
. O

The O
method O
resulted O
linear O
response O
in O
a O
range O
concentration O
between O
50 O
and O
800 O
mu O
M O
with O
a O
detection O
and O
quantification O
limit O
between O
0 O
. O
6 O
and O
2 O
mu O
M O
for O
the O
( B
+ I
) I
- I
fenamiphos I
, O
and O
between O
0 O
. O
7 O
and O
2 O
. O
3 O
mu O
M O
for O
the O
( B
- I
) I
- I
fenamiphos I
. O

The O
method O
resulted O
linear O
response O
in O
a O
range O
concentration O
between O
50 O
and O
800 O
mu O
M O
with O
a O
detection O
and O
quantification O
limit O
between O
0 O
. O
6 O
and O
2 O
mu O
M O
for O
the O
( B
+ I
) I
- I
fenamiphos I
, O
and O
between O
0 O
. O
7 O
and O
2 O
. O
3 O
mu O
M O
for O
the O
( B
- I
) I
- I
fenamiphos I
. O

The O
levels O
of O
the O
Ca B
( I
2 I
+ I
) I
- O
dependent O
hydrolysis O
( O
residual O
concentration O
[ O
mu O
M O
] O
) O
quantified O
during O
30min O
of O
reaction O
were O
only O
just O
4 O
- O
14 O
% O
for O
both O
fenamiphos B
enantiomers O
with O
the O
three O
alloforms O
of O
PON1 O
Q192R O
of O
the O
two O
groups O
of O
serum O
studied O
. O

A O
new O
vitamin B
B I
( I
12 I
) I
- O
GLP O
- O
1 O
conjugate O
is O
investigated O
and O
shown O
to O
have O
insulinotropic O
properties O
similar O
to O
the O
unmodified O
peptide O
. O

These O
results O
are O
critical O
to O
the O
exploitation O
of O
the O
vitamin B
B I
( I
12 I
) I
oral O
uptake O
pathway O
for O
peptide O
delivery O
. O

PEP O
- O
19 O
is O
a O
small O
, O
intrinsically O
disordered O
protein O
that O
binds O
to O
the O
C O
- O
domain O
of O
calmodulin O
( O
CaM O
) O
via O
an O
IQ O
motif O
and O
tunes O
its O
Ca B
( I
2 I
+ I
) I
binding O
properties O
via O
an O
acidic O
sequence O
. O

We O
show O
here O
that O
the O
acidic O
sequence O
of O
PEP O
- O
19 O
has O
intrinsic O
Ca B
( I
2 I
+ I
) I
binding O
activity O
, O
which O
may O
modulate O
Ca B
( I
2 I
+ I
) I
binding O
to O
CaM O
by O
stabilizing O
an O
initial O
Ca B
( I
2 I
+ I
) I
- O
CaM O
complex O
or O
by O
electrostatically O
steering O
Ca B
( I
2 I
+ I
) I
to O
and O
from O
CaM O
. O

We O
show O
here O
that O
the O
acidic O
sequence O
of O
PEP O
- O
19 O
has O
intrinsic O
Ca B
( I
2 I
+ I
) I
binding O
activity O
, O
which O
may O
modulate O
Ca B
( I
2 I
+ I
) I
binding O
to O
CaM O
by O
stabilizing O
an O
initial O
Ca B
( I
2 I
+ I
) I
- O
CaM O
complex O
or O
by O
electrostatically O
steering O
Ca B
( I
2 I
+ I
) I
to O
and O
from O
CaM O
. O

We O
show O
here O
that O
the O
acidic O
sequence O
of O
PEP O
- O
19 O
has O
intrinsic O
Ca B
( I
2 I
+ I
) I
binding O
activity O
, O
which O
may O
modulate O
Ca B
( I
2 I
+ I
) I
binding O
to O
CaM O
by O
stabilizing O
an O
initial O
Ca B
( I
2 I
+ I
) I
- O
CaM O
complex O
or O
by O
electrostatically O
steering O
Ca B
( I
2 I
+ I
) I
to O
and O
from O
CaM O
. O

We O
show O
here O
that O
the O
acidic O
sequence O
of O
PEP O
- O
19 O
has O
intrinsic O
Ca B
( I
2 I
+ I
) I
binding O
activity O
, O
which O
may O
modulate O
Ca B
( I
2 I
+ I
) I
binding O
to O
CaM O
by O
stabilizing O
an O
initial O
Ca B
( I
2 I
+ I
) I
- O
CaM O
complex O
or O
by O
electrostatically O
steering O
Ca B
( I
2 I
+ I
) I
to O
and O
from O
CaM O
. O

Because O
PEP O
- O
19 O
is O
expressed O
in O
cells O
that O
exhibit O
highly O
active O
Ca B
( I
2 I
+ I
) I
dynamics O
, O
we O
tested O
the O
hypothesis O
that O
it O
influences O
ligand O
- O
dependent O
Ca B
( I
2 I
+ I
) I
release O
. O

Because O
PEP O
- O
19 O
is O
expressed O
in O
cells O
that O
exhibit O
highly O
active O
Ca B
( I
2 I
+ I
) I
dynamics O
, O
we O
tested O
the O
hypothesis O
that O
it O
influences O
ligand O
- O
dependent O
Ca B
( I
2 I
+ I
) I
release O
. O

We O
show O
that O
PEP O
- O
19 O
increases O
the O
sensitivity O
of O
HeLa O
cells O
to O
ATP B
- O
induced O
Ca B
( I
2 I
+ I
) I
release O
to O
greatly O
increase O
the O
percentage O
of O
cells O
responding O
to O
sub O
- O
saturating O
doses O
of O
ATP B
and O
increases O
the O
frequency O
of O
Ca B
( I
2 I
+ I
) I
oscillations O
. O

We O
show O
that O
PEP O
- O
19 O
increases O
the O
sensitivity O
of O
HeLa O
cells O
to O
ATP B
- O
induced O
Ca B
( I
2 I
+ I
) I
release O
to O
greatly O
increase O
the O
percentage O
of O
cells O
responding O
to O
sub O
- O
saturating O
doses O
of O
ATP B
and O
increases O
the O
frequency O
of O
Ca B
( I
2 I
+ I
) I
oscillations O
. O

Mutations O
in O
the O
acidic O
sequence O
of O
PEP O
- O
19 O
that O
inhibit O
or O
prevent O
it O
from O
modulating O
Ca B
( I
2 I
+ I
) I
binding O
to O
CaM O
greatly O
inhibit O
its O
effect O
on O
ATP B
- O
induced O
Ca B
( I
2 I
+ I
) I
release O
. O

Mutations O
in O
the O
acidic O
sequence O
of O
PEP O
- O
19 O
that O
inhibit O
or O
prevent O
it O
from O
modulating O
Ca B
( I
2 I
+ I
) I
binding O
to O
CaM O
greatly O
inhibit O
its O
effect O
on O
ATP B
- O
induced O
Ca B
( I
2 I
+ I
) I
release O
. O

Tuning O
the O
activities O
of O
Ca B
( I
2 I
+ I
) I
mobilization O
pathways O
places O
PEP O
- O
19 O
at O
the O
top O
of O
CaM O
signaling O
cascades O
, O
with O
great O
potential O
to O
exert O
broad O
effects O
on O
downstream O
CaM O
targets O
, O
thus O
expanding O
the O
biological O
significance O
of O
this O
small O
regulator O
of O
CaM O
signaling O
. O

We O
describe O
an O
in O
- O
depth O
investigation O
on O
the O
dynamics O
and O
assembly O
behavior O
at O
polar O
- O
apolar O
interfaces O
of O
ferritin O
- O
PNIPAAm B
conjugates O
( O
poly B
- I
N I
- I
isopropylacrylamide I
) O
. O

This O
smart O
fluid O
is O
an O
aqueous O
solution O
of O
cationic O
surfactant O
oleyl B
bis I
( I
2 I
- I
hydroxyethyl I
) I
methyl I
ammonium I
chloride I
( O
OHAC B
, O
3 O
. O
4 O
mM O
) O
and O
the O
sodium B
salt O
of O
4 B
- I
phenylazo I
benzoic I
acid I
( O
ACA B
, O
2 O
mM O
) O
. O

The O
high O
- O
efficacy O
agonist O
R B
( I
- I
) I
- I
norpropylapomorphine I
[ O
( B
- I
) I
- I
NPA I
] O
, O
low O
- O
efficacy O
agonist O
aripiprazole B
( O
ARI B
) O
, O
and O
antagonist O
eticlopride B
( O
ETIC B
) O
were O
administered O
acutely O
to O
monkeys O
self O
- O
administering O
cocaine B
under O
a O
food O
- O
cocaine B
choice O
procedure O
in O
which O
a O
cocaine B
self O
- O
administration O
dose O
- O
effect O
curve O
was O
determined O
daily O
. O

The O
effects O
of O
5 O
- O
day O
treatment O
with O
ARI O
and O
( B
- I
) I
- I
NPA I
were O
characterized O
under O
conditions O
in O
which O
monkeys O
did O
( O
ARI B
) O
or O
did O
not O
[ O
ARI B
and O
( B
- I
) I
- I
NPA I
] O
self O
- O
administer O
cocaine B
during O
treatment O
. O

The O
effects O
of O
5 O
- O
day O
treatment O
with O
ARI O
and O
( B
- I
) I
- I
NPA I
were O
characterized O
under O
conditions O
in O
which O
monkeys O
did O
( O
ARI B
) O
or O
did O
not O
[ O
ARI B
and O
( B
- I
) I
- I
NPA I
] O
self O
- O
administer O
cocaine B
during O
treatment O
. O

When O
administered O
acutely O
, O
ARI B
and O
ETIC B
increased O
the O
choice O
of O
low O
cocaine B
doses O
, O
and O
only O
( B
- I
) I
- I
NPA I
decreased O
the O
choice O
of O
higher O
cocaine B
doses O
and O
cocaine B
intake O
; O
effects O
were O
similar O
across O
social O
ranks O
. O

When O
administered O
repeatedly O
while O
self O
administration O
occurred O
only O
on O
days O
1 O
and O
5 O
of O
treatment O
, O
ARI B
, O
but O
not O
( B
- I
) I
- I
NPA I
, O
decreased O
cocaine B
choice O
in O
dominant O
monkeys O
, O
whereas O
( B
- I
) I
- I
NPA I
, O
but O
not O
ARI B
, O
did O
so O
in O
subordinates O
. O

When O
administered O
repeatedly O
while O
self O
administration O
occurred O
only O
on O
days O
1 O
and O
5 O
of O
treatment O
, O
ARI B
, O
but O
not O
( B
- I
) I
- I
NPA I
, O
decreased O
cocaine B
choice O
in O
dominant O
monkeys O
, O
whereas O
( B
- I
) I
- I
NPA I
, O
but O
not O
ARI B
, O
did O
so O
in O
subordinates O
. O

In O
this O
paper O
, O
we O
focus O
on O
the O
multiple O
- O
channel O
reactions O
of O
CH B
( I
2 I
) I
XO I
( O
X O
= O
F B
, O
Cl B
, O
Br B
) O
radicals O
with O
the O
NO B
radical O
by O
means O
of O
direct O
dynamic O
methods O
. O

In O
addition O
, O
the O
red O
variety O
possessed O
higher O
antioxidant O
capacity O
as O
exemplified O
by O
the O
( B
* I
) I
OH I
scavenging O
abilities O
, O
Fe B
( I
2 I
+ I
) I
chelating O
ability O
, O
and O
inhibition O
of O
Fe B
( I
2 I
+ I
) I
- O
induced O
pancreatic O
lipid O
peroxidation O
in O
vitro O
. O

In O
addition O
, O
the O
red O
variety O
possessed O
higher O
antioxidant O
capacity O
as O
exemplified O
by O
the O
( B
* I
) I
OH I
scavenging O
abilities O
, O
Fe B
( I
2 I
+ I
) I
chelating O
ability O
, O
and O
inhibition O
of O
Fe B
( I
2 I
+ I
) I
- O
induced O
pancreatic O
lipid O
peroxidation O
in O
vitro O
. O

4 B
- I
tert I
- I
Octylphenol I
stimulates O
the O
expression O
of O
cathepsins O
in O
human O
breast O
cancer O
cells O
and O
xenografted O
breast O
tumors O
of O
a O
mouse O
model O
via O
an O
estrogen B
receptor O
- O
mediated O
signaling O
pathway O
. O

In O
this O
study O
, O
we O
examined O
the O
effect O
( O
s O
) O
of O
4 B
- I
tert I
- I
octylphenol I
( O
OP O
) O
, O
a O
potent O
EDC O
, O
on O
the O
expression O
of O
cathepsins O
B O
and O
D O
in O
human O
MCF O
- O
7 O
breast O
cancer O
cells O
and O
a O
xenograft O
mouse O
model O
. O

Antiviral O
activity O
of O
( B
+ I
) I
- I
sattabacin I
against O
varicella O
zoster O
. O

The O
first O
report O
of O
the O
antiviral O
activity O
of O
( B
+ I
) I
- I
sattabacin I
against O
varicella O
- O
zoster O
virus O
( O
VZV O
) O
is O
described O
. O

Our O
results O
show O
that O
( B
+ I
) I
- I
sattabacin I
potently O
inhibits O
the O
growth O
of O
VZV O
at O
concentrations O
in O
the O
range O
of O
other O
drugs O
commonly O
prescribed O
for O
VZV O
infection O
. O

Experiments O
detailing O
the O
synthesis O
of O
( B
+ I
) I
- I
sattabacin I
, O
quantification O
of O
cytotoxicity O
and O
gene O
expression O
data O
in O
human O
fibroblast O
cells O
are O
also O
presented O
. O

Gene O
expression O
data O
was O
obtained O
through O
microarray O
analysis O
from O
human O
fibroblast O
cells O
exposed O
to O
sattabacin B
in O
order O
to O
identify O
a O
possible O
mechanism O
by O
which O
( B
+ I
) I
- I
sattabacin I
inhibits O
VZV O
replication O
. O

Unlike O
previously O
reported O
6 B
- I
methyl I
- I
2 I
, I
4 I
- I
disubstituted I
pyridazin I
- I
3 I
( I
2H I
) I
- I
ones I
, O
whose O
R O
- O
forms O
preferentially O
activated O
FPR1 O
/ O
FPR2 O
, O
we O
found O
that O
four O
S O
- O
enantiomers O
in O
the O
seven O
ureidopropanamide B
pairs O
tested O
preferentially O
activated O
intracellular O
Ca B
( I
2 I
+ I
) I
flux O
in O
FPR2 O
- O
transfected O
cells O
, O
while O
the O
R O
- O
counterpart O
was O
more O
active O
in O
two O
enantiomer O
pairs O
. O

Single O
and O
repeated O
injections O
both O
demonstrated O
a O
statistically O
significant O
reduction O
in O
dyspareunia O
by O
VAS O
scores O
from O
54 O
to O
30 O
in O
the O
single O
injection O
group O
and O
from O
51 O
to O
23 O
in O
the O
multiple O
injection O
group O
( O
p O
= O
. O
001 O
) O
, O
non O
- O
menstrual O
pelvic O
pain O
VAS O
from O
37 O
to O
25 O
( O
p O
= O
. O
04 O
) O
, O
as O
well O
as O
vaginal O
pressures O
; O
40 O
versus O
34 O
cm O
H B
( I
2 I
) I
O I
( O
p O
= O
. O
02 O
) O
. O

Isoorientin B
( O
ISO B
) O
( O
CAS O
RN O
: O
4261 B
- I
42 I
- I
1 I
) O
is O
a O
flavonoid B
compound O
that O
can O
be O
extracted O
from O
several O
plant O
species O
, O
such O
as O
Phyllostachys O
pubescens O
, O
Patrinia O
, O
and O
Drosophyllum O
lusitanicum O
. O

Electrochemical O
analysis O
of O
bacterial O
cells O
exposed O
to O
Cu B
( I
2 I
+ I
) I
ions O
provides O
new O
insights O
into O
the O
mechanistic O
aspect O
of O
Cu B
( I
2 I
+ I
) I
ion O
reduction O
within O
the O
bacterial O
cell O
and O
indicates O
a O
strong O
link O
between O
the O
silver B
and O
copper B
resistance O
machinery O
of O
bacteria O
in O
the O
context O
of O
metal O
ion O
reduction O
. O

Electrochemical O
analysis O
of O
bacterial O
cells O
exposed O
to O
Cu B
( I
2 I
+ I
) I
ions O
provides O
new O
insights O
into O
the O
mechanistic O
aspect O
of O
Cu B
( I
2 I
+ I
) I
ion O
reduction O
within O
the O
bacterial O
cell O
and O
indicates O
a O
strong O
link O
between O
the O
silver B
and O
copper B
resistance O
machinery O
of O
bacteria O
in O
the O
context O
of O
metal O
ion O
reduction O
. O

2 B
- I
Phenoxy I
- I
nicotinamides I
are O
potent O
agonists O
at O
the O
bile B
acid I
receptor O
GPBAR1 O
( O
TGR5 O
) O
. O

Potency O
with O
potential O
: O
2 B
- I
Phenoxy I
- I
nicotinamides I
were O
identified O
as O
potent O
agonists O
at O
the O
GPBAR1 O
receptor O
, O
a O
target O
in O
the O
treatment O
of O
obesity O
, O
type O
2 O
diabetes O
and O
metabolic O
syndrome O
. O

It O
is O
noteworthy O
that O
the O
most O
active O
compounds O
described O
above O
possess O
the O
same O
terminal O
3 B
, I
5 I
- I
dinitrophenyl I
groups O
on O
their O
C O
- O
4 O
' O
' O
bisamide B
side O
chains O
. O

Ligand O
- O
exchange O
reactions O
of O
copper B
( I
I I
) I
precursors O
( O
[ B
Cu I
( I
CH I
( I
3 I
) I
CN I
) I
( I
4 I
) I
] I
BF I
( I
4 I
) I
, O
CuCl B
) O
with O
a O
panel O
of O
bis B
( I
azolyl I
) I
borates I
or O
poly B
( I
pyrazolyl I
) I
methanes I
and O
a O
tertiary B
monodentate I
phosphine I
( O
PTA B
= O
1 B
, I
3 I
, I
5 I
- I
triaza I
- I
7 I
- I
phosphaadamantane I
, O
PCN B
= O
tris B
( I
cyanoethyl I
) I
phosphine I
) O
produced O
two O
series O
of O
heteroleptic O
, O

Ligand O
- O
exchange O
reactions O
of O
copper B
( I
I I
) I
precursors O
( O
[ B
Cu I
( I
CH I
( I
3 I
) I
CN I
) I
( I
4 I
) I
] I
BF I
( I
4 I
) I
, O
CuCl B
) O
with O
a O
panel O
of O
bis B
( I
azolyl I
) I
borates I
or O
poly B
( I
pyrazolyl I
) I
methanes I
and O
a O
tertiary B
monodentate I
phosphine I
( O
PTA B
= O
1 B
, I
3 I
, I
5 I
- I
triaza I
- I
7 I
- I
phosphaadamantane I
, O
PCN B
= O
tris B
( I
cyanoethyl I
) I
phosphine I
) O
produced O
two O
series O
of O
heteroleptic O
, O

Ligand O
- O
exchange O
reactions O
of O
copper B
( I
I I
) I
precursors O
( O
[ B
Cu I
( I
CH I
( I
3 I
) I
CN I
) I
( I
4 I
) I
] I
BF I
( I
4 I
) I
, O
CuCl B
) O
with O
a O
panel O
of O
bis B
( I
azolyl I
) I
borates I
or O
poly B
( I
pyrazolyl I
) I
methanes I
and O
a O
tertiary B
monodentate I
phosphine I
( O
PTA B
= O
1 B
, I
3 I
, I
5 I
- I
triaza I
- I
7 I
- I
phosphaadamantane I
, O
PCN B
= O
tris B
( I
cyanoethyl I
) I
phosphine I
) O
produced O
two O
series O
of O
heteroleptic O
, O

In O
this O
complex O
, O
either O
the O
bis B
( I
triazolyl I
) I
borate I
and O
the O
PCN B
ligands O
act O
as O
bidentate O
, O
with O
PCN B
being O
also O
the O
mu O
( O
2 O
) O
- O
bridiging O
linker O
between O
adjacent O
monomers O
. O

Finally O
, O
we O
demonstrate O
direct O
binding O
of O
hsc70 O
to O
the O
SRY O
. O
CaM O
complex O
, O
with O
immunoprecipitation O
experiments O
from O
cell O
extracts O
showing O
association O
of O
hsc70 O
with O
wild O
type O
SRY O
, O
but O
not O
with O
a O
mutant O
derivative O
with O
impaired O
CaM O
binding O
, O
dependent O
on O
Ca B
( I
2 I
+ I
) I
. O

We O
also O
observed O
that O
Ca B
( I
2 I
+ I
) I
is O
a O
weak O
agonist O
of O
PTH1R O
, O
and O
Ca B
( I
2 I
+ I
) I
in O
millimolar O
concentration O
can O
switch O
PTH O
( O
1 O
- O
34 O
) O
from O
an O
inverse O
agonist O
to O
an O
agonist O
. O

We O
also O
observed O
that O
Ca B
( I
2 I
+ I
) I
is O
a O
weak O
agonist O
of O
PTH1R O
, O
and O
Ca B
( I
2 I
+ I
) I
in O
millimolar O
concentration O
can O
switch O
PTH O
( O
1 O
- O
34 O
) O
from O
an O
inverse O
agonist O
to O
an O
agonist O
. O

Higher O
tolerance O
to O
As B
( I
3 I
+ I
) I
[ O
maximum O
tolerable O
concentration O
( O
MTC O
) O
: O
> O
= O
10 O
mM O
] O
, O
As B
( O
5 O
+ O
) O
( O
MTC O
: O
> O
= O
100 O
mM O
) O
and O
other O
heavy O
metals O
like O
Cu B
( I
2 I
+ I
) I
, O
Cr B
( I
2 I
+ I
) I
, O
Ni B
( I
2 I
+ I
) I
etc O
. O

Higher O
tolerance O
to O
As B
( I
3 I
+ I
) I
[ O
maximum O
tolerable O
concentration O
( O
MTC O
) O
: O
> O
= O
10 O
mM O
] O
, O
As B
( O
5 O
+ O
) O
( O
MTC O
: O
> O
= O
100 O
mM O
) O
and O
other O
heavy O
metals O
like O
Cu B
( I
2 I
+ I
) I
, O
Cr B
( I
2 I
+ I
) I
, O
Ni B
( I
2 I
+ I
) I
etc O
. O

Higher O
tolerance O
to O
As B
( I
3 I
+ I
) I
[ O
maximum O
tolerable O
concentration O
( O
MTC O
) O
: O
> O
= O
10 O
mM O
] O
, O
As B
( O
5 O
+ O
) O
( O
MTC O
: O
> O
= O
100 O
mM O
) O
and O
other O
heavy O
metals O
like O
Cu B
( I
2 I
+ I
) I
, O
Cr B
( I
2 I
+ I
) I
, O
Ni B
( I
2 I
+ I
) I
etc O
. O

Higher O
tolerance O
to O
As B
( I
3 I
+ I
) I
[ O
maximum O
tolerable O
concentration O
( O
MTC O
) O
: O
> O
= O
10 O
mM O
] O
, O
As B
( O
5 O
+ O
) O
( O
MTC O
: O
> O
= O
100 O
mM O
) O
and O
other O
heavy O
metals O
like O
Cu B
( I
2 I
+ I
) I
, O
Cr B
( I
2 I
+ I
) I
, O
Ni B
( I
2 I
+ I
) I
etc O
. O

Although O
no O
direct O
correlation O
among O
taxonomic O
identity O
of O
bacterial O
strains O
and O
their O
metabolic O
abilities O
as O
mentioned O
above O
was O
apparent O
, O
several O
isolates O
affiliated O
to O
genera O
Ochrobactrum O
, O
Achromobacter O
and O
unclassified O
Rhizobiaceae O
members O
were O
found O
to O
be O
highly O
resistant O
to O
As B
( I
3 I
+ I
) I
and O
As B
( I
5 I
+ I
) I
and O
positive O
for O
all O
the O
test O
properties O
. O

Although O
no O
direct O
correlation O
among O
taxonomic O
identity O
of O
bacterial O
strains O
and O
their O
metabolic O
abilities O
as O
mentioned O
above O
was O
apparent O
, O
several O
isolates O
affiliated O
to O
genera O
Ochrobactrum O
, O
Achromobacter O
and O
unclassified O
Rhizobiaceae O
members O
were O
found O
to O
be O
highly O
resistant O
to O
As B
( I
3 I
+ I
) I
and O
As B
( I
5 I
+ I
) I
and O
positive O
for O
all O
the O
test O
properties O
. O

Based O
on O
the O
results O
we O
propose O
that O
under O
the O
prevailing O
low O
nutrient O
condition O
inhabitant O
bacteria O
capable O
of O
using O
inorganic O
electron O
donors O
play O
a O
synergistic O
role O
wherein O
siderophores O
and O
phosphatase O
activities O
facilitate O
the O
release O
of O
sediment O
bound O
As B
( I
5 I
+ I
) I
, O
which O
is O
subsequently O
reduced O
by O
arsenate B
reductase O
resulting O
into O
the O
mobilization O
of O
As B
( I
3 I
+ I
) I
in O
groundwater O
. O

Based O
on O
the O
results O
we O
propose O
that O
under O
the O
prevailing O
low O
nutrient O
condition O
inhabitant O
bacteria O
capable O
of O
using O
inorganic O
electron O
donors O
play O
a O
synergistic O
role O
wherein O
siderophores O
and O
phosphatase O
activities O
facilitate O
the O
release O
of O
sediment O
bound O
As B
( I
5 I
+ I
) I
, O
which O
is O
subsequently O
reduced O
by O
arsenate B
reductase O
resulting O
into O
the O
mobilization O
of O
As B
( I
3 I
+ I
) I
in O
groundwater O
. O

A O
series O
of O
17 B
, I
17 I
- I
dialkyl I
- I
3 I
, I
14 I
- I
diaryltetrabenzofluo I
were O
efficiently O
prepared O
by O
using O
Suzuki O
- O
Miyaura O
cross O
- O
coupling O
reactions O
of O
the O
corresponding O
3 B
, I
14 I
- I
dibromo I
derivatives O
. O

A O
multiscale O
investigation O
was O
carried O
out O
to O
study O
the O
dark O
and O
light O
- O
enhanced O
bactericidal O
mechanisms O
of O
poly B
( I
phenylene I
ethynylene I
) I
( O
PPE B
) O
- O
based O
cationic O
conjugated O
polyelectrolytes O
( O
CPEs O
) O
and O
oligo B
- I
phenylene I
ethynylenes I
( O
OPEs B
) O
. O

Large O
polystyrene B
particles O
stabilized O
by O
poly B
( I
acrylic I
acid I
) I
( O
PAA B
) O
( O
L O
- O
PS B
( I
PAA I
) I
) O
( O
as O
the O
core O
) O
and O
small O
polystyrene B
particles O
stabilized O
by O
poly B
( I
vinyl I
pyrrolidone I
) I
( O
PVP B
) O
( O
S O
- O
PS B
( I
PVP I
) I
) O
( O
as O
the O
corona O
) O
were O
successfully O
used O
to O
prepare O
raspberry O
- O
like O
particles O
by O
a O
heterocoagulation O
technique O
utilizing O
the O
hydrogen B
bonding O
interaction O
between O
PAA B
and O
PVP B
. O

Large O
polystyrene B
particles O
stabilized O
by O
poly B
( I
acrylic I
acid I
) I
( O
PAA B
) O
( O
L O
- O
PS B
( I
PAA I
) I
) O
( O
as O
the O
core O
) O
and O
small O
polystyrene B
particles O
stabilized O
by O
poly B
( I
vinyl I
pyrrolidone I
) I
( O
PVP B
) O
( O
S O
- O
PS B
( I
PVP I
) I
) O
( O
as O
the O
corona O
) O
were O
successfully O
used O
to O
prepare O
raspberry O
- O
like O
particles O
by O
a O
heterocoagulation O
technique O
utilizing O
the O
hydrogen B
bonding O
interaction O
between O
PAA B
and O
PVP B
. O

Moreover O
, O
the O
heterocoagulation O
of O
large O
poly B
( I
methyl I
methacrylate I
) I
particles O
stabilized O
by O
PAA B
( O
L O
- O
PMMA B
( I
PAA I
) I
) O
and O
S O
- O
PS B
( I
PVP I
) I
particles O
was O
also O
accomplished O
, O
resulting O
in O
the O
formation O
of O
L O
- O
PMMA B
( I
PAA I
) I
- O
core O
/ O
S O
- O
PS B
( I
PVP I
) I
- O
corona O
raspberry O
- O
like O
composite O
particles O
. O

The O
cationic O
polymer O
nanobrush O
was O
synthesized O
on O
a O
gold O
substrate O
by O
AIBN B
photoinitiated O
polymerization O
, O
using O
a O
70 O
: O
30 O
ratio O
of O
2 B
- I
aminoethyl I
methacrylate I
hydrochloride I
( O
AEMA B
) O
: O
N B
- I
isopropylacrylamide I
( O
NIPAAM B
) O
. O

Here O
the O
feasibility O
of O
6 O
clinically O
approved O
CAs O
( O
Gd B
- I
DTPA I
, O
Gd B
- I
BOPTA I
, O
Gd B
- I
DOTA I
, O
Gd B
- I
BT I
- I
DO3A I
, O
Gd B
- I
DTPA I
- I
BMA I
, O
and O
Gd B
- I
HP I
- I
DO3A I
) O
for O
formulation O
into O
TSL O
was O
investigated O
. O

Here O
the O
feasibility O
of O
6 O
clinically O
approved O
CAs O
( O
Gd B
- I
DTPA I
, O
Gd B
- I
BOPTA I
, O
Gd B
- I
DOTA I
, O
Gd B
- I
BT I
- I
DO3A I
, O
Gd B
- I
DTPA I
- I
BMA I
, O
and O
Gd B
- I
HP I
- I
DO3A I
) O
for O
formulation O
into O
TSL O
was O
investigated O
. O

Here O
the O
feasibility O
of O
6 O
clinically O
approved O
CAs O
( O
Gd B
- I
DTPA I
, O
Gd B
- I
BOPTA I
, O
Gd B
- I
DOTA I
, O
Gd B
- I
BT I
- I
DO3A I
, O
Gd B
- I
DTPA I
- I
BMA I
, O
and O
Gd B
- I
HP I
- I
DO3A I
) O
for O
formulation O
into O
TSL O
was O
investigated O
. O

The O
formulation O
approaches O
used O
were O
as O
follows O
: O
( O
a O
) O
an O
inclusion O
complex O
with O
hydroxypropyl B
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
, O
( O
b O
) O
a O
solid O
dispersion O
with O
Soluplus B
( O
R O
) O
, O
a O
new O
highly O
water O
soluble O
polyvinyl B
caprolactam I
- O
polyvinyl B
acetate I
- O
polyethylene B
glycol I
graft O
copolymer O
and O
( O
c O
) O
a O
ternary O
inclusion O
complex O
with O
both O
HP B
- I
beta I
- I
CD I
and O
Soluplus B
( O
R O
) O
. O

The O
formulation O
approaches O
used O
were O
as O
follows O
: O
( O
a O
) O
an O
inclusion O
complex O
with O
hydroxypropyl B
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
, O
( O
b O
) O
a O
solid O
dispersion O
with O
Soluplus B
( O
R O
) O
, O
a O
new O
highly O
water O
soluble O
polyvinyl B
caprolactam I
- O
polyvinyl B
acetate I
- O
polyethylene B
glycol I
graft O
copolymer O
and O
( O
c O
) O
a O
ternary O
inclusion O
complex O
with O
both O
HP B
- I
beta I
- I
CD I
and O
Soluplus B
( O
R O
) O
. O

The O
formulation O
approaches O
used O
were O
as O
follows O
: O
( O
a O
) O
an O
inclusion O
complex O
with O
hydroxypropyl B
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
, O
( O
b O
) O
a O
solid O
dispersion O
with O
Soluplus B
( O
R O
) O
, O
a O
new O
highly O
water O
soluble O
polyvinyl B
caprolactam I
- O
polyvinyl B
acetate I
- O
polyethylene B
glycol I
graft O
copolymer O
and O
( O
c O
) O
a O
ternary O
inclusion O
complex O
with O
both O
HP B
- I
beta I
- I
CD I
and O
Soluplus B
( O
R O
) O
. O

Based O
on O
the O
results O
of O
the O
present O
study O
, O
the O
bioavailability O
of O
both O
drugs O
in O
the O
fixed O
dose O
combination O
is O
likely O
to O
be O
increased O
after O
oral O
administration O
of O
the O
new O
formulations O
, O
especially O
when O
the O
fixed O
dose O
combination O
is O
formulated O
as O
a O
ternary O
complex O
consisting O
of O
HP B
- I
beta I
- I
CD I
and O
Soluplus B
( O
R O
) O
. O

Percutaneous O
transdermal O
absorption O
of O
esculetin B
( O
6 B
, I
7 I
- I
dihydroxycoumarin I
) O
, O
an O
oxidative O
damage O
inhibitor O
, O
was O
evaluated O
by O
means O
of O
in O
vitro O
permeation O
studies O
in O
which O
vertical O
Franz O
- O
type O
diffusion O
cells O
and O
pig O
ear O
skin O
were O
employed O
. O

An O
integral O
asymmetric O
membrane O
was O
fabricated O
in O
a O
fast O
and O
one O
- O
step O
process O
by O
combining O
the O
self O
- O
assembly O
of O
an O
amphiphilic O
block O
copolymer O
( O
PS B
- I
b I
- I
P4VP I
) O
with O
nonsolvent O
- O
induced O
phase O
separation O
. O

WNT O
- O
5A O
engages O
noncanonical O
WNT O
signaling O
pathways O
, O
as O
inhibition O
of O
Ca B
( I
2 I
+ I
) I
and O
c O
- O
Jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
signaling O
attenuated O
this O
TGF O
- O
beta O
response O
, O
whereas O
the O
canonical O
WNT O
antagonist O
Dickkopf O
1 O
( O
DKK O
- O
1 O
) O
did O
not O
. O

This O
method O
allows O
rapid O
access O
to O
various O
1 B
, I
4 I
- I
dienes I
or O
trienes B
including O
the O
biologically O
active O
natural O
products O
( B
- I
) I
- I
nyasol I
and O
( B
- I
) I
- I
hinokiresinol I
. O

This O
method O
allows O
rapid O
access O
to O
various O
1 B
, I
4 I
- I
dienes I
or O
trienes B
including O
the O
biologically O
active O
natural O
products O
( B
- I
) I
- I
nyasol I
and O
( B
- I
) I
- I
hinokiresinol I
. O

This O
method O
allows O
rapid O
access O
to O
various O
1 B
, I
4 I
- I
dienes I
or O
trienes B
including O
the O
biologically O
active O
natural O
products O
( B
- I
) I
- I
nyasol I
and O
( B
- I
) I
- I
hinokiresinol I
. O

Gene O
expression O
analysis O
showed O
that O
25HC3S B
significantly O
suppressed O
the O
SREBP O
- O
1c O
signaling O
pathway O
that O
was O
associated O
with O
the O
suppression O
of O
the O
key O
enzymes O
involved O
in O
lipogenesis O
: O
fatty B
acid I
synthase O
, O
acetyl B
- I
CoA I
carboxylase O
1 O
, O
and O
glycerol B
- I
3 I
- I
phosphate I
acyltransferase O
. O

The O
surface O
of O
graphene B
oxide I
is O
first O
sensitized O
by O
Sn B
( I
2 I
+ I
) I
ions O
, O
and O
subsequently O
, O
Pd B
or O
Pt B
nanoparticles O
are O
deposited O
on O
the O
surface O
of O
graphene B
oxide I
. O

Identification O
of O
benzofuran B
central O
cores O
for O
the O
inhibition O
of O
leukotriene B
A I
( I
4 I
) I
hydrolase O
. O

Leukotriene B
A I
( I
4 I
) I
hydrolase O
( O
LTA O
( O
4 O
) O
H O
) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA B
( I
4 I
) I
to O
LTB B
( I
4 I
) I
. O

The O
outcome O
of O
these O
tests O
grouped O
the O
tested O
compounds O
in O
three O
categories O
following O
their O
detoxification O
effect O
( O
benzo B
( I
a I
) I
pyrene I
, O
valproic B
acid I
) O
, O
their O
bio O
- O
activation O
effect O
( O
aflatoxin B
B1 I
) O
and O
their O
specific O
effect O
on O
inhibition O
of O
cell O
proliferation O
( O
cycloheximide B
, O
sodium B
lauryl I
sulphate I
, O
atropine B
sulphate I
monohydrate I
, O
acetylsalicylic B
acid I
) O
. O

This O
research O
investigates O
the O
release O
of O
DS O
- O
SILY O
from O
fast O
- O
dissolving O
polymer O
films O
composed O
of O
poly B
( I
vinyl I
alcohol I
) I
( O
PVA B
) O
and O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
. O

This O
research O
investigates O
the O
release O
of O
DS O
- O
SILY O
from O
fast O
- O
dissolving O
polymer O
films O
composed O
of O
poly B
( I
vinyl I
alcohol I
) I
( O
PVA B
) O
and O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
. O

Hepatoprotective O
effect O
of O
2 B
, I
3 I
- I
dehydrosilybin I
on O
carbon B
tetrachloride I
- O
induced O
liver O
injury O
in O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
protective O
effect O
of O
2 B
, I
3 I
- I
dehydrosilybin I
( O
DHS B
) O
against O
carbon B
tetrachloride I
( O
CCl B
( I
4 I
) I
) O
- O
induced O
liver O
injury O
in O
rats O
. O

E B
- I
beta I
- I
ocimene I
( O
53 O
. O
81 O
% O
) O
, O
R O
- O
D O
- O
decalactone O
( O
12 O
. O
75 O
% O
) O
, O
alpha B
- I
pinene I
( O
6 O
. O
43 O
% O
) O
, O
n B
- I
heptanol I
( O
6 O
. O
27 O
% O
) O
, O
beta B
- I
phellanderne I
( O
2 O
. O
70 O
% O
) O
and O
linalool B
( O
1 O
. O
89 O
% O
) O
were O
the O
major O
constituents O
. O

Subsequently O
the O
methods O
were O
applied O
for O
the O
identification O
and O
quantification O
of O
chlorogenic B
acid I
( O
5 B
- I
CQA I
) O
and O
1 B
, I
5 I
- I
dicaffeoylquinic I
acid I
( O
1 B
, I
5 I
- I
DCQA I
) O
as O
main O
compounds O
in O
samples O
. O

There O
was O
a O
significant O
variability O
from O
89 O
to O
571 O
mg O
/ O
100g O
for O
5 B
- I
CQA I
and O
48 O
to O
486 O
mg O
/ O
100g O
for O
1 B
, I
5 I
- I
DCQA I
in O
dry O
material O
. O

E O
had O
the O
largest O
effect O
on O
antioxidant O
activity O
against O
oxygen B
, O
hydroxyl B
, O
and O
ABTS B
( I
. I
+ I
) I
radicals O
. O

ABTS B
( I
. I
+ I
) I
radical O
scavenging O
capacity O
had O
a O
positive O
correlation O
with O
average O
air O
temperature O
( O
r O
= O
0 O
. O
705 O
, O
p O
< O
0 O
. O
01 O
) O
, O
while O
hydroxyl B
radical O
scavenging O
capacity O
had O
a O
negative O
correlation O
with O
temperature O
( O
r O
= O
- O
0 O
. O
269 O
. O
p O
< O
0 O
. O
01 O
) O
. O

The O
ripeness O
of O
the O
raw O
strawberries O
influences O
the O
concentrations O
of O
some O
of O
the O
compounds O
in O
the O
spreads O
, O
such O
as O
isobutyl B
acetate I
, O
butyl B
butyrate I
, O
3 B
- I
hexen I
- I
1 I
- I
yl I
acetate I
or O
propan B
- I
2 I
- I
ol I
. O

Discovery O
and O
preliminary O
structure O
- O
activity O
relationship O
analysis O
of O
1 B
, I
14 I
- I
sperminediphenylacet I
as O
potent O
and O
selective O
antimalarial O
lead O
compounds O
. O

Screening O
of O
synthesized O
and O
isolated O
marine O
natural O
products O
for O
in O
vitro O
activity O
against O
four O
parasitic O
protozoa O
has O
identified O
the O
ascidian O
metabolite O
1 B
, I
14 I
- I
sperminedihomovanill I
( O
orthidine B
F I
, O
1 O
) O
as O
being O
a O
non O
- O
toxic O
, O
moderate O
growth O
inhibitor O
of O
Plasmodium O
falciparum O
( O
IC O
( O
50 O
) O
0 O
. O
89 O
mu O
M O
) O
. O

These O
neurotoxins O
display O
different O
biochemical O
activities O
, O
but O
similarly O
alter O
the O
presynaptic O
membrane O
permeability O
causing O
Ca B
( I
2 I
+ I
) I
overload O
within O
the O
nerve O
terminals O
, O
which O
in O
turn O
induces O
nerve O
degeneration O
. O

Tri B
- I
and I
diorganotin I
( I
IV I
) I
orotates I
of O
general O
formula O
, O
R B
( I
n I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
m I
) I
[ O
n O
= O
3 O
/ O
2 O
, O
m O
= O
1 O
/ O
2 O
, O
R O
= O
Me B
, O
n B
- I
Bu I
, O
n B
- I
Oct I
and O
Ph B
; O
H B
( I
2 I
) I
Or I
( I
- I
) I
= O
monoanion O
of O
orotic B
acid I
( O
H B
( I
3 I
) I
Or I
) O
] O
( O
n B
- I
Bu I
( I
2 I
) I
Sn I
( I
HOr I
) I
as O
an O
exception O
) O
have O
been O
synthesized O
. O

However O
, O
Cramb816 B
partially O
blocked O
Ca B
( I
2 I
+ I
) I
, O
while O
NcrambA2 B
did O
not O
. O

Since O
the O
blocking O
effect O
of O
Cramb816 B
on O
calcium B
currents O
has O
not O
been O
previously O
reported O
in O
detail O
, O
we O
further O
pharmacologically O
isolated O
the O
two O
main O
fractions O
of O
HVA O
Ca B
( I
2 I
+ I
) I
channels O
in O
neurons O
and O
investigated O
the O
Cramb816 B
effect O
on O
them O
. O

The O
coupling O
distance O
between O
presynaptic O
Ca B
( I
2 I
+ I
) I
influx O
and O
the O
sensor O
for O
vesicular O
transmitter O
release O
determines O
speed O
and O
reliability O
of O
synaptic O
transmission O
. O

We O
quantified O
the O
coupling O
distance O
by O
combining O
multiprobability O
fluctuation O
analyses O
, O
presynaptic O
Ca B
( I
2 I
+ I
) I
imaging O
, O
and O
reaction O
- O
diffusion O
simulations O
in O
wild O
- O
type O
and O
calretinin O
- O
deficient O
mice O
. O

ATPase O
stimulation O
kinetics O
could O
be O
modeled O
for O
the O
entactogen O
3 B
, I
4 I
- I
methylenedioxy I
- I
alpha I
- I
ethylphenethylamine I
( O
3 B
, I
4 I
- I
BDB I
) O
, O
the O
hallucinogen O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
( O
DOI B
) O
, O
the O
abused O
alkaloid O
glaucine B
, O
the O
opioid O
- O
like O
drugs O
N B
- I
iso I
- I
propyl I
- I
1 I
, I
2 I
- I
diphenylethylamine I
( O
NPDPA B
) O
, O
and O
N B
- I
( I
1 I
- I
phenylcyclohexyl I
) I
- I

Electrical O
stimulation O
, O
ATP B
, O
and O
insulin O
each O
increased O
fluorescent O
2 B
- I
NBD I
- I
Glucose I
( O
2 B
- I
NBDG I
) O
uptake O
in O
primary O
myotubes O
, O
but O
only O
electrical O
stimulation O
and O
ATP B
- O
dependent O
2 B
- I
NBDG I
uptake O
were O
inhibited O
by O
adenosine B
- I
phosphate I
phosphatase O
and O
by O
purinergic O
receptor O
blockade O
( O
suramin B
) O
. O

We O
synthesized O
copolymers O
composed O
of O
methyl B
methacrylate I
and O
2 B
- I
aminoethyl I
methacrylate I
with O
different O
protecting O
groups O
or O
ion O
- O
complexes O
on O
their O
amino B
groups O
, O
then O
dip O
- O
coated O
the O
copolymers O
onto O
a O
poly B
( I
methyl I
methacrylate I
) I
( O
PMMA B
) O
substrate O
. O

Development O
of O
a O
dry O
, O
stable O
and O
inhalable O
acyl B
- I
homoserine I
- I
lactone I
- O
acylase O
powder O
formulation O
for O
the O
treatment O
of O
pulmonary O
Pseudomonas O
aeruginosa O
infections O
. O

Synthesis O
and O
biological O
activity O
against O
Trypanosoma O
cruzi O
of O
substituted O
1 B
, I
4 I
- I
naphthoquinones I
. O

New O
substituted O
1 B
, I
4 I
- I
naphthoquinones I
were O
synthesized O
and O
tested O
against O
the O
infective O
bloodstream O
form O
of O
Trypanosoma O
cruzi O
, O
the O
etiological O
agent O
of O
Chagas O
disease O
. O

The O
maximal O
concentrations O
of O
4 B
- I
iso I
- I
nonylphenol I
and O
estrone B
were O
115 O
mg O
/ O
kg O
dry O
weight O
and O
20 O
micro O
g O
/ O
kg O
dry O
weight O
at O
the O
sampling O
site O
Luppe O
, O
which O
showed O
in O
accordance O
the O
highest O
biological O
activity O
. O

Under O
consideration O
of O
compound O
concentration O
and O
compound O
specific O
estrogenic O
activity O
the O
4 B
- I
iso I
- I
nonylphenols I
contributed O
most O
to O
the O
observed O
estrogenic O
effect O
. O

A O
strong O
correlation O
between O
the O
measured O
estrogenic O
activity O
and O
the O
concentration O
of O
the O
sediment O
- O
associated O
4 B
- I
iso I
- I
nonylphenol I
underlines O
the O
relevance O
of O
this O
compound O
class O
as O
a O
xenoestrogen O
in O
the O
catchment O
area O
of O
the O
river O
Saale O
. O

Nortriptyline B
( O
N B
- I
desmethyl I
amitriptyline I
) O
and O
amitriptyline B
- I
N I
- I
oxide I
were O
identified O
as O
major O
transformation O
products O
in O
all O
three O
soils O
by O
high O
performance O
liquid O
chromatography O
with O
photodiode O
array O
detector O
and O
time O
- O
of O
- O
flight O
mass O
spectrometry O
( O
HPLC O
- O
TOF O
- O
MS O
/ O
UV O
) O
. O

Hydrosoluble O
benzo B
[ I
e I
] I
pyridoindolones I
as O
potent O
inhibitors O
of O
aurora O
kinases O
. O

We O
identified O
benzo B
[ I
e I
] I
pyridoindoles I
( O
BePI B
) O
as O
powerful O
aurora O
kinase O
inhibitors O
. O

New O
hydrosoluble O
benzo B
[ I
e I
] I
pyridoindolones I
were O
subsequently O
designed O
, O
and O
their O
efficacy O
was O
tested O
by O
a O
combination O
of O
cell O
- O
cycle O
analysis O
and O
time O
- O
lapse O
experiments O
in O
live O
cells O
. O

In O
this O
paper O
, O
the O
fabrication O
, O
characterization O
, O
and O
application O
in O
oxygen B
sensing O
are O
reported O
for O
a O
novel O
multifunctional O
nanomaterial O
of O
[ O
Ru B
( I
bpy I
) I
( I
2 I
) I
phen I
- O
MMS O
] O
( O
bpy B
, O
2 B
, I
2 I
' I
- I
bipyridyl I
; O
phen B
, O
phenathrolin B
) O
which O
was O
simply O
prepared O
by O
covalently O
grafting O
the O
ruthenium B
( I
II I
) I
polypyridyl I
compounds O
into O
the O
channels O
of O
magnetic O
mesoporous O
silica B
nanocomposites O
( O
MMS O
) O
. O

In O
this O
study O
, O
we O
found O
that O
inhibition O
of O
T O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
in O
GBM O
cells O
significantly O
reduced O
their O
survival O
and O
resistance O
to O
therapy O
. O

The O
apoptotic O
response O
was O
specific O
for O
T O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
, O
as O
inhibition O
of O
L O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
did O
not O
induce O
similar O
effects O
. O

The O
apoptotic O
response O
was O
specific O
for O
T O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
, O
as O
inhibition O
of O
L O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
did O
not O
induce O
similar O
effects O
. O

Our O
results O
implicate O
T O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
as O
distinct O
entities O
for O
survival O
signaling O
in O
GBM O
cells O
and O
suggest O
that O
they O
are O
a O
novel O
molecular O
target O
for O
tumor O
therapy O
. O

The O
consecutive O
arrangement O
of O
2 B
' I
- I
deoxy I
- I
6 I
- I
thioguanosines I
( O
s B
( I
6 I
) I
Gs I
) O
and O
4 B
- I
thiothymidines I
( O
s B
( I
4 I
) I
Ts I
) O
in O
antiparallel O
triplex O
- O
forming O
oligonucleotides O
( O
TFOs O
) O
considerably O
stabilized O
the O
resulting O
antiparallel O
triplexes O
with O
high O
base O
recognition O
ability O
by O
the O
strong O
stacking O
effects O
of O
thiocarbonyl B
groups O
. O

The O
consecutive O
arrangement O
of O
2 B
' I
- I
deoxy I
- I
6 I
- I
thioguanosines I
( O
s B
( I
6 I
) I
Gs I
) O
and O
4 B
- I
thiothymidines I
( O
s B
( I
4 I
) I
Ts I
) O
in O
antiparallel O
triplex O
- O
forming O
oligonucleotides O
( O
TFOs O
) O
considerably O
stabilized O
the O
resulting O
antiparallel O
triplexes O
with O
high O
base O
recognition O
ability O
by O
the O
strong O
stacking O
effects O
of O
thiocarbonyl B
groups O
. O

Moreover O
, O
in O
comparison O
with O
unmodified O
TFOs O
, O
it O
was O
found O
that O
TFOs O
containing O
s B
( I
6 I
) I
Gs I
and O
s B
( I
4 I
) I
Ts I
could O
selectively O
bind O
to O
the O
complementary O
DNA O
duplex O
but O
not O
to O
mismatched O
DNA O
duplexes O
or O
single O
- O
stranded O
RNA O
. O

Moreover O
, O
in O
comparison O
with O
unmodified O
TFOs O
, O
it O
was O
found O
that O
TFOs O
containing O
s B
( I
6 I
) I
Gs I
and O
s B
( I
4 I
) I
Ts I
could O
selectively O
bind O
to O
the O
complementary O
DNA O
duplex O
but O
not O
to O
mismatched O
DNA O
duplexes O
or O
single O
- O
stranded O
RNA O
. O

Mechanistic O
studies O
reveal O
that O
the O
NOGEL O
is O
dependent O
upon O
repair O
of O
O B
( I
6 I
) I
- I
methylguanine I
( O
O B
( I
6 I
) I
MeG I
) O
by O
the O
suicide O
enzyme O
O B
( I
6 I
) I
MeG I
- O
DNA O
methyltransferase O
( O
MGMT O
) O
. O

Mechanistic O
studies O
reveal O
that O
the O
NOGEL O
is O
dependent O
upon O
repair O
of O
O B
( I
6 I
) I
- I
methylguanine I
( O
O B
( I
6 I
) I
MeG I
) O
by O
the O
suicide O
enzyme O
O B
( I
6 I
) I
MeG I
- O
DNA O
methyltransferase O
( O
MGMT O
) O
. O

Induced O
expression O
of O
cytochrome O
P450 O
1A O
and O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
determined O
at O
mRNA O
, O
protein O
, O
and O
enzyme O
activity O
levels O
in O
rats O
exposed O
to O
the O
carcinogenic O
azo B
dye O
1 B
- I
phenylazo I
- I
2 I
- I
naphthol I
( O
Sudan B
I I
) O
. O

Western O
blots O
using O
antibodies O
raised O
against O
various O
P450s O
, O
NADPH B
: O
P450 O
reductase O
, O
and O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
1 O
( O
NQO1 O
) O
showed O
that O
the O
expression O
of O
P450 O
1A1 O
and O
NQO1 O
was O
induced O
in O
the O
liver O
, O
kidney O
, O
and O
lung O
of O
rats O
treated O
with O
Sudan B
I I
. O

Effects O
on O
gene O
expression O
in O
rat O
liver O
after O
administration O
of O
RXR O
agonists O
: O
UAB30 B
, O
4 B
- I
methyl I
- I
UAB30 I
, O
and O
Targretin B
( O
Bexarotene B
) O
. O

Examination O
of O
three O
retinoid B
X O
receptor O
( O
RXR O
) O
agonists O
[ O
Targretin B
( O
TRG B
) O
, O
UAB30 B
, O
and O
4 B
- I
methyl I
- I
UAB30 I
( O
4 B
- I
Me I
- I
UAB30 I
) O
] O
showed O
that O
all O
inhibited O
mammary O
cancer O
in O
rodents O
and O
two O
( O
TRG B
and O
4 B
- I
Me I
- I
UAB30 I
) O
strikingly O
increased O
serum O
triglyceride B
levels O
. O

Examination O
of O
three O
retinoid B
X O
receptor O
( O
RXR O
) O
agonists O
[ O
Targretin B
( O
TRG B
) O
, O
UAB30 B
, O
and O
4 B
- I
methyl I
- I
UAB30 I
( O
4 B
- I
Me I
- I
UAB30 I
) O
] O
showed O
that O
all O
inhibited O
mammary O
cancer O
in O
rodents O
and O
two O
( O
TRG B
and O
4 B
- I
Me I
- I
UAB30 I
) O
strikingly O
increased O
serum O
triglyceride B
levels O
. O

Examination O
of O
three O
retinoid B
X O
receptor O
( O
RXR O
) O
agonists O
[ O
Targretin B
( O
TRG B
) O
, O
UAB30 B
, O
and O
4 B
- I
methyl I
- I
UAB30 I
( O
4 B
- I
Me I
- I
UAB30 I
) O
] O
showed O
that O
all O
inhibited O
mammary O
cancer O
in O
rodents O
and O
two O
( O
TRG B
and O
4 B
- I
Me I
- I
UAB30 I
) O
strikingly O
increased O
serum O
triglyceride B
levels O
. O

For O
proliferator O
- O
activated O
receptor O
alpha O
/ O
RXR O
- O
activated O
genes O
, O
the O
strongest O
response O
was O
TRG B
> O
4 B
- I
Me I
- I
UAB30 I
> O
UAB30 B
. O

Many O
liver O
X O
receptor O
/ O
RXR O
- O
related O
genes O
( O
e O
. O
g O
. O
, O
Scd O
- O
1 O
and O
Srebf1 O
, O
which O
are O
associated O
with O
increased O
triglycerides B
) O
were O
highly O
expressed O
in O
TRG B
and O
4 B
- I
Me I
- I
UAB30 I
- O
but O
not O
UAB30 B
- O
treated O
livers O
. O

Cotreatments O
of O
5 O
, O
10 O
and O
20 O
micro O
g O
/ O
mL O
concentrations O
of O
MEP O
with O
aflatoxin B
B I
( I
1 I
) I
decreased O
the O
frequencies O
of O
SCE O
and O
the O
malondialdehyde B
level O
and O
increased O
amount O
of O
superoxide B
dismutase O
, O
glutathione B
and O
glutathione B
peroxidase O
which O
were O
decreased O
by O
aflatoxin B
. O

Three O
new O
ent B
- I
eudesmane I
sesquiterpenoids I
, O
arundinols B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
one O
isochroman B
- I
1 I
- I
one I
, O
arundinone B
A I
( O
4 O
) O
, O
and O
a O
polyoxygenated B
benzofuran I
- I
3 I
( I
2H I
) I
- I
one I
dimer O
, O
arundinone B
B I
( O
5 O
) O
, O
were O
isolated O
from O
the O
extract O
of O
a O
plant O
endophytic O
fungus O
, O
Microsphaeropsis O
arundinis O
. O

GSNO B
treatment O
of O
CBR1 O
resulted O
in O
a O
2 O
- O
5 O
- O
fold O
decrease O
in O
kcat O
with O
menadione B
, O
4 B
- I
benzoylpyridine I
, O
2 B
, I
3 I
- I
hexanedione I
, O
daunorubicin B
and O
1 B
, I
4 I
- I
naphthoquinone I
. O

GSNO B
treatment O
of O
CBR1 O
resulted O
in O
a O
2 O
- O
5 O
- O
fold O
decrease O
in O
kcat O
with O
menadione B
, O
4 B
- I
benzoylpyridine I
, O
2 B
, I
3 I
- I
hexanedione I
, O
daunorubicin B
and O
1 B
, I
4 I
- I
naphthoquinone I
. O

In O
contrast O
, O
the O
same O
treatment O
increased O
kcat O
for O
substrates O
containing O
a O
1 B
, I
2 I
- I
diketo I
group O
in O
a O
ring O
structure O
( O
1 B
, I
2 I
- I
naphthoquinone I
, O
9 B
, I
10 I
- I
phenanthrenequinone I
, O
isatin B
) O
. O

In O
contrast O
, O
the O
same O
treatment O
increased O
kcat O
for O
substrates O
containing O
a O
1 B
, I
2 I
- I
diketo I
group O
in O
a O
ring O
structure O
( O
1 B
, I
2 I
- I
naphthoquinone I
, O
9 B
, I
10 I
- I
phenanthrenequinone I
, O
isatin B
) O
. O

In O
contrast O
, O
the O
same O
treatment O
increased O
kcat O
for O
substrates O
containing O
a O
1 B
, I
2 I
- I
diketo I
group O
in O
a O
ring O
structure O
( O
1 B
, I
2 I
- I
naphthoquinone I
, O
9 B
, I
10 I
- I
phenanthrenequinone I
, O
isatin B
) O
. O

Except O
for O
9 B
, I
10 I
- I
phenanthrenequinone I
, O
all O
changes O
in O
kcat O
were O
at O
least O
in O
part O
compensated O
for O
by O
a O
similar O
change O
in O
Km O
, O
overall O
yielding O
no O
drastic O
changes O
in O
catalytic O
efficiency O
. O

Contractions O
were O
produced O
by O
electrical O
field O
stimulation O
of O
perivascular O
nerves O
( O
EFS O
) O
, O
norepinephrine B
( O
NE O
) O
, O
adenosine B
5 I
' I
- I
triphosphate I
( O
ATP B
) O
, O
high O
K B
( I
+ I
) I
solution O
and O
by O
calcium B
chloride I
( O
CaCl B
( I
2 I
) I
) O
in O
Ca B
( I
2 I
+ I
) I
- O
free O
and O
high O
K B
( I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
- O
free O
solution O
. O

Contractions O
were O
produced O
by O
electrical O
field O
stimulation O
of O
perivascular O
nerves O
( O
EFS O
) O
, O
norepinephrine B
( O
NE O
) O
, O
adenosine B
5 I
' I
- I
triphosphate I
( O
ATP B
) O
, O
high O
K B
( I
+ I
) I
solution O
and O
by O
calcium B
chloride I
( O
CaCl B
( I
2 I
) I
) O
in O
Ca B
( I
2 I
+ I
) I
- O
free O
and O
high O
K B
( I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
- O
free O
solution O
. O

Contractions O
were O
produced O
by O
electrical O
field O
stimulation O
of O
perivascular O
nerves O
( O
EFS O
) O
, O
norepinephrine B
( O
NE O
) O
, O
adenosine B
5 I
' I
- I
triphosphate I
( O
ATP B
) O
, O
high O
K B
( I
+ I
) I
solution O
and O
by O
calcium B
chloride I
( O
CaCl B
( I
2 I
) I
) O
in O
Ca B
( I
2 I
+ I
) I
- O
free O
and O
high O
K B
( I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
- O
free O
solution O
. O

The O
smooth O
muscle O
Ca B
( I
2 I
+ I
) I
channels O
and O
/ O
or O
Ca B
( I
2 I
+ I
) I
mobilizing O
through O
cells O
might O
be O
involved O
in O
the O
effects O
of O
resveratrol B
on O
the O
contractility O
of O
RPV O
. O

The O
smooth O
muscle O
Ca B
( I
2 I
+ I
) I
channels O
and O
/ O
or O
Ca B
( I
2 I
+ I
) I
mobilizing O
through O
cells O
might O
be O
involved O
in O
the O
effects O
of O
resveratrol B
on O
the O
contractility O
of O
RPV O
. O

Effect O
of O
major O
cations O
( O
Ca B
( I
2 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
) O
and O
anions O
( O
SO B
42 I
- I
, O
Cl B
( I
- I
) I
, O
NO B
3 I
- I
) O
on O
Ni B
accumulation O
and O
toxicity O
in O
aquatic O
plant O
( O
Lemna O
minor O
L O
. O
) O
: O
implications O
For O
Ni B
risk O
assessment O
. O

Effect O
of O
major O
cations O
( O
Ca B
( I
2 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
) O
and O
anions O
( O
SO B
42 I
- I
, O
Cl B
( I
- I
) I
, O
NO B
3 I
- I
) O
on O
Ni B
accumulation O
and O
toxicity O
in O
aquatic O
plant O
( O
Lemna O
minor O
L O
. O
) O
: O
implications O
For O
Ni B
risk O
assessment O
. O

The O
effect O
of O
major O
cation O
activity O
( O
Ca B
( I
2 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
) O
on O
Ni B
toxicity O
, O
with O
dose O
expressed O
as O
exposure O
( O
total O
dissolved O
Ni B
concentration O
NiTot O
) O
or O
free O
Ni B
ion O
activity O
( O
in O
solution O
Ni B
( I
2 I
+ I
) I
) O
, O
or O
as O
tissue O
residue O
( O
Ni B
concentration O
in O
plant O
tissue O
NiTiss O
) O
to O
the O
aquatic O
plant O
Lemna O
minor O
L O
. O
was O
examined O
. O

The O
effect O
of O
major O
cation O
activity O
( O
Ca B
( I
2 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
) O
on O
Ni B
toxicity O
, O
with O
dose O
expressed O
as O
exposure O
( O
total O
dissolved O
Ni B
concentration O
NiTot O
) O
or O
free O
Ni B
ion O
activity O
( O
in O
solution O
Ni B
( I
2 I
+ I
) I
) O
, O
or O
as O
tissue O
residue O
( O
Ni B
concentration O
in O
plant O
tissue O
NiTiss O
) O
to O
the O
aquatic O
plant O
Lemna O
minor O
L O
. O
was O
examined O
. O

The O
effect O
of O
major O
cation O
activity O
( O
Ca B
( I
2 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
) O
on O
Ni B
toxicity O
, O
with O
dose O
expressed O
as O
exposure O
( O
total O
dissolved O
Ni B
concentration O
NiTot O
) O
or O
free O
Ni B
ion O
activity O
( O
in O
solution O
Ni B
( I
2 I
+ I
) I
) O
, O
or O
as O
tissue O
residue O
( O
Ni B
concentration O
in O
plant O
tissue O
NiTiss O
) O
to O
the O
aquatic O
plant O
Lemna O
minor O
L O
. O
was O
examined O
. O

For O
example O
, O
Ca B
( I
2 I
+ I
) I
and O
Mg B
( I
2 I
+ I
) I
( O
sulfate B
as O
counter O
- O
anion O
) O
had O
an O
anticompetitive O
effect O
on O
Ni B
accumulation O
, O
suggesting O
that O
Ca B
or O
Mg B
forms O
a O
ternary O
complex O
with O
Ni B
- O
biotic O
ligand O
. O

For O
example O
, O
Ca B
( I
2 I
+ I
) I
and O
Mg B
( I
2 I
+ I
) I
( O
sulfate B
as O
counter O
- O
anion O
) O
had O
an O
anticompetitive O
effect O
on O
Ni B
accumulation O
, O
suggesting O
that O
Ca B
or O
Mg B
forms O
a O
ternary O
complex O
with O
Ni B
- O
biotic O
ligand O
. O

Generally O
, O
sulfate B
and O
chloride B
influenced O
plant O
response O
while O
nitrate B
did O
not O
, O
even O
when O
compared O
within O
the O
same O
range O
of O
Ca B
( I
2 I
+ I
) I
, O
which O
suggests O
that O
the O
anion O
dominated O
the O
observed O
plant O
response O
. O

Overall O
, O
although O
an O
effect O
of O
major O
cations O
on O
Ni B
toxicity O
to O
L O
. O
minor O
L O
. O
was O
observed O
at O
a O
physiological O
level O
, O
Ni B
( I
2 I
+ I
) I
or O
NiTot O
alone O
modeled O
plant O
response O
, O
generally O
within O
a O
span O
of O
twofold O
, O
over O
a O
wide O
range O
of O
water O
chemistry O
. O

The O
analysis O
of O
medium O
polarity O
constituents O
led O
to O
the O
isolation O
of O
several O
glycosides O
, O
such O
as O
flavonoids B
, O
i O
. O
e O
. O
scutellarein B
derivatives O
; O
phenylethanoids B
, O
i O
. O
e O
. O
verbascoside B
; O
and O
iridoids B
, O
i O
. O
e O
. O
melittoside B
and O
5 B
- I
allosyloxy I
- I
aucubin I
, O
besides O
the O
diterpene O
siderol B
. O

Tunable O
morphology O
and O
mesophase O
formation O
by O
naphthalene B
- O
containing O
poly B
( I
aryl I
ether I
) I
dendron O
- O
based O
low O
- O
molecular O
- O
weight O
fluorescent O
gels O
. O

Novel O
poly B
( I
aryl I
ether I
) I
dendron O
- O
based O
low O
- O
molecular O
- O
weight O
organogelaters O
( O
LMWG O
) O
containing O
naphthalene B
units O
at O
the O
core O
have O
been O
synthesized O
, O
and O
the O
self O
- O
assembly O
of O
the O
system O
has O
been O
examined O
in O
a O
variety O
of O
solvents O
and O
solvent O
mixtures O
. O

The O
present O
work O
unravels O
the O
subtle O
role O
of O
minute O
structural O
change O
in O
altering O
the O
properties O
of O
LMWGs O
based O
on O
poly B
( I
aryl I
ether I
) I
dendrons O
. O

The O
method O
consists O
of O
antisolvent O
co O
- O
precipitation O
from O
an O
aqueous O
solution O
containing O
both O
an O
amino B
acid I
core O
material O
( O
e O
. O
g O
. O
D B
, I
L I
- I
valine I
) O
, O
and O
either O
bovine O
serum O
albumin O
( O
BSA O
) O
or O
lysozyme O
( O
Lys O
) O
as O
model O
proteins O
. O

Synthesis O
, O
characterization O
and O
targeting O
potential O
of O
zidovudine B
loaded O
sialic B
acid I
conjugated O
- O
mannosylated B
poly I
( I
propyleneimine I
) I
dendrimers O
. O

The O
present O
investigation O
was O
aimed O
at O
exploring O
dual O
targeting O
of O
anti O
- O
HIV O
drug O
, O
zidovudine B
( O
ZDV B
) O
via O
sialic B
acid I
conjugated O
- O
mannosylated B
poly I
( I
propyleneimine I
) I
( O
PPI B
) O
dendritic O
nano O
- O
constructs O
. O

Biodegradable O
and O
amphiphilic O
block O
copolymers O
based O
on O
poly B
( I
epsilon I
- I
caprolactone I
) I
( O
PCL B
= O
B O
) O
and O
poly B
( I
ethylene I
oxide I
) I
( O
PEO B
= O
A O
) O
, O
with O
AB O
and O
ABA O
architectures O
, O
were O
assembled O
in O
" O
core O
- O
shell O
" O
NPs O
and O
loaded O
with O
both O
DTX B
and O
ZnPc B
employing O
the O
melting O
/ O
sonication O
method O
. O

Both O
CYP2B6 O
. O
6 O
and O
CYP2B6 O
. O
1 O
showed O
similar O
stereoselectivity O
( O
S B
> I
R I
- I
methadone I
) O
. O

The O
polyethylenimine B
( O
PEI B
) O
derivatives O
( O
PTn O
) O
are O
prepared O
by O
treating O
PEI25k O
with O
Tris B
( I
hydroxymethyl I
) I
acrylamidomethane I
via O
the O
Michael O
addition O
. O

Eight O
new O
compounds O
, O
including O
two O
cyclopenta B
[ I
b I
] I
benzopyran I
derivatives O
( O
1 O
, O
2 O
) O
, O
two O
cyclopenta B
[ I
b I
] I
benzofuran I
derivatives O
( O
3 O
, O
4 O
) O
, O
three O
cycloartane B
triterpenoids I
( O
5 O
- O
7 O
) O
, O
and O
an O
apocarotenoid O
( O
8 O
) O
, O
together O
with O
16 O
known O
compounds O
, O
were O
isolated O
from O
the O
chloroform B
- O
soluble O
partitions O
of O
separate O
methanol B
extracts O
of O
a O
combination O
of O
the O
fruits O
, O
leaves O
, O
and O
twigs O
and O
of O
the O
roots O
of O
Aglaia O

Eight O
new O
compounds O
, O
including O
two O
cyclopenta B
[ I
b I
] I
benzopyran I
derivatives O
( O
1 O
, O
2 O
) O
, O
two O
cyclopenta B
[ I
b I
] I
benzofuran I
derivatives O
( O
3 O
, O
4 O
) O
, O
three O
cycloartane B
triterpenoids I
( O
5 O
- O
7 O
) O
, O
and O
an O
apocarotenoid O
( O
8 O
) O
, O
together O
with O
16 O
known O
compounds O
, O
were O
isolated O
from O
the O
chloroform B
- O
soluble O
partitions O
of O
separate O
methanol B
extracts O
of O
a O
combination O
of O
the O
fruits O
, O
leaves O
, O
and O
twigs O
and O
of O
the O
roots O
of O
Aglaia O

The O
Mosher O
ester O
method O
was O
employed O
to O
determine O
the O
absolute O
configurations O
of O
5 O
- O
7 O
, O
and O
the O
absolute O
configuration O
of O
the O
9 O
, O
10 O
- O
diol B
unit O
of O
compound O
8 O
was O
established O
by O
a O
dimolybdenum B
tetraacetate I
[ O
Mo2 B
( I
AcO I
) I
4 I
] O
induced O
circular O
dichroism O
procedure O
. O

Among O
these O
derivatives O
were O
N B
- I
( I
3 I
- I
oxobutyl I
) I
- I
Tyr I
and O
two O
acetylated O
compounds O
, O
N B
- I
acetyl I
- I
Tyr I
and O
O B
- I
acetyl I
- I
Tyr I
, O
which O
were O
synthesized O
by O
reaction O
of O
Tyr B
with O
methyl B
vinyl I
ketone I
and O
acetic B
anhydride I
, O
respectively O
, O
at O
37 O
degrees O
C O
. O

Among O
these O
derivatives O
were O
N B
- I
( I
3 I
- I
oxobutyl I
) I
- I
Tyr I
and O
two O
acetylated O
compounds O
, O
N B
- I
acetyl I
- I
Tyr I
and O
O B
- I
acetyl I
- I
Tyr I
, O
which O
were O
synthesized O
by O
reaction O
of O
Tyr B
with O
methyl B
vinyl I
ketone I
and O
acetic B
anhydride I
, O
respectively O
, O
at O
37 O
degrees O
C O
. O

Exploiting O
catalytic O
promiscuity O
: O
The O
proline B
- O
based O
enzyme O
4 B
- I
oxalocrotonate I
tautomerase O
( O
4 B
- I
OT I
) O
promiscuously O
catalyzes O
asymmetric O
Michael O
- O
type O
additions O
of O
linear O
aldehydes B
- O
- O
ranging O
from O
acetaldehyde B
to O
octanal B
- O
- O
to O
trans B
- I
beta I
- I
nitrostyrene I
in O
aqueous O
solvent O
. O

Reaction O
of O
N B
- I
formylnorglaucine I
( O
3a O
) O
with O
90 O
% O
H2SO4 B
, O
however O
, O
yielded O
the O
9 B
- I
sulfonyl I
- I
seco I
product O
as O
a O
major O
product O
. O

We O
investigate O
the O
effects O
of O
variation O
in O
chemical O
conditions O
( O
solvent O
composition O
, O
water O
content O
, O
polymer O
concentration O
, O
and O
added O
salt O
) O
on O
the O
morphologies O
formed O
by O
PS B
- I
b I
- I
PAA I
in O
DMF B
/ O
dioxane B
/ O
water O
mixtures O
in O
a O
two O
- O
phase O
gas O
- O
liquid O
segmented O
microfluidic O
reactor O
. O

Trimethylamine B
- I
N I
- I
oxide I
, O
a O
metabolite O
associated O
with O
atherosclerosis O
, O
exhibits O
complex O
genetic O
and O
dietary O
regulation O
. O

Circulating O
trimethylamine B
- I
N I
- I
oxide I
( O
TMAO B
) O
levels O
are O
strongly O
associated O
with O
atherosclerosis O
. O

N B
- I
Acyl I
4 I
- I
( I
5 I
- I
pyrimidine I
- I
2 I
, I
4 I
- I
dionyl I
) I
phenylalanine I
derivatives O
of O
type O
4 O
were O
designed O
to O
replace O
the O
2 B
, I
6 I
- I
dichlorobenzoylamine I
portion O
of O
compound O
1 O
in O
order O
to O
identify O
novel O
compounds O
with O
improved O
potency O
against O
alpha O
4 O
- O
integrins O
. O

( B
- I
) I
- I
Xanthatin I
up O
- O
regulation O
of O
the O
GADD45 O
gamma O
tumor O
suppressor O
gene O
in O
MDA O
- O
MB O
- O
231 O
breast O
cancer O
cells O
: O
role O
of O
topoisomerase O
II O
alpha O
inhibition O
and O
reactive O
oxygen B
species O
. O

Previously O
, O
we O
reported O
that O
( B
- I
) I
- I
xanthatin I
, O
a O
naturally O
occurring O
xanthanolide B
present O
in O
the O
Cocklebur O
plant O
, O
exhibits O
potent O
anti O
- O
proliferative O
effects O
on O
human O
breast O
cancer O
cells O
, O
accompanied O
by O
an O
induction O
of O
the O
growth O
arrest O
and O
DNA O
damage O
- O
inducible O
gene O
45 O
gamma O
( O
GADD45 O
gamma O
) O
, O
recognized O
recently O
as O
a O
novel O
tumor O
suppressor O
gene O
. O

Topoisomerase O
II O
alpha O
( O
Topo O
II O
alpha O
) O
inhibition O
has O
been O
reported O
to O
produce O
a O
cell O
death O
response O
accompanied O
by O
an O
atypical O
DNA O
laddering O
fragmentation O
profile O
, O
similar O
to O
that O
noted O
previously O
for O
( B
- I
) I
- I
xanthatin I
. O

Therefore O
we O
hypothesized O
that O
( B
- I
) I
- I
xanthatin I
' O
s O
GADD45 O
gamma O
activation O
was O
mediated O
through O
the O
Topo O
II O
alpha O
pathway O
. O

Here O
, O
we O
identify O
that O
( B
- I
) I
- I
xanthatin I
does O
function O
as O
a O
catalytic O
inhibitor O
of O
Topo O
II O
alpha O
, O
promoting O
DNA O
damage O
. O

Mechanistically O
, O
it O
was O
determined O
that O
the O
induced O
levels O
of O
GADD45 O
gamma O
mRNA O
resulting O
from O
( B
- I
) I
- I
xanthatin I
exposures O
were O
stabilized O
by O
coordinately O
produced O
ROS O
, O
and O
that O
the O
consequent O
induction O
of O
GADD45 O
gamma O
mRNA O
, O
GADD45 O
gamma O
protein O
and O
ROS O
generation O
were O
abrogated O
by O
co O
- O
treatment O
with O
N B
- I
acetyl I
- I
l I
- I
cysteine I
. O

Taken O
together O
, O
the O
data O
support O
the O
concept O
that O
Topo O
II O
alpha O
inhibition O
by O
( B
- I
) I
- I
xanthatin I
is O
a O
trigger O
that O
stimulates O
expression O
of O
DNA O
damage O
- O
inducible O
GADD45 O
gamma O
mRNA O
and O
that O
concomitantly O
produced O
ROS O
act O
downstream O
to O
further O
enhance O
the O
GADD45 O
gamma O
mRNA O
/ O
GADD45 O
gamma O
protein O
induction O
process O
, O
resulting O
in O
breast O
cancer O
cell O
death O
. O

The O
asymmetric O
synthesis O
of O
8 B
, I
4 I
' I
- I
oxyneolignans I
( B
- I
) I
- I
virolin I
, O
( B
- I
) I
- I
surinamensin I
and O
a O
number O
of O
analogues O
has O
been O
achieved O
. O

The O
asymmetric O
synthesis O
of O
8 B
, I
4 I
' I
- I
oxyneolignans I
( B
- I
) I
- I
virolin I
, O
( B
- I
) I
- I
surinamensin I
and O
a O
number O
of O
analogues O
has O
been O
achieved O
. O

Although O
the O
levels O
of O
amino B
acid I
neurotransmitters O
, O
including O
glutamate B
, O
did O
not O
show O
marked O
alteration O
, O
the O
expression O
of O
the O
glutamatergic O
signaling O
pathway O
such O
as O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
, O
a B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methylisoxazole I
- I
4 I
- I
propionic I
acid I
receptor O
, O
calmodulin O
, O
Ca B
( I
2 I
+ I
) I
/ O
calmodulin O
- O
dependent O
protein O
kinases O
- O
II O
and O
cyclic B
adenosine I
monophosphate I
responsive O
element O
binding O
protein O
, O
was O
significantly O
reduced O
by O
TBT B
exposure O

In O
the O
present O
study O
, O
we O
aimed O
to O
examine O
the O
effect O
of O
blockade O
of O
L O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
( O
LTCC O
) O
and O
in O
addition O
the O
removal O
of O
extracellular O
Ca B
( I
2 I
+ I
) I
, O
on O
EFS O
- O
induced O
relaxations O
in O
rings O
of O
rat O
mesenteric O
artery O
. O

In O
the O
present O
study O
, O
we O
aimed O
to O
examine O
the O
effect O
of O
blockade O
of O
L O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
( O
LTCC O
) O
and O
in O
addition O
the O
removal O
of O
extracellular O
Ca B
( I
2 I
+ I
) I
, O
on O
EFS O
- O
induced O
relaxations O
in O
rings O
of O
rat O
mesenteric O
artery O
. O

Upon O
removal O
of O
Ca B
( I
2 I
+ I
) I
, O
EFS O
with O
the O
same O
stimulation O
parameters O
produced O
frequency O
- O
dependent O
transient O
contractions O
. O

These O
results O
suggest O
that O
in O
the O
absence O
of O
extracellular O
Ca B
( I
2 I
+ I
) I
EFS O
through O
membrane O
depolarization O
, O
evokes O
the O
opening O
of O
the O
LTCCs O
which O
subsequently O
leads O
to O
the O
release O
of O
Ca B
( I
2 I
+ I
) I
from O
internal O
stores O
via O
InsP3 O
receptors O
, O
a O
phenomenon O
known O
as O
Ca B
( I
2 I
+ I
) I
channel O
- O
induced O
Ca B
( I
2 I
+ I
) I
release O
( O
CCICR O
) O
, O
to O
trigger O
vasoconstriction O
. O

These O
results O
suggest O
that O
in O
the O
absence O
of O
extracellular O
Ca B
( I
2 I
+ I
) I
EFS O
through O
membrane O
depolarization O
, O
evokes O
the O
opening O
of O
the O
LTCCs O
which O
subsequently O
leads O
to O
the O
release O
of O
Ca B
( I
2 I
+ I
) I
from O
internal O
stores O
via O
InsP3 O
receptors O
, O
a O
phenomenon O
known O
as O
Ca B
( I
2 I
+ I
) I
channel O
- O
induced O
Ca B
( I
2 I
+ I
) I
release O
( O
CCICR O
) O
, O
to O
trigger O
vasoconstriction O
. O

These O
results O
suggest O
that O
in O
the O
absence O
of O
extracellular O
Ca B
( I
2 I
+ I
) I
EFS O
through O
membrane O
depolarization O
, O
evokes O
the O
opening O
of O
the O
LTCCs O
which O
subsequently O
leads O
to O
the O
release O
of O
Ca B
( I
2 I
+ I
) I
from O
internal O
stores O
via O
InsP3 O
receptors O
, O
a O
phenomenon O
known O
as O
Ca B
( I
2 I
+ I
) I
channel O
- O
induced O
Ca B
( I
2 I
+ I
) I
release O
( O
CCICR O
) O
, O
to O
trigger O
vasoconstriction O
. O

These O
results O
suggest O
that O
in O
the O
absence O
of O
extracellular O
Ca B
( I
2 I
+ I
) I
EFS O
through O
membrane O
depolarization O
, O
evokes O
the O
opening O
of O
the O
LTCCs O
which O
subsequently O
leads O
to O
the O
release O
of O
Ca B
( I
2 I
+ I
) I
from O
internal O
stores O
via O
InsP3 O
receptors O
, O
a O
phenomenon O
known O
as O
Ca B
( I
2 I
+ I
) I
channel O
- O
induced O
Ca B
( I
2 I
+ I
) I
release O
( O
CCICR O
) O
, O
to O
trigger O
vasoconstriction O
. O

That O
activation O
of O
LTCCs O
causes O
arterial O
relaxation O
or O
contraction O
depending O
on O
the O
Ca B
( I
2 I
+ I
) I
status O
apparently O
exemplifies O
how O
the O
same O
messenger O
fulfils O
opposing O
physiological O
functions O
in O
a O
given O
cell O
. O

We O
have O
recently O
reported O
that O
divalent B
Mn I
( O
Mn B
( I
2 I
+ I
) I
) O
stimulates O
brain O
microglia O
to O
produce O
and O
release O
hydrogen B
peroxide I
( O
H2O2 B
) O
, O
and O
microglial O
- O
free O
radical O
generation O
facilitates O
Mn B
( I
2 I
+ I
) I
- O
induced O
dopaminergic O
neurotoxicity O
. O

We O
have O
recently O
reported O
that O
divalent B
Mn I
( O
Mn B
( I
2 I
+ I
) I
) O
stimulates O
brain O
microglia O
to O
produce O
and O
release O
hydrogen B
peroxide I
( O
H2O2 B
) O
, O
and O
microglial O
- O
free O
radical O
generation O
facilitates O
Mn B
( I
2 I
+ I
) I
- O
induced O
dopaminergic O
neurotoxicity O
. O

The O
goal O
of O
this O
study O
was O
to O
elucidate O
the O
underlying O
mechanism O
of O
the O
Mn B
( I
2 I
+ I
) I
- O
induced O
H2O2 B
production O
in O
microglia O
. O

Exposure O
to O
low O
micromolar O
concentrations O
of O
Mn B
( I
2 I
+ I
) I
, O
but O
not O
divalent B
copper I
, I
cadmium I
, I
nickel I
, I
cobalt I
, I
zinc I
, I
and I
iron I
, O
induced O
a O
significant O
production O
of O
H2O2 B
from O
rat O
microglial O
but O
not O
astroglial O
cells O
. O

Subcellular O
fractionation O
studies O
revealed O
that O
Mn B
( I
2 I
+ I
) I
was O
capable O
of O
inducing O
significant O
H2O2 B
production O
in O
the O
mitochondrial O
but O
not O
the O
cytosolic O
or O
nuclear O
fraction O
prepared O
from O
microglia O
. O

Analysis O
of O
the O
relative O
contribution O
of O
mitochondrial O
respiratory O
chain O
complexes O
indicated O
that O
Mn B
( I
2 I
+ I
) I
- O
induced O
mitochondrial O
H2O2 B
production O
required O
the O
presence O
of O
complex O
II O
substrate O
succinate B
. O

In O
contrast O
, O
complex O
I O
substrates O
malate B
and O
glutamate B
failed O
to O
support O
H2O2 B
production O
in O
the O
presence O
of O
Mn B
( I
2 I
+ I
) I
. O

Furthermore O
, O
the O
succinate B
- O
supported O
Mn B
( I
2 I
+ I
) I
- O
induced O
mitochondrial O
H2O2 B
production O
was O
abolished O
by O
pharmacological O
inhibition O
of O
complex O
II O
but O
not O
that O
of O
complexes O
I O
and O
III O
, O
suggesting O
that O
mitochondrial O
complex O
II O
is O
a O
key O
mediator O
in O
Mn B
( I
2 I
+ I
) I
- O
induced O
H2O2 B
production O
. O

Furthermore O
, O
the O
succinate B
- O
supported O
Mn B
( I
2 I
+ I
) I
- O
induced O
mitochondrial O
H2O2 B
production O
was O
abolished O
by O
pharmacological O
inhibition O
of O
complex O
II O
but O
not O
that O
of O
complexes O
I O
and O
III O
, O
suggesting O
that O
mitochondrial O
complex O
II O
is O
a O
key O
mediator O
in O
Mn B
( I
2 I
+ I
) I
- O
induced O
H2O2 B
production O
. O

Human O
embryonic O
stem O
cell O
- O
derived O
cardiomyocytes O
( O
hESC O
- O
CMs O
) O
and O
the O
rat O
myoblastic O
H9c2 O
cell O
lines O
were O
used O
to O
phenotypically O
profile O
a O
panel O
of O
structural O
cardiotoxins O
by O
live O
- O
cell O
fluorescent O
imaging O
of O
mitochondrial O
membrane O
potential O
, O
endoplasmic O
reticulum O
integrity O
, O
Ca B
( I
2 I
+ I
) I
mobilization O
, O
and O
membrane O
permeability O
combined O
with O
an O
assessment O
of O
cell O
viability O
( O
ATP B
depletion O
) O
. O

Oxidative O
and O
nitrosative O
stress O
and O
apoptosis O
in O
oral O
mucosa O
cells O
after O
ex O
vivo O
exposure O
to O
lead O
and O
benzo B
[ I
a I
] I
pyrene I
. O

Exposure O
of O
human O
oral O
mucosa O
to O
lead O
( O
Pb B
) O
and O
benzo B
[ I
a I
] I
pyrene I
( O
BaP B
) O
by O
inhalation O
and O
ingestion O
can O
lead O
to O
pathological O
conditions O
via O
apoptosis O
and O
oxidative O
and O
nitrosative O
stress O
. O

Ex O
vivo O
samples O
of O
human O
oral O
mucosa O
were O
exposed O
to O
Pb B
or O
BaP B
, O
and O
immunohistochemical O
staining O
was O
performed O
to O
evaluate O
active O
caspase O
- O
3 O
, O
8 B
- I
epi I
- I
prostaglandin I
F2 I
alpha I
( O
8 B
- I
epi I
- I
PGF2a I
) O
, O
and O
3 B
- I
nitrotyrosine I
( O
3 B
- I
NT I
) O
. O

8 B
- I
Epi I
- I
PGF2a I
level O
increased O
only O
after O
prolonged O
incubation O
with O
Pb B
, O
and O
this O
elevation O
was O
irrespective O
of O
BaP B
incubation O
duration O
. O

FosA O
is O
a O
manganese B
- O
dependent O
enzyme O
that O
utilizes O
a O
Mn B
( I
2 I
+ I
) I
ion O
to O
catalyze O
the O
inactivation O
of O
the O
fosfomycin B
antibiotic O
by O
glutathione B
( O
GSH B
) O
addition O
. O

The O
second O
step O
is O
rate O
- O
limiting O
and O
is O
facilitated O
by O
the O
presence O
of O
the O
high O
- O
spin O
Mn B
( I
2 I
+ I
) I
ion O
that O
functions O
as O
a O
Lewis B
acid I
and O
stabilizes O
the O
leaving O
oxyanion O
through O
direct O
coordination O
. O

A O
reduction O
in O
myocardial O
necrosis O
was O
further O
evidenced O
by O
the O
tri B
- I
phenyl I
tetrazolium I
chloride I
( O
TTC B
) O
stain O
in O
isolated O
test O
drug O
pretreated O
rats O
. O

Well O
structured O
: O
As O
a O
new O
triose B
phosphate I
isomerase O
( O
TIM O
) O
barrel O
- O
fold O
prenyl O
transferase O
, O
PcrB O
catalyzes O
the O
production O
of O
heptaprenylglyceryl B
phosphate I
from O
heptaprenyl B
diphosphate I
and O
glycerol B
- I
1 I
- I
phosphate I
. O

Furthermore O
, O
the O
structure O
- O
activity O
relationship O
of O
a O
bis B
( I
aryl I
) I
ether I
C B
- O
terminal O
capping O
group O
mimicking O
dipeptide B
interactions O
was O
probed O
through O
ring O
substitutions O
, O
allowing O
increased O
complementarity O
with O
the O
primary O
hydrophobic O
pocket O
. O

All B
- I
trans I
retinoic I
acid I
( O
RA O
) O
has O
been O
proved O
to O
play O
important O
roles O
in O
regulating O
cell O
growth O
in O
various O
types O
of O
cells O
. O

This O
protozoan O
parasite O
relies O
on O
inosine B
5 I
' I
- I
monophosphate I
dehydrogenase O
( O
IMPDH O
) O
for O
the O
production O
of O
guanine B
nucleotides I
. O

Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly B
- I
ADP I
- I
ribose I
polymerase O
( O
PARP O
) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
( O
AEG1 O
) O
and O
survivin O
in O
HepG2 O
cells O
. O

Abstract O
Objective O
: O
To O
design O
and O
evaluate O
a O
novel O
pressure O
sensitive O
adhesive O
( O
PSA O
) O
patch O
containing O
traditional O
Chinese O
medicine O
( O
TCM O
) O
using O
styrene B
- I
isoprene I
- I
styrene I
( O
SIS B
) O
copolymer O
. O

The O
macrocyclic O
peptide O
natural O
product O
CJ B
- I
15 I
, I
208 I
is O
orally O
active O
and O
prevents O
reinstatement O
of O
extinguished O
cocaine B
- O
seeking O
behavior O
. O

The O
macrocyclic B
tetrapeptide I
natural O
product O
CJ B
- I
15 I
, I
208 I
( O
cyclo B
[ I
Phe I
- I
d I
- I
Pro I
- I
Phe I
- I
Trp I
] I
) O
exhibited O
both O
dose O
- O
dependent O
antinociception O
and O
kappa O
opioid O
receptor O
( O
KOR O
) O
antagonist O
activity O
after O
oral O
administration O
. O

CJ B
- I
15 I
, I
208 I
antagonized O
a O
centrally O
administered O
KOR O
selective O
agonist O
, O
providing O
strong O
evidence O
it O
crosses O
the O
blood O
- O
brain O
barrier O
to O
reach O
KOR O
in O
the O
CNS O
. O

Orally O
administered O
CJ B
- I
15 I
, I
208 I
also O
prevented O
both O
cocaine B
- O
and O
stress O
- O
induced O
reinstatement O
of O
extinguished O
cocaine B
- O
seeking O
behavior O
in O
the O
conditioned O
place O
preference O
assay O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
. O

Thus O
, O
CJ B
- I
15 I
, I
208 I
is O
a O
promising O
lead O
compound O
with O
a O
unique O
activity O
profile O
for O
potential O
development O
, O
particularly O
as O
a O
therapeutic O
to O
prevent O
relapse O
to O
drug O
- O
seeking O
behavior O
in O
abstinent O
subjects O
. O

The O
membrane O
potential O
measured O
by O
the O
sensitive O
dye O
4 B
- I
Di I
- I
ANNEPS I
demonstrated O
that O
RuBPY B
induces O
cell O
membrane O
hyperpolarization O
. O

The O
inhibition O
of O
HIF O
- O
2 O
alpha O
on O
the O
ATM O
/ O
Chk O
- O
2 O
pathway O
is O
involved O
in O
the O
promotion O
effect O
of O
arsenite B
on O
benzo B
( I
a I
) I
pyrene I
- O
induced O
cell O
transformation O
. O

Both O
arsenite B
and O
benzo B
( I
a I
) I
pyrene I
( O
BaP B
) O
are O
known O
human O
carcinogens O
. O

Small O
molecules O
with O
oxathiazol B
- I
2 I
- I
one I
moiety O
were O
recently O
reported O
as O
potent O
inhibitors O
of O
Mycobacterium O
bovis O
var O
. O
bacilli O
Calmette O
- O
Gu O
e O
rin O
( O
BCG O
) O
, O
among O
which O
HT1171 B
was O
the O
most O
potent O
and O
selective O
proteasome O
inhibitor O
. O

Herein O
we O
synthesized O
a O
series O
of O
novel O
compounds O
by O
bioisosteric O
replacement O
of O
the O
oxathiazol B
- I
2 I
- I
one I
ring O
with O
3H B
- I
1 I
, I
2 I
, I
4 I
- I
dithiazol I
- I
3 I
- I
one I
, O
and O
also O
fifteen O
1 B
, I
3 I
, I
4 I
- I
oxathiazol I
- I
2 I
- I
one I
molecules O
in O
order O
for O
potency O
comparison O
and O
structure O
- O
activity O
relationship O
elucidation O
since O
their O
antibacterial O
effects O
on O
the O
virulent O
strains O
were O
not O
evaluated O
before O
. O

Electronic O
and O
EPR O
spectra O
of O
the O
species O
involved O
in O
[ B
W10O32 I
] I
4 I
- I
photocatalysis O
. O

The O
essential O
oils O
consisted O
mainly O
of O
monoterpenes B
, O
alpha B
- I
pinene I
( O
27 O
. O
4 O
- O
59 O
. O
2 O
% O
) O
and O
1 B
, I
8 I
- I
cineole I
( O
6 O
. O
1 O
- O
34 O
. O
3 O
% O
) O
being O
the O
major O
components O
. O

Subgroups O
IA O
and O
IB O
could O
be O
distinguished O
by O
their O
contents O
of O
alpha B
- I
pinene I
and O
1 B
, I
8 I
- I
cineole I
. O

Subgroups O
IIA O
and O
IIB O
differed O
substantially O
in O
their O
contents O
of O
1 B
, I
8 I
- I
cineole I
and O
limonene B
. O

The O
catalytic O
reactivity O
of O
Co B
( I
II I
) I
( I
Ch I
) I
was O
much O
higher O
than O
that O
of O
a O
cobalt B
porphyrin I
complex O
( O
Co B
( I
II I
) I
( I
OEP I
) I
, O
OEP B
( I
2 I
- I
) I
= O
octaethylporphyrin B
dianion O
) O
, O
which O
is O
a O
typical O
porphyrinoid O
complex O
. O

The O
two O
- O
electron O
reduction O
of O
O B
( I
2 I
) I
by O
1 B
, I
1 I
' I
- I
dibromoferrocene I
( O
Br B
( I
2 I
) I
Fc I
) O
was O
catalyzed O
by O
Co B
( I
II I
) I
( I
Ch I
) I
, O
whereas O
virtually O
no O
reduction O
of O
O B
( I
2 I
) I
occurred O
with O
Co B
( I
II I
) I
( I
OEP I
) I
. O

The O
controlled O
nature O
of O
the O
polymerization O
of O
the O
said O
chiral O
monomers O
in O
N B
, I
N I
- I
dimethylformamide I
( O
DMF B
) O
at O
70 O
degrees O
C O
is O
evident O
from O
the O
formation O
of O
narrow O
polydisperse O
polymers O
, O
the O
molecular O
weight O
controlled O
by O
the O
monomer O
/ O
chain O
transfer O
agent O
( O
CTA O
) O
molar O
ratio O
and O
the O
linear O
relationship O
between O
molecular O
weight O
and O
monomer O
conversion O
. O

The O
resulting O
well O
- O
defined O
polymers O
were O
used O
as O
macro O
- O
CTAs O
to O
prepare O
corresponding O
diblock O
copolymers O
by O
RAFT O
polymerization O
of O
methyl B
( I
meth I
) I
acrylate I
monomers O
. O

It O
was O
marked O
by O
significant O
accumulation O
of O
lipid O
droplets O
as O
determined O
by O
Oil B
- I
Red I
- I
O I
( O
ORO B
) O
based O
colorimetric O
assay O
, O
increased O
triacylglycerol B
( O
TAG B
) O
and O
increased O
lipid O
peroxidation O
. O

The O
stereoisomer O
( B
+ I
) I
- I
naloxone I
potentiates O
G O
- O
protein O
coupling O
and O
feeding O
associated O
with O
stimulation O
of O
mu O
opioid O
receptors O
in O
the O
parabrachial O
nucleus O
. O

Treatment O
with O
ultra O
- O
low O
doses O
of O
the O
nonselective O
opioid O
antagonist O
( B
- I
) I
- I
naloxone I
or O
its O
inactive O
enantiomer O
( B
+ I
) I
- I
naloxone I
blocks O
this O
excitatory O
effect O
and O
enhances O
Gi O
- O
coupling O
. O

Treatment O
with O
ultra O
- O
low O
doses O
of O
the O
nonselective O
opioid O
antagonist O
( B
- I
) I
- I
naloxone I
or O
its O
inactive O
enantiomer O
( B
+ I
) I
- I
naloxone I
blocks O
this O
excitatory O
effect O
and O
enhances O
Gi O
- O
coupling O
. O

Pretreatment O
with O
( B
- I
) I
- I
naloxone I
blocks O
this O
effect O
. O

We O
used O
this O
parabrachial O
circuit O
as O
a O
model O
to O
assess O
cellular O
actions O
of O
ultra O
- O
low O
doses O
of O
( B
- I
) I
- I
naloxone I
and O
( B
+ I
) I
- I
naloxone I
in O
modifying O
the O
effects O
of O
DAMGO B
. O

We O
used O
this O
parabrachial O
circuit O
as O
a O
model O
to O
assess O
cellular O
actions O
of O
ultra O
- O
low O
doses O
of O
( B
- I
) I
- I
naloxone I
and O
( B
+ I
) I
- I
naloxone I
in O
modifying O
the O
effects O
of O
DAMGO B
. O

Our O
results O
showed O
that O
an O
ultra O
- O
low O
concentration O
of O
( B
- I
) I
- I
naloxone I
( O
0 O
. O
001 O
nM O
) O
and O
several O
concentrations O
of O
( B
+ I
) I
- I
naloxone I
( O
0 O
. O
01 O
- O
10 O
nM O
) O
enhanced O
DAMGO B
- O
stimulated O
guanosine B
- I
5 I
' I
- I
0 I
- I
( I
gamma I
- I
thio I
) I
- I
triphosphate I
incorporation O
in O
parabrachial O
sections O
in O
vitro O
. O

Our O
results O
showed O
that O
an O
ultra O
- O
low O
concentration O
of O
( B
- I
) I
- I
naloxone I
( O
0 O
. O
001 O
nM O
) O
and O
several O
concentrations O
of O
( B
+ I
) I
- I
naloxone I
( O
0 O
. O
01 O
- O
10 O
nM O
) O
enhanced O
DAMGO B
- O
stimulated O
guanosine B
- I
5 I
' I
- I
0 I
- I
( I
gamma I
- I
thio I
) I
- I
triphosphate I
incorporation O
in O
parabrachial O
sections O
in O
vitro O
. O

In O
the O
present O
study O
, O
we O
show O
that O
( B
+ I
) I
- I
naloxone I
can O
potentiate O
DAMGO B
- O
induced O
feeding O
at O
doses O
at O
which O
( B
- I
) I
- I
naloxone I
was O
an O
antagonist O
. O

In O
the O
present O
study O
, O
we O
show O
that O
( B
+ I
) I
- I
naloxone I
can O
potentiate O
DAMGO B
- O
induced O
feeding O
at O
doses O
at O
which O
( B
- I
) I
- I
naloxone I
was O
an O
antagonist O
. O

These O
results O
implicated O
( B
+ I
) I
- I
naloxone I
as O
a O
novel O
tool O
for O
studying O
mu O
- O
opioid O
receptor O
functions O
and O
suggest O
that O
( B
+ I
) I
- I
naloxone I
may O
have O
therapeutic O
value O
to O
enhance O
clinical O
actions O
of O
opiate O
drugs O
. O

These O
results O
implicated O
( B
+ I
) I
- I
naloxone I
as O
a O
novel O
tool O
for O
studying O
mu O
- O
opioid O
receptor O
functions O
and O
suggest O
that O
( B
+ I
) I
- I
naloxone I
may O
have O
therapeutic O
value O
to O
enhance O
clinical O
actions O
of O
opiate O
drugs O
. O

In O
the O
vasculature O
, O
insulin O
signaling O
plays O
a O
critical O
role O
in O
normal O
vascular O
function O
via O
endothelial O
cell O
nitric B
oxide I
production O
and O
modulation O
of O
Ca B
( I
2 I
+ I
) I
handling O
and O
sensitivity O
in O
vascular O
smooth O
muscle O
cells O
. O

A O
combination O
of O
NMR O
analyses O
, O
transient O
absorption O
spectroscopy O
, O
and O
fluorescence O
measurements O
in O
water O
and O
acetonitrile B
reveal O
that O
complex O
1 O
( O
2 O
+ O
) O
must O
be O
hydrated O
at O
the O
quinone B
functionality O
, O
giving O
[ B
( I
phen I
) I
( I
2 I
) I
Ru I
( I
phenH I
( I
2 I
) I
O I
) I
] I
( I
2 I
+ I
) I
( O
1H B
( I
2 I
) I
O I
( I
2 I
+ I
) I
, O
where O
phenH B
( I
2 I
) I
O I
= O
1 B
, I
10 I
- I
phenanthroline I
- I
6 I
- I
one I
- I
5 I
- I
diol I
) O
, O
in O
order O
to O
access O
a O
long O
- O
lived O
( O
3 O
) O

MLCT O
( O
hydrate B
) O
state O
( O
tau O
~ O
360 O
ns O
in O
H B
( I
2 I
) I
O I
) O
which O
is O
responsible O
for O
DNA O
cleavage O
. O

Increased O
protein O
sorption O
in O
poly B
( I
acrylic I
acid I
) I
- O
containing O
films O
through O
incorporation O
of O
comb O
- O
like O
polymers O
and O
film O
adsorption O
at O
low O
pH O
and O
high O
ionic O
strength O
. O

In O
the O
absence O
of O
added O
salt O
, O
alternating O
adsorption O
of O
5 O
bilayers O
of O
protonated O
poly B
( I
allylamine I
) I
( O
PAH B
) O
and O
comb O
- O
like O
poly B
( I
2 I
- I
hydroxyethyl I
methacrylate I
) I
- I
graft I
- I
poly I
( I
acrylic I
acid I
) I
( O
PHEMA B
- I
g I
- I
PAA I
) O
leads O
to O
~ O
2 O
- O
fold O
thicker O
coatings O
than O
adsorption O
of O
PAH B
and O
linear O
PAA B
, O
and O
the O
difference O
in O
the O
thicknesses O
of O
the O
two O
coatings O
increases O
with O
the O
number O
of O
bilayers O
. O

Moreover O
, O
the O
( O
PAH B
/ O
PHEMA B
- I
g I
- I
PAA I
) O
n O
films O
sorb O
2 O
- O
to O
4 O
- O
fold O
more O
protein O
than O
corresponding O
films O
prepared O
with O
linear O
PAA B
, O
and O
coatings O
deposited O
at O
pH O
3 O
. O
0 O
sorb O
more O
protein O
than O
coatings O
adsorbed O
at O
pH O
5 O
. O
0 O
, O
7 O
. O
0 O
, O
or O
9 O
. O
0 O
. O

When O
deposited O
from O
0 O
. O
5 O
M O
NaCl B
at O
pH O
3 O
. O
0 O
, O
both O
( O
PAH B
/ O
PHEMA B
- I
g I
- I
PAA I
) O
5 O
and O
( O
PAH B
/ O
PAA B
) O
5 O
films O
increase O
in O
thickness O
more O
than O
400 O
% O
upon O
adsorption O
of O
lysozyme O
. O

When O
the O
strain O
was O
grown O
in O
the O
presence O
of O
1 B
, I
4 I
- I
butanediol I
( O
BDO B
) O
as O
a O
4HB B
precursor O
, O
P4HB B
block O
was O
formed O
. O

Sequential O
supplementation O
of O
1 B
, I
3 I
- I
propanediol I
( O
PDO B
) O
as O
a O
3HP B
precursor O
allowed O
the O
strain O
to O
produce O
P3HP B
block O
. O

Thermal O
, O
NMR O
, O
fractionation O
, O
and O
mechanical O
characterizations O
confirmed O
the O
resulting O
polymer O
as O
a O
block O
copolymer O
of O
P3HP B
- I
b I
- I
P4HB I
. O

Five O
new O
series O
of O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyridines I
carrying O
biologically O
active O
pyrazoline B
( O
4a O
- O
e O
) O
, O
cyanopyridone B
( O
5a O
, O
b O
) O
, O
cyanopyridine B
( O
6a O
- O
f O
) O
, O
2 B
- I
aminopyrimidine I
( O
7a O
- O
f O
) O
and O
pyrimidine B
- I
2 I
- I
thione I
( O
8a O
- O
d O
) O
systems O
were O
designed O
and O
synthesized O
as O
prominent O
anticonvulsant O
agents O
. O

Encapsulation O
of O
Nod1 O
and O
Nod2 O
receptor O
ligands O
into O
poly B
( I
lactic I
acid I
) I
nanoparticles O
potentiates O
their O
immune O
properties O
. O

As O
activation O
of O
intracytoplasmic O
NLRs O
is O
able O
to O
induce O
proinflammatory O
molecules O
, O
the O
added O
value O
of O
encapsulation O
of O
Nod1 O
and O
Nod2 O
receptor O
ligands O
into O
Poly B
( I
Lactic I
Acid I
) I
( O
PLA B
) O
biodegradable O
nanocarriers O
to O
modulate O
their O
immune O
properties O
on O
human O
dendritic O
cells O
( O
DCs O
) O
maturation O
has O
been O
evaluated O
. O

Differential O
regulation O
of O
drug O
transporter O
expression O
by O
all B
- I
trans I
retinoic I
acid I
in O
hepatoma O
HepaRG O
cells O
and O
human O
hepatocytes O
. O

All B
- I
trans I
retinoic I
acid I
( O
atRA B
) O
is O
the O
active O
form O
of O
vitamin B
A I
, O
known O
to O
activate O
retinoid O
receptors O
, O
especially O
the O
heterodimer O
retinoid O
X O
receptor O
( O
RXR O
) O
: O
retinoic B
acid I
receptor O
( O
RAR O
) O
that O
otherwise O
may O
play O
a O
role O
in O
regulation O
of O
some O
drug O
transporters O
. O

Cytotoxicity O
of O
lapachol B
, O
beta B
- I
lapachone I
and O
related O
synthetic O
1 B
, I
4 I
- I
naphthoquinones I
against O
oesophageal O
cancer O
cells O
. O

The O
secondary O
metabolites O
lapachol O
, O
alpha B
- I
and I
beta I
- I
lapachone I
and O
a O
series O
of O
25 O
related O
synthetic O
1 B
, I
4 I
- I
naphthoquinones I
were O
screened O
against O
the O
oesophageal O
cancer O
cell O
line O
( O
WHCO1 O
) O
. O

[ O
Zn B
( I
fpedtc I
) I
2 I
] O
( O
1 O
) O
, O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
py I
) I
] O
( O
2 O
) O
, O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
1 I
, I
10 I
- I
phen I
) I
] O
( O
3 O
) O
and O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
2 I
, I
2 I
' I
- I
bipy I
) I
] O
( O
4 O
) O
( O
where O
fpedtc B
= O
N B
- I
furfuryl I
- I
N I
- I
( I
2 I
- I
phenylethyl I
) I
dithiocarbamate I
, O
py O
= O
pyridine B
, O
1 B
, I
10 I
- I
phen I
= O

[ O
Zn B
( I
fpedtc I
) I
2 I
] O
( O
1 O
) O
, O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
py I
) I
] O
( O
2 O
) O
, O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
1 I
, I
10 I
- I
phen I
) I
] O
( O
3 O
) O
and O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
2 I
, I
2 I
' I
- I
bipy I
) I
] O
( O
4 O
) O
( O
where O
fpedtc B
= O
N B
- I
furfuryl I
- I
N I
- I
( I
2 I
- I
phenylethyl I
) I
dithiocarbamate I
, O
py O
= O
pyridine B
, O
1 B
, I
10 I
- I
phen I
= O

1 B
, I
10 I
- I
phenanthroline I
and O
2 B
, I
2 I
' I
- I
bipy I
= O
2 B
, I
2 I
' I
- I
bipyridine I
) O
were O
synthesized O
. O

242084 I
) O
, O
and O
5 O
- O
HT2B O
/ O
2C O
( O
SB B
- I
206553 I
) O
receptors O
attenuated O
the O
DOI B
- O
elicited O
- O
HTR O
. O

These O
agents O
include O
newer O
incretin O
- O
based O
therapies O
and O
PPAR O
agonists O
, O
as O
well O
as O
new O
therapeutic O
classes O
such O
as O
sodium B
- O
coupled O
glucose B
cotransporter O
2 O
inhibitors O
, O
free O
fatty B
acid I
receptor O
agonists O
, O
11 B
- I
beta I
- I
hydroxysteroid I
dehydrogenase O
type O
1 O
inhibitors O
, O
glucokinase O
activators O
, O
and O
several O
others O
that O
may O
enter O
clinical O
use O
over O
the O
next O
decade O
. O

PEG B
- O
Modified O
Macroporous O
Poly B
( I
Glycidyl I
Methacrylate I
) I
and O
Poly B
( I
2 I
- I
Hydroxyethyl I
Methacrylate I
) I
Microspheres O
to O
Reduce O
Non O
- O
Specific O
Protein O
Adsorption O
. O

To O
minimize O
non O
- O
specific O
protein O
adsorption O
on O
macroporous O
poly B
( I
glycidyl I
methacrylate I
) I
and O
poly B
( I
2 I
- I
hydroxyethyl I
methacrylate I
) I
microspheres O
containing O
amino B
and O
/ O
or O
carboxyl B
groups O
, O
the O
microspheres O
are O
coated O
with O
alpha B
, I
omega I
- I
bis I
- I
carboxy I
poly I
( I
ethylene I
glycol I
) I
and O
amino B
- O
terminated O
poly B
( I
ethylene I
glycol I
- I
co I
- I
propylene I
glycol I
) I
or O
alpha B
- I
methoxy I
- I
omega I
- I
amino I

We O
measure O
concentration O
- O
dependent O
diffusion O
rates O
for O
n B
- I
hexane I
, O
n B
- I
octane I
, O
n B
- I
decane I
, O
2 B
, I
7 I
- I
dimethyloctane I
, O
and O
cyclodecane B
, O
which O
have O
different O
carbon B
numbers O
and O
geometries O
: O
straight O
chain O
, O
branched O
chain O
, O
and O
cyclic O
. O

pi O
- O
Conjugated O
nickel B
bis I
( I
dithiolene I
) I
complex O
nanosheet O
. O

A O
pi O
- O
conjugated O
nanosheet O
comprising O
planar O
nickel B
bis I
( I
dithiolene I
) I
complexes O
was O
synthesized O
by O
a O
bottom O
- O
up O
method O
. O

A O
liquid O
- O
liquid O
interfacial O
reaction O
using O
benzenehexathiol B
in O
the O
organic O
phase O
and O
nickel B
( I
II I
) I
acetate I
in O
the O
aqueous O
phase O
produced O
a O
semiconducting O
bulk O
material O
with O
a O
thickness O
of O
several O
micrometers O
. O

The O
average O
charge O
and O
discharge O
potentials O
are O
~ O
2 O
. O
03 O
and O
~ O
1 O
. O
0 O
V O
, O
respectively O
for O
the O
decomposition O
/ O
formation O
of O
Li B
( I
3 I
) I
N I
as O
determined O
by O
electroanalytical O
techniques O
. O

While O
the O
cation O
exchange O
procedure O
, O
performed O
in O
solution O
phase O
approach O
, O
was O
restricted O
so O
far O
to O
chalcogenide O
based O
semiconductor O
nanocrystals O
, O
here O
ferrite B
- O
based O
nanocrystals O
were O
subjected O
to O
a O
Fe B
( I
2 I
+ I
) I
to O
Co B
( I
2 I
+ I
) I
cation O
exchange O
procedure O
. O

While O
the O
cation O
exchange O
procedure O
, O
performed O
in O
solution O
phase O
approach O
, O
was O
restricted O
so O
far O
to O
chalcogenide O
based O
semiconductor O
nanocrystals O
, O
here O
ferrite B
- O
based O
nanocrystals O
were O
subjected O
to O
a O
Fe B
( I
2 I
+ I
) I
to O
Co B
( I
2 I
+ I
) I
cation O
exchange O
procedure O
. O

For O
core O
/ O
shell O
nanoheterostructures O
a O
selective O
doping O
of O
either O
the O
shell O
or O
predominantly O
of O
the O
core O
with O
Co B
( I
2 I
+ I
) I
is O
demonstrated O
. O

Manx O
is O
a O
symmetric O
bicyclic O
compound O
consisting O
of O
two O
fused O
1 B
, I
3 I
- I
dioxane I
rings O
and O
bearing O
two O
primary O
hydroxyl B
groups O
. O

In O
addition O
, O
random O
copolyesters O
( O
PBxManxyS O
) O
covering O
a O
broad O
range O
of O
compositions O
have O
been O
obtained O
using O
mixtures O
of O
Manx O
and O
1 B
, I
4 I
- I
butanediol I
in O
the O
reaction O
with O
dimethyl B
succinate I
. O

Organometallic O
half O
- O
sandwich O
complexes O
[ B
M I
( I
p I
- I
cymene I
) I
( I
azo I
/ I
imino I
- I
pyridine I
) I
X I
] I
( I
+ I
) I
where O
M B
= I
Ru I
( I
II I
) I
or I
Os I
( I
II I
) I
and O
X B
= I
Cl I
or I
I I
, O
exhibit O
potent O
antiproliferative O
activity O
toward O
a O
range O
of O
cancer O
cells O
. O

A O
hydrothermal O
reaction O
of O
HNbO B
3 I
and O
LiOH B
. I
H I
2 I
O I
in O
PEG200 B
and O
water O
at O
~ O
180 O
degrees O
C O
yields O
~ O
15 O
- O
40 O
nm O
Li B
3 I
NbO I
4 I
particles O
. O

Environmentally O
friendly O
poly B
( I
butylenesuccinate I
- I
co I
- I
butyleneazelate I
) I
( O
P B
( I
BS I
- I
co I
- I
BAz I
) I
s I
) O
aliphatic B
copolyesters I
with O
composition O
- O
dependent O
thermomechanical O
properties O
were O
synthesized O
from O
succinic B
acid I
( O
SuA B
) O
, O
1 B
, I
4 I
- I
butanediol I
( O
BDO B
) O
, O
and O
dimethylazelate B
( O
DMAz B
) O
through O
a O
two O
- O
step O
polycondensation O
reaction O
. O

Vitamin B
D I
( I
3 I
) I
and O
probucol B
were O
detected O
at O
265 O
nm O
and O
vitamin B
K I
( I
1 I
) I
at O
239 O
nm O
. O

Vitamin B
D I
( I
3 I
) I
and O
probucol B
were O
detected O
at O
265 O
nm O
and O
vitamin B
K I
( I
1 I
) I
at O
239 O
nm O
. O

The O
limit O
of O
quantification O
( O
LOQ O
) O
was O
20 O
ng O
/ O
mL O
for O
vitamin B
D I
( I
3 I
) I
and O
40 O
ng O
/ O
mL O
for O
K O
( O
1 O
) O
. O

The O
pharmacokinetic O
parameters O
of O
vitamin B
D I
( I
3 I
) I
following O
intravenous O
administration O
were O
: O
AUC O
( O
0 O
- O
infinity O
) O
= O
11323 O
+ O
/ O
- O
1081 O
h O
x O
ng O
/ O
mL O
, O
V O
( O
d O
) O
= O
218 O
+ O
/ O
- O
80 O
mL O
/ O
kg O
, O
CL O
= O
8 O
. O
9 O
+ O
/ O
- O
0 O
. O
8 O
mL O
/ O
h O
/ O
kg O
, O
t O
( O
1 O
/ O
2 O
) O
= O
16 O
. O
8 O
+ O
/ O
- O
5 O
h O
; O
and O
of O
vitamin B
K I
( I
1 I
) I
: O
AUC O
( O
0 O
- O
infinity O
) O
= O
2495 O
+ O
/ O
- O
297 O
h O
x O
ng O
/ O
mL O
, O

The O
pharmacokinetic O
parameters O
of O
vitamin B
D I
( I
3 I
) I
following O
intravenous O
administration O
were O
: O
AUC O
( O
0 O
- O
infinity O
) O
= O
11323 O
+ O
/ O
- O
1081 O
h O
x O
ng O
/ O
mL O
, O
V O
( O
d O
) O
= O
218 O
+ O
/ O
- O
80 O
mL O
/ O
kg O
, O
CL O
= O
8 O
. O
9 O
+ O
/ O
- O
0 O
. O
8 O
mL O
/ O
h O
/ O
kg O
, O
t O
( O
1 O
/ O
2 O
) O
= O
16 O
. O
8 O
+ O
/ O
- O
5 O
h O
; O
and O
of O
vitamin B
K I
( I
1 I
) I
: O
AUC O
( O
0 O
- O
infinity O
) O
= O
2495 O
+ O
/ O
- O
297 O
h O
x O
ng O
/ O
mL O
, O

A O
higher O
dose O
of O
vitamin B
K I
( I
1 I
) I
should O
be O
used O
in O
future O
studies O
for O
accurate O
estimation O
of O
pharmacokinetic O
parameters O
. O

This O
work O
aims O
to O
resolve O
some O
controversies O
about O
astatine B
( I
III I
) I
hydroxide I
species O
present O
in O
oxidant O
aqueous O
solution O
. O

Projection O
analysis O
of O
the O
chemical O
shift O
changes O
by O
site O
- O
specific O
amino B
acid I
substitutions O
and O
ligand O
titrations O
indicates O
that O
alpha O
TS O
has O
three O
important O
conformational O
states O
: O
ligand O
- O
free O
, O
glyceraldehyde B
- I
3 I
- I
phosphate I
- O
bound O
( O
like O
) O
, O
and O
the O
active O
states O
. O

This O
enzyme O
hardly O
acts O
on O
an O
oxidized O
form O
of O
GMP B
( O
8 B
- I
oxo I
- I
GMP I
) O
formed O
by O
the O
oxidation O
of O
GMP B
or O
by O
the O
cleavage O
of O
8 B
- I
oxo I
- I
GDP I
and O
8 B
- I
oxo I
- I
GTP I
by O
MutT O
protein O
. O

This O
enzyme O
hardly O
acts O
on O
an O
oxidized O
form O
of O
GMP B
( O
8 B
- I
oxo I
- I
GMP I
) O
formed O
by O
the O
oxidation O
of O
GMP B
or O
by O
the O
cleavage O
of O
8 B
- I
oxo I
- I
GDP I
and O
8 B
- I
oxo I
- I
GTP I
by O
MutT O
protein O
. O

This O
enzyme O
hardly O
acts O
on O
an O
oxidized O
form O
of O
GMP B
( O
8 B
- I
oxo I
- I
GMP I
) O
formed O
by O
the O
oxidation O
of O
GMP B
or O
by O
the O
cleavage O
of O
8 B
- I
oxo I
- I
GDP I
and O
8 B
- I
oxo I
- I
GTP I
by O
MutT O
protein O
. O

Although O
the O
formation O
of O
8 B
- I
oxo I
- I
GDP I
from O
8 B
- I
oxo I
- I
GMP I
is O
thus O
prevented O
, O
8 B
- I
oxo I
- I
GDP I
itself O
may O
be O
produced O
by O
the O
oxidation O
of O
GDP B
by O
reactive O
oxygen B
species O
. O

Although O
the O
formation O
of O
8 B
- I
oxo I
- I
GDP I
from O
8 B
- I
oxo I
- I
GMP I
is O
thus O
prevented O
, O
8 B
- I
oxo I
- I
GDP I
itself O
may O
be O
produced O
by O
the O
oxidation O
of O
GDP B
by O
reactive O
oxygen B
species O
. O

Although O
the O
formation O
of O
8 B
- I
oxo I
- I
GDP I
from O
8 B
- I
oxo I
- I
GMP I
is O
thus O
prevented O
, O
8 B
- I
oxo I
- I
GDP I
itself O
may O
be O
produced O
by O
the O
oxidation O
of O
GDP B
by O
reactive O
oxygen B
species O
. O

The O
8 B
- I
oxo I
- I
GDP I
thus O
formed O
can O
be O
converted O
to O
8 B
- I
oxo I
- I
GTP I
because O
nucleoside B
- I
diphosphate I
kinase O
and O
adenylate B
kinase O
, O
both O
of O
which O
catalyze O
the O
conversion O
of O
GDP B
to O
GTP B
, O
do O
not O
discriminate O
8 B
- I
oxo I
- I
GDP I
from O
normal O
GDP B
. O

The O
8 B
- I
oxo I
- I
GDP I
thus O
formed O
can O
be O
converted O
to O
8 B
- I
oxo I
- I
GTP I
because O
nucleoside B
- I
diphosphate I
kinase O
and O
adenylate B
kinase O
, O
both O
of O
which O
catalyze O
the O
conversion O
of O
GDP B
to O
GTP B
, O
do O
not O
discriminate O
8 B
- I
oxo I
- I
GDP I
from O
normal O
GDP B
. O

The O
8 B
- I
oxo I
- I
GDP I
thus O
formed O
can O
be O
converted O
to O
8 B
- I
oxo I
- I
GTP I
because O
nucleoside B
- I
diphosphate I
kinase O
and O
adenylate B
kinase O
, O
both O
of O
which O
catalyze O
the O
conversion O
of O
GDP B
to O
GTP B
, O
do O
not O
discriminate O
8 B
- I
oxo I
- I
GDP I
from O
normal O
GDP B
. O

The O
8 B
- I
oxo I
- I
GTP I
produced O
in O
this O
way O
and O
by O
the O
oxidation O
of O
GTP B
can O
be O
used O
for O
RNA O
synthesis O
. O

This O
misincorporation O
is O
prevented O
by O
MutT O
protein O
, O
which O
has O
the O
potential O
to O
cleave O
8 B
- I
oxo I
- I
GTP I
as O
well O
as O
8 B
- I
oxo I
- I
GDP I
to O
8 B
- I
oxo I
- I
GMP I
. O

This O
misincorporation O
is O
prevented O
by O
MutT O
protein O
, O
which O
has O
the O
potential O
to O
cleave O
8 B
- I
oxo I
- I
GTP I
as O
well O
as O
8 B
- I
oxo I
- I
GDP I
to O
8 B
- I
oxo I
- I
GMP I
. O

This O
misincorporation O
is O
prevented O
by O
MutT O
protein O
, O
which O
has O
the O
potential O
to O
cleave O
8 B
- I
oxo I
- I
GTP I
as O
well O
as O
8 B
- I
oxo I
- I
GDP I
to O
8 B
- I
oxo I
- I
GMP I
. O

PURPOSE O
: O
The O
impact O
of O
prophylactic O
supplementation O
of O
N B
- I
acetyl I
- I
cysteine I
( O
NAC B
) O
and O
epigallocatechin B
gallate I
( O
EGCG B
) O
on O
intramuscular O
expression O
of O
proteolytic O
genes O
after O
unaccustomed O
eccentric O
muscle O
contractions O
was O
investigated O
. O

A O
triphosphate B
of O
d4T B
- I
6PEG I
- I
TIBO I
conjugate O
was O
successfully O
synthesized O
that O
is O
recognized O
as O
a O
substrate O
by O
HIV O
- O
1 O
RT O
and O
incorporated O
into O
a O
double O
- O
stranded O
DNA O
. O

Acitretin B
induced O
Ca B
( I
2 I
+ I
) I
- O
mediated O
mitochondrial O
permeability O
transition O
( O
MPT O
) O
and O
decreased O
the O
adenine B
nucleotide I
translocase O
( O
ANT O
) O
content O
. O

Therefore O
, O
our O
results O
, O
including O
the O
decrease O
in O
the O
state O
3 O
respiration O
and O
the O
increase O
in O
the O
lag O
phase O
of O
phosphorylation O
cycle O
, O
the O
ATP B
depletion O
and O
the O
induction O
of O
Ca B
( I
2 I
+ I
) I
- O
mediated O
MPT O
, O
indicate O
that O
acitretin B
- O
associated O
liver O
toxicity O
and O
apoptosis O
is O
possibly O
related O
with O
mitochondrial O
dysfunctions O
due O
to O
interactions O
with O
the O
ANT O
. O

Previously O
, O
we O
reported O
the O
synthesis O
of O
amphiphilic O
polyvinyl B
alcohol I
and O
dextrin O
- O
based O
nanogel O
conjugates O
with O
the O
phosphorylated B
5 I
- I
FU I
nucleoside I
Floxuridine B
and O
demonstrated O
their O
enhanced O
activity O
against O
regular O
and O
drug O
- O
resistant O
cancers O
( O
T O
. O
H O
. O
Senanayake O
, O
G O
. O
Warren O
, O
S O
. O
V O
. O
Vinogradov O
, O
Novel O
anticancer O
polymeric O
conjugates O
of O
activated O
nucleoside B
analogs O
, O
Bioconjug O
. O
Chem O
. O
22 O
( O
2011 O
) O
1983 O
- O
1993 O
) O
. O

Uridine B
5 I
' I
- I
diphosphate I
- O
glucuronosyltransfer O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic B
acids I
to O
acyl B
glucuronides I
, O
but O
it O
is O
currently O
unknown O
if O
acyl B
glucuronides I
, O
being O
esters B
, O
also O
interact O
with O
carboxylesterases O
. O

Four O
new O
germacranes B
[ O
heyneanones B
A I
- I
D I
( O
1 O
- O
4 O
) O
] O
, O
three O
new O
guaianes B
[ O
4 B
, I
10 I
- I
epizedoarondiol I
( O
5 O
) O
, O
15 B
- I
hydroxyprocurcumenol I
( O
6 O
) O
, O
12 B
- I
hydroxycurcumenol I
( O
7 O
) O
] O
, O
and O
two O
new O
spirolactones B
[ O
curcumanolides B
C O
( O
8 O
) O
and O
D O
( O
9 O
) O
] O
were O
isolated O
from O
the O
rhizomes O
of O
Curcuma O
heyneana O
together O
with O
13 O
known O
sesquiterpenes B
and O

Among O
the O
isolated O
compounds O
, O
heyneanone B
A I
( O
1 O
) O
, O
heyneanone B
C I
( O
3 O
) O
, O
4 B
, I
10 I
- I
epizedoarondiol I
( O
5 O
) O
, O
procurcumenol B
( O
16 O
) O
, O
aerugidiol B
( O
17 O
) O
, O
zerumin B
A I
( O
23 O
) O
, O
and O
( B
E I
) I
- I
15 I
, I
16 I
- I
bisnorlabda I
- I
8 I
( I
17 I
) I
, I
11 I
- I
dien I
- I
13 I
- I
one I
( O
24 O
) O
inhibited O
protein O
tyrosine B
phosphatase O
1B O
( O
PTP1B O
) O
with O
IC O
( O
50 O
) O
values O
of O
42 O

The O
amphiphilic O
diblock O
copolymer O
poly B
( I
epsilon I
- I
caprolactone I
) I
- I
b I
- I
poly I
( I
ethylene I
oxide I
) I
( O
PCL B
- I
b I
- I
PEO I
) O
was O
first O
conjugated O
with O
the O
cyclic B
( I
Arginine I
- I
Glycine I
- I
Aspartic I
acid I
- I
d I
- I
Phenylalanine I
- I
Lysine I
) I
( O
c O
( O
RGDfK O
) O
) O
and O
fluorescein B
isothiocyannate I
( O
FITC B
) O
via O
the O
functional O
terminal O
groups O
of O
hydrophilic O
block O
, O
and O
then O
assembled O
into O
micelles O
. O

The O
c O
( O
RGDfK O
) O
modified O
micelles O
assembled O
from O
PCL B
- I
b I
- I
PEO I
diblock O
copolymers O
developed O
in O
this O
study O
are O
of O
great O
potentials O
as O
nano O
- O
scaled O
drug O
delivery O
system O
for O
intravesical O
instilled O
chemotherapy O
of O
superficial O
bladder O
cancer O
. O

Blocking O
of O
either O
Ca B
( I
2 I
+ I
) I
- O
release O
or O
Ca B
( I
2 I
+ I
) I
- O
influx O
reduced O
agonist O
- O
induced O
contraction O
of O
ventral O
rings O
, O
however O
, O
a O
considerable O
amount O
of O
contractility O
remained O
even O
with O
both O
blockers O
. O

Blocking O
of O
either O
Ca B
( I
2 I
+ I
) I
- O
release O
or O
Ca B
( I
2 I
+ I
) I
- O
influx O
reduced O
agonist O
- O
induced O
contraction O
of O
ventral O
rings O
, O
however O
, O
a O
considerable O
amount O
of O
contractility O
remained O
even O
with O
both O
blockers O
. O

Inhibitors O
of O
ROCK O
and O
PKC O
partially O
inhibited O
NA O
- O
induced O
contractions O
, O
whereas O
a O
combination O
of O
Ca B
( I
2 I
+ I
) I
- O
blockers O
and O
Ca B
( I
2 I
+ I
) I
- O
sensitization O
inhibitors O
strongly O
suppressed O
the O
contraction O
. O

Inhibitors O
of O
ROCK O
and O
PKC O
partially O
inhibited O
NA O
- O
induced O
contractions O
, O
whereas O
a O
combination O
of O
Ca B
( I
2 I
+ I
) I
- O
blockers O
and O
Ca B
( I
2 I
+ I
) I
- O
sensitization O
inhibitors O
strongly O
suppressed O
the O
contraction O
. O

In O
ventral O
prostate O
smooth O
muscle O
, O
Ca B
( I
2 I
+ I
) I
- O
release O
, O
Ca B
( I
2 I
+ I
) I
- O
influx O
, O
and O
ROCK O
- O
and O
PKC O
- O
mediated O
Ca B
( I
2 I
+ I
) I
- O
sensitizations O
are O
all O
involved O
in O
NA O
- O
induced O
contractions O
. O

In O
ventral O
prostate O
smooth O
muscle O
, O
Ca B
( I
2 I
+ I
) I
- O
release O
, O
Ca B
( I
2 I
+ I
) I
- O
influx O
, O
and O
ROCK O
- O
and O
PKC O
- O
mediated O
Ca B
( I
2 I
+ I
) I
- O
sensitizations O
are O
all O
involved O
in O
NA O
- O
induced O
contractions O
. O

In O
ventral O
prostate O
smooth O
muscle O
, O
Ca B
( I
2 I
+ I
) I
- O
release O
, O
Ca B
( I
2 I
+ I
) I
- O
influx O
, O
and O
ROCK O
- O
and O
PKC O
- O
mediated O
Ca B
( I
2 I
+ I
) I
- O
sensitizations O
are O
all O
involved O
in O
NA O
- O
induced O
contractions O
. O

The O
Au102 B
( I
pMBA I
) I
44 I
nanocluster O
becomes O
a O
superatom O
paramagnet O
after O
chemical O
oxidation O
. O

Solutions O
of O
paramagnetic O
Au102 B
( I
pMBA I
) I
44 I
heat O
in O
an O
oscillating O
magnetic O
field O
component O
of O
an O
RF O
field O
, O
but O
not O
in O
the O
electric O
component O
. O

Combined O
, O
these O
experiments O
suggest O
that O
paramagnetic O
Au102 B
( I
pMBA I
) I
44 I
heats O
through O
interactions O
of O
spin O
magnetic O
moment O
with O
an O
external O
oscillating O
magnetic O
field O
. O

The O
Ar B
- I
CH2 I
bond O
rotational O
barrier O
for O
encapsulated O
ortho B
- I
substituted I
benzyl I
phosphonium I
guest O
molecules O
is O
sensitive O
to O
the O
size O
and O
shape O
of O
the O
host O
interior O
space O
. O

5 B
- I
Methoxy I
- I
N I
, I
N I
- I
dimethyltryptamine I
( O
5 B
- I
MeO I
- I
DMT I
or O
street O
name O
" O
5 B
- I
MEO I
" O
) O
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines B
. O

Our O
recent O
study O
has O
demonstrated O
that O
coadministration O
of O
monoamine B
oxidase O
A O
( O
MAO O
- O
A O
) O
inhibitor O
harmaline B
( O
5 O
mg O
/ O
kg O
) O
increases O
systemic O
exposure O
to O
5 B
- I
MeO I
- I
DMT I
( O
2 O
mg O
/ O
kg O
) O
and O
active O
metabolite O
bufotenine O
. O

This O
study O
is O
aimed O
at O
delineating O
harmaline B
and O
5 B
- I
MeO I
- I
DMT I
pharmacokinetic O
( O
PK O
) O
interactions O
at O
multiple O
dose O
levels O
, O
as O
well O
as O
the O
impact O
of O
CYP2D6 O
that O
affects O
harmaline B
PK O
and O
determines O
5 B
- I
MeO I
- I
DMT I
O B
- O
demethylation O
to O
produce O
bufotenine B
. O

This O
study O
is O
aimed O
at O
delineating O
harmaline B
and O
5 B
- I
MeO I
- I
DMT I
pharmacokinetic O
( O
PK O
) O
interactions O
at O
multiple O
dose O
levels O
, O
as O
well O
as O
the O
impact O
of O
CYP2D6 O
that O
affects O
harmaline B
PK O
and O
determines O
5 B
- I
MeO I
- I
DMT I
O B
- O
demethylation O
to O
produce O
bufotenine B
. O

Our O
data O
revealed O
that O
inhibition O
of O
MAO O
- O
A O
- O
mediated O
metabolic O
elimination O
by O
harmaline B
( O
2 O
, O
5 O
, O
and O
15 O
mg O
/ O
kg O
) O
led O
to O
a O
sharp O
increase O
in O
systemic O
and O
cerebral O
exposure O
to O
5 B
- I
MeO I
- I
DMT I
( O
2 O
and O
10 O
mg O
/ O
kg O
) O
at O
all O
dose O
combinations O
. O

A O
more O
pronounced O
effect O
on O
5 B
- I
MeO I
- I
DMT I
PK O
was O
associated O
with O
greater O
exposure O
to O
harmaline B
in O
wild O
- O
type O
mice O
than O
CYP2D6 O
- O
humanized O
( O
Tg O
- O
CYP2D6 O
) O
mice O
. O

Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO O
- O
A O
- O
and O
CYP2D6 O
- O
catalyzed O
5 B
- I
MeO I
- I
DMT I
metabolism O
by O
harmaline B
was O
developed O
to O
describe O
blood O
harmaline B
, O
5 B
- I
MeO I
- I
DMT I
, O
and O
bufotenine B
PK O
profiles O
in O
both O
wild O
- O
type O
and O
Tg O
- O
CYP2D6 O
mouse O
models O
. O

Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO O
- O
A O
- O
and O
CYP2D6 O
- O
catalyzed O
5 B
- I
MeO I
- I
DMT I
metabolism O
by O
harmaline B
was O
developed O
to O
describe O
blood O
harmaline B
, O
5 B
- I
MeO I
- I
DMT I
, O
and O
bufotenine B
PK O
profiles O
in O
both O
wild O
- O
type O
and O
Tg O
- O
CYP2D6 O
mouse O
models O
. O

This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline B
and O
5 B
- I
MeO I
- I
DMT I
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 O
status O
, O
and O
drive O
harmaline B
- O
5 B
- I
MeO I
- I
DMT I
pharmacodynamics O
. O

This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline B
and O
5 B
- I
MeO I
- I
DMT I
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 O
status O
, O
and O
drive O
harmaline B
- O
5 B
- I
MeO I
- I
DMT I
pharmacodynamics O
. O

Thymidylate B
kinase O
( O
TMPK O
) O
is O
a O
key O
enzyme O
for O
pyrimidine B
synthesis O
that O
catalyzes O
the O
phosphorylation O
of O
thymidine B
5 I
' I
- I
monophosphate I
( O
dTMP B
) O
in O
the O
presence O
of O
ATP B
and O
Mg B
( I
2 I
+ I
) I
to O
form O
thymidine B
5 I
' I
- I
diphosphate I
( O
dTDP B
) O
, O
which O
is O
then O
converted O
to O
thymidine B
5 I
' I
- I
triphosphate I
( O
dTTP B
) O
by O
nucleoside B
- I
diphosphate I
kinase O
( O
NDK O
) O
. O

Thymidylate B
kinase O
( O
TMPK O
) O
is O
a O
key O
enzyme O
for O
pyrimidine B
synthesis O
that O
catalyzes O
the O
phosphorylation O
of O
thymidine B
5 I
' I
- I
monophosphate I
( O
dTMP B
) O
in O
the O
presence O
of O
ATP B
and O
Mg B
( I
2 I
+ I
) I
to O
form O
thymidine B
5 I
' I
- I
diphosphate I
( O
dTDP B
) O
, O
which O
is O
then O
converted O
to O
thymidine B
5 I
' I
- I
triphosphate I
( O
dTTP B
) O
by O
nucleoside B
- I
diphosphate I
kinase O
( O
NDK O
) O
. O

Thymidylate B
kinase O
( O
TMPK O
) O
is O
a O
key O
enzyme O
for O
pyrimidine B
synthesis O
that O
catalyzes O
the O
phosphorylation O
of O
thymidine B
5 I
' I
- I
monophosphate I
( O
dTMP B
) O
in O
the O
presence O
of O
ATP B
and O
Mg B
( I
2 I
+ I
) I
to O
form O
thymidine B
5 I
' I
- I
diphosphate I
( O
dTDP B
) O
, O
which O
is O
then O
converted O
to O
thymidine B
5 I
' I
- I
triphosphate I
( O
dTTP B
) O
by O
nucleoside B
- I
diphosphate I
kinase O
( O
NDK O
) O
. O

Thymidylate B
kinase O
( O
TMPK O
) O
is O
a O
key O
enzyme O
for O
pyrimidine B
synthesis O
that O
catalyzes O
the O
phosphorylation O
of O
thymidine B
5 I
' I
- I
monophosphate I
( O
dTMP B
) O
in O
the O
presence O
of O
ATP B
and O
Mg B
( I
2 I
+ I
) I
to O
form O
thymidine B
5 I
' I
- I
diphosphate I
( O
dTDP B
) O
, O
which O
is O
then O
converted O
to O
thymidine B
5 I
' I
- I
triphosphate I
( O
dTTP B
) O
by O
nucleoside B
- I
diphosphate I
kinase O
( O
NDK O
) O
. O

We O
have O
prepared O
and O
characterized O
a O
new O
set O
of O
highly O
fluorescent O
gold O
nanoclusters O
( O
AuNCs O
) O
using O
one O
- O
step O
aqueous O
reduction O
of O
a O
gold O
precursor O
in O
the O
presence O
of O
bidentate O
ligands O
made O
of O
lipoic B
acid I
anchoring O
groups O
, O
appended O
with O
either O
a O
poly B
( I
ethylene I
glycol I
) I
short O
chain O
or O
a O
zwitterion O
group O
. O

Osteoclast O
maturation O
and O
function O
primarily O
depend O
on O
receptor O
activator O
of O
NF O
- O
kappa O
B O
ligand O
( O
RANKL O
) O
- O
mediated O
induction O
of O
nuclear O
factor O
of O
activated O
T O
cells O
c1 O
( O
NFATc1 O
) O
, O
which O
is O
further O
activated O
via O
increased O
intracellular O
calcium B
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
) O
oscillation O
. O

However O
, O
the O
coordination O
mechanism O
that O
mediates O
Ca B
( I
2 I
+ I
) I
oscillation O
during O
osteoclastogenesis O
remains O
ill O
defined O
. O

Here O
, O
we O
identified O
transmembrane O
protein O
64 O
( O
Tmem64 O
) O
as O
a O
regulator O
of O
Ca B
( I
2 I
+ I
) I
oscillation O
during O
osteoclastogenesis O
. O

Using O
in O
vitro O
osteoclast O
culture O
systems O
, O
we O
show O
here O
that O
Tmem64 O
interacts O
with O
sarcoplasmic O
endoplasmic O
reticulum O
Ca B
( I
2 I
+ I
) I
ATPase O
2 O
( O
SERCA2 O
) O
and O
modulates O
its O
activity O
. O

Consequently O
, O
Tmem64 O
deficiency O
significantly O
diminishes O
RANKL O
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
oscillation O
, O
which O
results O
in O
reduced O
Ca B
( I
2 I
+ I
) I
/ O
calmodulin O
- O
dependent O
protein O
kinases O
( O
CaMK O
) O
IV O
and O
mitochondrial O
ROS O
, O
both O
of O
which O
contribute O
to O
achieving O
the O
CREB O
activity O
necessary O
for O
osteoclast O
formation O
. O

Consequently O
, O
Tmem64 O
deficiency O
significantly O
diminishes O
RANKL O
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
oscillation O
, O
which O
results O
in O
reduced O
Ca B
( I
2 I
+ I
) I
/ O
calmodulin O
- O
dependent O
protein O
kinases O
( O
CaMK O
) O
IV O
and O
mitochondrial O
ROS O
, O
both O
of O
which O
contribute O
to O
achieving O
the O
CREB O
activity O
necessary O
for O
osteoclast O
formation O
. O

These O
data O
demonstrate O
that O
Tmem64 O
is O
a O
positive O
modulator O
of O
osteoclast O
differentiation O
via O
SERCA2 O
- O
dependent O
Ca B
( I
2 I
+ I
) I
signaling O
. O

Ion O
- O
poor O
conditions O
led O
to O
increases O
in O
the O
expression O
of O
PRL O
receptor O
( O
prlra O
) O
, O
Na B
( I
+ I
) I
/ O
Cl B
( I
- I
) I
cotransporter O
( O
ncc O
; O
slc12a10 O
. O
2 O
) O
, O
Na B
( I
+ I
) I
/ O
H B
( I
+ I
) I
exchanger O
( O
nhe3b O
; O
slc9a3 O
. O
2 O
) O
, O
and O
epithelial O
Ca B
( I
2 I
+ I
) I
channel O
( O
ecac O
; O
trpv6 O
) O
transcripts O
within O
the O
gill O
. O

The O
optimal O
coating O
- O
1 O
ALD O
cycle O
, O
which O
amounts O
to O
< O
1 O
monolayer O
of O
Co B
( I
OH I
) I
2 I
/ O
Co3O4 B
- O
resulted O
in O
significantly O
enhanced O
photoelectrochemical O
water O
oxidation O
performance O
. O

Furthermore O
, O
the O
optical O
transparency O
of O
the O
ultrathin O
Co B
( I
OH I
) I
2 I
/ O
Co3O4 B
coating O
establishes O
it O
as O
a O
particularly O
advantageous O
treatment O
for O
nanostructured O
water O
oxidation O
photoanodes O
. O

Exposure O
to O
SeMet B
significantly O
down O
- O
regulated O
mRNA O
abundance O
of O
protein O
tyrosine B
phosphatase O
1B O
( O
PTP O
1B O
) O
in O
muscle O
, O
and O
beta B
- I
hydroxyacyl I
coenzyme I
A I
dehydrogenase O
( O
HOAD O
) O
, O
sterol B
regulatory O
element O
binding O
protein O
1 O
( O
SREBP O
1 O
) O
and O
methionine B
adenosyltransferase O
1 O
alpha O
( O
MAT O
1A O
) O
in O
liver O
of O
adult O
zebrafish O
. O

The O
Lignan B
( B
- I
) I
- I
Cubebin I
Inhibits O
Vascular O
Contraction O
and O
Induces O
Relaxation O
Via O
Nitric B
Oxide I
Activation O
in O
Isolated O
Rat O
Aorta O
. O

This O
study O
investigated O
the O
vasorelaxant O
effect O
produced O
by O
( B
- I
) I
- I
cubebin I
in O
isolated O
rat O
aortic O
rings O
pre O
- O
contracted O
with O
phenylephrine B
( O
Phe B
) O
, O
and O
the O
possible O
mechanism O
involved O
in O
this O
event O
was O
evaluated O
. O

Endothelium O
- O
dependent O
relaxation O
was O
evoked O
by O
acetylcholine B
and O
( B
- I
) I
- I
cubebin I
in O
intact O
aortic O
rings O
, O
while O
endothelium O
- O
independent O
vasorelaxation O
was O
elicited O
by O
sodium B
nitroprusside I
and O
( B
- I
) I
- I
cubebin I
in O
denuded O
rings O
. O

Endothelium O
- O
dependent O
relaxation O
was O
evoked O
by O
acetylcholine B
and O
( B
- I
) I
- I
cubebin I
in O
intact O
aortic O
rings O
, O
while O
endothelium O
- O
independent O
vasorelaxation O
was O
elicited O
by O
sodium B
nitroprusside I
and O
( B
- I
) I
- I
cubebin I
in O
denuded O
rings O
. O

Cumulative O
concentration O
- O
response O
curves O
for O
Phe B
( O
10 O
( O
- O
10 O
) O
- O
10 O
( O
- O
5 O
) O
M O
) O
were O
determined O
for O
endothelium O
- O
intact O
and O
endothelium O
- O
denuded O
aortic O
rings O
in O
either O
the O
presence O
or O
absence O
of O
( B
- I
) I
- I
cubebin I
. O

( B
- I
) I
- I
Cubebin I
was O
found O
to O
exert O
a O
vasorelaxant O
effect O
irrespective O
of O
the O
presence O
of O
endothelium O
, O
which O
was O
abolished O
by O
pretreatment O
with O
L B
- I
NAME I
and O
ODQ B
, O
but O
not O
with O
indomethacin B
. O

In O
addition O
, O
( B
- I
) I
- I
cubebin I
was O
able O
to O
reduce O
Phe B
contraction O
in O
the O
case O
of O
intact O
rings O
. O

These O
results O
suggest O
that O
( B
- I
) I
- I
cubebin I
promotes O
vasorelaxation O
via O
NO B
/ O
cGMP B
pathway O
in O
rat O
aorta O
, O
without O
prostacyclin B
involvement O
. O

[ B
6 I
] I
- I
Shogaol I
Attenuates O
Neuronal O
Apoptosis O
in O
Hydrogen B
Peroxide I
- O
Treated O
Astrocytes O
Through O
the O
Up O
- O
Regulation O
of O
Neurotrophic O
Factors O
. O

[ B
6 I
] I
- I
shogaol I
, O
a O
bio O
- O
active O
compound O
in O
ginger O
, O
possesses O
potent O
anti O
- O
inflammatory O
actions O
and O
has O
recently O
emerged O
as O
a O
potential O
therapeutic O
agent O
for O
neurodegenerative O
disorders O
. O

However O
, O
the O
effects O
of O
[ B
6 I
] I
- I
shogaol I
on O
astroglial O
apoptosis O
following O
exogenously O
induced O
oxidative O
stress O
has O
not O
yet O
been O
investigated O
. O

Here O
, O
we O
show O
that O
the O
anti O
- O
apoptotic O
activity O
of O
[ B
6 I
] I
- I
shogaol I
in O
astrocytes O
following O
exposure O
to O
hydrogen B
peroxide I
( O
H B
( I
2 I
) I
O I
( I
2 I
) I
) O
involves O
a O
marked O
up O
- O
regulation O
of O
neurotrophic O
factors O
such O
as O
nerve O
growth O
factor O
, O
glial O
cell O
line O
- O
derived O
neurotrophic O
factor O
, O
and O
brain O
- O
derived O
neurotrophic O
factor O
. O

Astrocytes O
co O
- O
treated O
with O
[ B
6 I
] I
- I
shogaol I
and O
H B
( I
2 I
) I
O I
( I
2 I
) I
for O
1 O
h O
showed O
decrease O
in O
reactive O
oxygen B
species O
production O
compared O
with O
those O
only O
treated O
with O
H B
( I
2 I
) I
O I
( I
2 I
) I
. O

Moreover O
, O
[ B
6 I
] I
- I
shogaol I
counteracted O
the O
reduced O
expression O
of O
ERK1 O
/ O
2 O
in O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
treated O
astrocytes O
and O
protected O
these O
cells O
from O
oxidative O
stress O
and O
apoptosis O
by O
attenuating O
the O
impairment O
of O
mitochondrial O
function O
proteins O
such O
as O
Bcl O
- O
2 O
and O
Bcl O
- O
xL O
. O

Additionally O
, O
[ B
6 I
] I
- I
shogaol I
inhibits O
the O
expression O
of O
the O
apoptotic O
proteins O
Bax O
and O
caspase O
- O
3 O
in O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
treated O
astrocytes O
. O

This O
data O
suggest O
that O
following O
oxidative O
stress O
, O
[ B
6 I
] I
- I
shogaol I
protects O
astrocytes O
from O
oxidative O
damage O
through O
the O
up O
- O
regulating O
levels O
of O
neurotrophic O
factors O
. O

These O
findings O
provide O
further O
support O
for O
the O
use O
of O
[ B
6 I
] I
- I
shogaol I
as O
a O
therapeutic O
agent O
in O
neurodegenerative O
disorders O
. O

The O
90 O
% O
CI O
for O
the O
AUC0 O
- O
t O
ratio O
of O
omeprazole B
but O
not O
for O
omeprazole B
/ O
5 B
- I
OH I
- I
omeprazole I
plasma O
ratio O
3 O
hours O
post O
- O
dose O
or O
omeprazole B
/ O
5 B
- I
OH I
- I
omeprazole I
AUC0 O
- O
t O
ratio O
( O
secondary O
CYP2C19 O
metrics O
) O
was O
above O
the O
predefined O
threshold O
of O
1 O
. O
43 O
, O
probably O
caused O
by O
the O
inherent O
high O
variability O
of O
omeprazole B
pharmacokinetics O
. O

The O
90 O
% O
CI O
for O
the O
AUC0 O
- O
t O
ratio O
of O
omeprazole B
but O
not O
for O
omeprazole B
/ O
5 B
- I
OH I
- I
omeprazole I
plasma O
ratio O
3 O
hours O
post O
- O
dose O
or O
omeprazole B
/ O
5 B
- I
OH I
- I
omeprazole I
AUC0 O
- O
t O
ratio O
( O
secondary O
CYP2C19 O
metrics O
) O
was O
above O
the O
predefined O
threshold O
of O
1 O
. O
43 O
, O
probably O
caused O
by O
the O
inherent O
high O
variability O
of O
omeprazole B
pharmacokinetics O
. O

Poly B
( I
lactic I
acid I
) I
- I
block I
- I
poly I
( I
ethylene I
glycol I
) I
copolymers O
( O
PLA B
- I
b I
- I
PEG I
) O
featuring O
varying O
tacticities O
( O
atactic O
, O
heterotactic O
, O
isotactic O
) O
in O
the O
PLA B
block O
were O
synthesized O
and O
investigated O
for O
their O
micellar O
stability O
, O
degradation O
, O
and O
thermal O
properties O
. O

Interestingly O
, O
while O
tin B
( I
II I
) I
bis I
( I
2 I
- I
ethylhexanoate I
) I
and O
aluminum B
salan I
- O
catalyzed O
PLA B
- I
b I
- I
PEG I
copolymers O
exhibited O
similar O
micellization O
behavior O
, O
the O
aluminum B
salen I
- O
catalyzed O
PLA B
- I
b I
- I
PEG I
exhibited O
unique O
behavior O
at O
high O
micelle O
concentration O
in O
the O
presence O
of O
the O
pyrene B
probe O
. O

Interestingly O
, O
while O
tin B
( I
II I
) I
bis I
( I
2 I
- I
ethylhexanoate I
) I
and O
aluminum B
salan I
- O
catalyzed O
PLA B
- I
b I
- I
PEG I
copolymers O
exhibited O
similar O
micellization O
behavior O
, O
the O
aluminum B
salen I
- O
catalyzed O
PLA B
- I
b I
- I
PEG I
exhibited O
unique O
behavior O
at O
high O
micelle O
concentration O
in O
the O
presence O
of O
the O
pyrene B
probe O
. O

Metal O
catalyzed O
oxidation O
via O
the O
oxidative O
system O
Cu B
( I
2 I
+ I
) I
/ O
ascorbate B
is O
known O
to O
induce O
aggregation O
of O
therapeutic O
proteins O
, O
resulting O
in O
enhanced O
immunogenicity O
. O

Insulin O
( O
1mg O
/ O
ml O
) O
was O
oxidized O
with O
40 O
mu O
M O
Cu B
( I
2 I
+ I
) I
and O
4mM O
ascorbic B
acid I
in O
absence O
or O
presence O
of O
excipients O
. O

After O
30min O
of O
treatment O
, O
antofine O
induced O
a O
rapid O
increase O
in O
the O
intracellular O
Ca B
( I
2 I
+ I
) I
concentration O
and O
activation O
of O
protein O
kinase O
C O
( O
PKC O
) O
alpha O
/ O
beta O
II O
, O
which O
was O
maintained O
for O
at O
least O
6h O
. O

Co O
- O
treatment O
of O
astrocytes O
with O
antofine B
and O
the O
intracellular O
Ca B
( I
2 I
+ I
) I
chelator O
BAPTA B
- I
AM I
prevented O
downregulation O
of O
Cx43 O
and O
inhibition O
of O
GJIC O
. O

Samples O
( O
0 O
. O
5 O
g O
) O
were O
extracted O
using O
80 O
% O
methanol B
and O
immunoreactive O
metabolites O
measured O
using O
the O
11 B
- I
KT I
EIA O
and O
an O
already O
established O
11 B
, I
17 I
- I
dioxoandrostane I
( O
11 B
, I
17 I
- I
DOA I
) O
EIA O
. O

Samples O
( O
0 O
. O
5 O
g O
) O
were O
extracted O
using O
80 O
% O
methanol B
and O
immunoreactive O
metabolites O
measured O
using O
the O
11 B
- I
KT I
EIA O
and O
an O
already O
established O
11 B
, I
17 I
- I
dioxoandrostane I
( O
11 B
, I
17 I
- I
DOA I
) O
EIA O
. O

Concentrations O
of O
11 B
, I
17 I
- I
DOA I
showed O
the O
same O
pattern O
, O
but O
the O
values O
were O
2 O
to O
4 O
times O
higher O
. O

Ruthenium B
( I
II I
) I
polypyridyl I
complexes O
as O
G O
- O
quadruplex O
inducing O
and O
stabilizing O
ligands O
in O
telomeric O
DNA O
. O

Two O
ruthenium B
( I
ii I
) I
polypyridyl I
complexes O
[ B
Ru I
( I
phen I
) I
2 I
( I
4idip I
) I
] I
( I
ClO4 I
) I
2 I
( O
) O
and O
[ B
Ru I
( I
bpy I
) I
2 I
( I
4idip I
) I
] I
( I
ClO4 I
) I
2 I
( O
) O
( O
phen B
= O
1 B
, I
10 I
- I
phenanthroline I
, O
bpy B
= O
2 B
, I
2 I
' I
- I
bipyridine I
, O
4idip B
= O
4 B
- I
indoleimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
[ I
1 I
, I
10 I
] I
phenanthroline I
) O
designed O
as O
telomeric O

Two O
ruthenium B
( I
ii I
) I
polypyridyl I
complexes O
[ B
Ru I
( I
phen I
) I
2 I
( I
4idip I
) I
] I
( I
ClO4 I
) I
2 I
( O
) O
and O
[ B
Ru I
( I
bpy I
) I
2 I
( I
4idip I
) I
] I
( I
ClO4 I
) I
2 I
( O
) O
( O
phen B
= O
1 B
, I
10 I
- I
phenanthroline I
, O
bpy B
= O
2 B
, I
2 I
' I
- I
bipyridine I
, O
4idip B
= O
4 B
- I
indoleimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
[ I
1 I
, I
10 I
] I
phenanthroline I
) O
designed O
as O
telomeric O

Magnetometer O
coil O
recordings O
demonstrated O
that O
the O
non O
- O
hallucinogenic O
compounds O
( B
+ I
) I
- I
amphetamine I
( O
2 O
. O
5 O
and O
5 O
. O
0 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
lisuride B
( O
0 O
. O
8 O
, O
1 O
. O
6 O
, O
and O
3 O
. O
2 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
did O
not O
induce O
the O
HTR O
. O

Brominated B
diphenyl I
ether I
- I
209 I
was O
the O
dominant O
congener O
, O
accounting O
for O
87 O
% O
of O
sum O
8 O
PBDE B
. O

Synthesis O
and O
NMR O
studies O
of O
novel O
chromone B
- I
2 I
- I
carboxamide I
derivatives O
. O

Protein O
recognition O
of O
the O
S23906 B
- I
1 I
- O
DNA O
adduct O
by O
nuclear O
proteins O
: O
direct O
involvement O
of O
glyceraldehyde B
- I
3 I
- I
phosphate I
dehydrogenase O
( O
GAPDH O
) O
1 O
. O

The O
benzo B
- I
b I
- I
acronycine I
derivative O
S23906 B
- I
1 I
alkylates O
guanine B
nucleobases I
in O
the O
minor O
groove O
of O
the O
DNA O
helix O
and O
presents O
an O
original O
ability O
to O
locally O
open O
the O
double O
helix O
of O
DNA O
, O
which O
appears O
to O
be O
associated O
with O
its O
cytotoxic O
activity O
. O

We O
found O
that O
GAPDH O
( O
glyceraldehyde B
- I
3 I
- I
phosphate I
dehydrogenase O
) O
is O
a O
protein O
that O
binds O
to O
S23906 B
- O
alkylated O
single O
- O
stranded O
, O
double O
- O
stranded O
and O
telomeric O
sequences O
in O
a O
drug O
- O
dependent O
and O
DNA O
sequence O
/ O
structure O
- O
dependent O
manner O
. O

A O
simple O
and O
sensitive O
spectrophotometric O
method O
to O
the O
simultaneous O
determination O
of O
Mn B
( I
2 I
+ I
) I
and O
Fe B
( I
3 I
+ I
) I
in O
foods O
, O
vegetable O
and O
water O
sample O
with O
the O
aid O
of O
artificial O
neural O
networks O
( O
ANNs O
) O
is O
described O
. O

A O
simple O
and O
sensitive O
spectrophotometric O
method O
to O
the O
simultaneous O
determination O
of O
Mn B
( I
2 I
+ I
) I
and O
Fe B
( I
3 I
+ I
) I
in O
foods O
, O
vegetable O
and O
water O
sample O
with O
the O
aid O
of O
artificial O
neural O
networks O
( O
ANNs O
) O
is O
described O
. O

The O
analytical O
data O
show O
that O
the O
ratio O
of O
ligand O
to O
metal O
in O
metal O
complexes O
is O
1 O
: O
1 O
and O
1 O
: O
2 O
for O
Fe B
( I
3 I
+ I
) I
and O
Mn B
( I
2 I
+ I
) I
, O
respectively O
. O

The O
analytical O
data O
show O
that O
the O
ratio O
of O
ligand O
to O
metal O
in O
metal O
complexes O
is O
1 O
: O
1 O
and O
1 O
: O
2 O
for O
Fe B
( I
3 I
+ I
) I
and O
Mn B
( I
2 I
+ I
) I
, O
respectively O
. O

The O
results O
showed O
that O
Mn B
( I
2 I
+ I
) I
and O
Fe B
( I
3 I
+ I
) I
could O
be O
determined O
simultaneously O
in O
the O
range O
of O
0 O
. O
20 O
- O
7 O
. O
5 O
and O
0 O
. O
30 O
- O
9 O
. O
0 O
mgl O
( O
- O
1 O
) O
, O
respectively O
. O

The O
results O
showed O
that O
Mn B
( I
2 I
+ I
) I
and O
Fe B
( I
3 I
+ I
) I
could O
be O
determined O
simultaneously O
in O
the O
range O
of O
0 O
. O
20 O
- O
7 O
. O
5 O
and O
0 O
. O
30 O
- O
9 O
. O
0 O
mgl O
( O
- O
1 O
) O
, O
respectively O
. O

The O
total O
phenolic O
content O
of O
the O
root O
tuber O
extract O
was O
evaluated O
and O
its O
major O
phenolic B
constituents O
, O
caffeic B
acid I
, O
chlorogenic B
acid I
and O
3 B
, I
5 I
dicaffeoylquinic I
acid I
, O
known O
to O
possess O
antioxidant O
activity O
, O
were O
quantified O
. O

Total O
phenolics B
, O
radical O
scavenging O
activity O
( O
RSA O
) O
on O
DPPH B
, O
ascorbic B
acid I
content O
and O
chelating O
activity O
on O
Fe B
( I
2 I
+ I
) I
of O
Pleurotus O
citrinopileatus O
, O
Pleurotus O
djamor O
, O
Pleurotus O
eryngii O
, O
Pleurotus O
flabellatus O
, O
Pleurotus O
florida O
, O
Pleurotus O
ostreatus O
, O
Pleurotus O
sajor O
- O
caju O
and O
Hypsizygus O
ulmarius O
have O
been O
evaluated O
. O

To O
further O
evaluate O
the O
reliability O
of O
hydrogen B
isotopes O
of O
organic O
molecules O
, O
we O
examined O
the O
isotope O
exchangeability O
in O
fatty B
acids I
within O
phospholipid O
bilayers O
exposed O
to O
D B
( I
2 I
) I
O I
for O
12h O
. O

The O
results O
indicate O
that O
the O
isotope O
ratio O
is O
clearly O
increased O
during O
all O
examines O
( O
e O
. O
g O
. O
, O
93 O
- O
328 O
/ O
1000 O
in O
50 O
% O
D B
( I
2 I
) I
O I
) O
, O
in O
which O
its O
magnitude O
depends O
on O
type O
of O
fatty B
acids I
and O
state O
of O
bilayers O
. O

C O
. O
pilosula O
also O
reversed O
Ca B
( I
2 I
+ I
) I
influx O
, O
MOMP O
and O
apoptosis O
increased O
by O
AngII O
plus O
Leu B
( O
27 O
) O
- O
IGFII O
. O

In O
this O
study O
, O
the O
anti O
- O
proliferative O
and O
apoptosis O
mechanisms O
of O
BA B
- I
beta I
- I
CD I
on O
human O
breast O
cancer O
MCF O
- O
7 O
cells O
were O
further O
investigated O
. O

It O
has O
been O
observed O
that O
the O
administration O
of O
hydroxypropyl B
- I
beta I
- I
cyclodextrin I
( O
HPBCD B
) O
delays O
onset O
of O
clinical O
symptoms O
and O
reduces O
accumulation O
of O
cholesterol B
and O
gangliosides B
within O
neuronal O
cells O
. O

Developing O
the O
potential O
ophthalmic O
applications O
of O
pilocarpine B
entrapped O
into O
polyvinylpyrrolidone B
- O
poly B
( I
acrylic I
acid I
) I
nanogel O
dispersions O
prepared O
by O
gamma O
radiation O
. O

Thus O
, O
pH O
- O
sensitive O
polyvinylpyrrolidone B
- O
poly B
( I
acrylic I
acid I
) I
( O
PVP B
/ O
PAAc B
) O
nanogels O
prepared O
by O
gamma O
radiation O
- O
induced O
polymerization O
of O
acrylic B
acid I
( O
AAc B
) O
in O
an O
aqueous O
solution O
of O
polyvinylpyrrolidone B
( O
PVP B
) O
as O
a O
template O
polymer O
were O
used O
to O
encapsulate O
pilocarpine B
. O

Influence O
of O
the O
bifunctional O
chelator O
on O
the O
pharmacokinetic O
properties O
of O
99mTc B
( I
CO I
) I
3 I
- O
labeled O
cyclic B
alpha I
- I
melanocyte I
stimulating I
hormone I
analog O
. O

Discovery O
of O
novel O
7 B
- I
membered I
cyclic I
amide I
derivatives O
that O
inhibit O
11beta B
- I
hydroxysteroid I
dehydrogenase O
type O
1 O
. O

We O
discovered O
these O
7 B
- I
membered I
cyclic I
amide I
derivatives O
by O
introducing O
a O
distinctive O
linker O
through O
pharmacophore O
analysis O
of O
known O
ligands O
included O
in O
X O
- O
ray O
co O
- O
crystal O
structures O
. O

Design O
and O
synthesis O
of O
bicyclic B
pyrazinone I
and I
pyrimidinone I
amides I
as O
potent O
TF O
- O
FVIIa O
inhibitors O
. O

Bicyclic B
pyrazinone I
and I
pyrimidinone I
amides I
were O
designed O
and O
synthesized O
as O
potent O
TF O
- O
FVIIa O
inhibitors O
. O

Following O
administration O
of O
the O
5 B
- I
HT I
( O
1A O
/ O
7 O
) O
agonist O
8 B
- I
hydroxy I
- I
2 I
- I
( I
di I
- I
n I
- I
propylamino I
) I
tetralin I
( O
8 B
- I
OH I
- I
DPAT I
) O
, O
stereotypical O
head O
weaving O
and O
forepaw O
treading O
were O
increased O
more O
in O
DAT O
- O
KO O
mice O
than O
in O
DAT O
- O
WT O
or O
- O
HET O
mice O
. O

Excess O
nicotinamide B
, O
a O
form O
of O
vitamin B
B I
( I
3 I
) I
, O
is O
metabolized O
through O
two O
enzymatic O
systems O
and O
eventually O
excreted O
from O
the O
body O
. O

Beyond O
H B
( I
2 I
) I
S I
and O
NO B
Interplay O
: O
Hydrogen B
Sulfide I
and O
Nitroprusside B
React O
Directly O
to O
Give O
Nitroxyl B
( O
HNO B
) O
. O

Hydrogen B
sulfide I
( O
H B
( I
2 I
) I
S I
) O
has O
been O
increasingly O
recognized O
as O
an O
important O
signaling O
molecule O
that O
regulates O
both O
blood O
pressure O
and O
neuronal O
activity O
. O

Here O
, O
we O
provide O
evidence O
that O
the O
physiological O
effects O
observed O
upon O
the O
application O
of O
sodium B
nitroprusside I
( O
SNP B
) O
and O
H B
( I
2 I
) I
S I
can O
be O
ascribed O
to O
the O
generation O
of O
nitroxyl B
( O
HNO B
) O
, O
which O
is O
a O
direct O
product O
of O
the O
reaction O
between O
SNP B
and O
H B
( I
2 I
) I
S I
, O
not O
a O
consequence O
of O
released O
NO B
subsequently O
reacting O
with O
H B
( I
2 I
) I
S I
. O

Here O
, O
we O
provide O
evidence O
that O
the O
physiological O
effects O
observed O
upon O
the O
application O
of O
sodium B
nitroprusside I
( O
SNP B
) O
and O
H B
( I
2 I
) I
S I
can O
be O
ascribed O
to O
the O
generation O
of O
nitroxyl B
( O
HNO B
) O
, O
which O
is O
a O
direct O
product O
of O
the O
reaction O
between O
SNP B
and O
H B
( I
2 I
) I
S I
, O
not O
a O
consequence O
of O
released O
NO B
subsequently O
reacting O
with O
H B
( I
2 I
) I
S I
. O

Here O
, O
we O
provide O
evidence O
that O
the O
physiological O
effects O
observed O
upon O
the O
application O
of O
sodium B
nitroprusside I
( O
SNP B
) O
and O
H B
( I
2 I
) I
S I
can O
be O
ascribed O
to O
the O
generation O
of O
nitroxyl B
( O
HNO B
) O
, O
which O
is O
a O
direct O
product O
of O
the O
reaction O
between O
SNP B
and O
H B
( I
2 I
) I
S I
, O
not O
a O
consequence O
of O
released O
NO B
subsequently O
reacting O
with O
H B
( I
2 I
) I
S I
. O

Unlike O
with O
other O
thiols B
, O
SNP B
reacts O
with O
H B
( I
2 I
) I
S I
in O
the O
same O
way O
as O
rhodanese O
, O
i O
. O
e O
. O
, O
the O
cyanide B
transforms O
into O
a O
thiocyanate B
. O

These O
findings O
shed O
new O
light O
on O
how O
H B
( I
2 I
) I
S I
is O
understood O
to O
interact O
with O
nitroprusside B
. O

The O
potent O
and O
selective O
activity O
of O
semi O
- O
synthetic O
naphthothiazoles B
against O
promastigotes O
and O
amastigotes O
reveals O
that O
the O
2 B
- I
amino I
- I
naphthothiazole I
ring O
may O
represent O
a O
scaffold O
for O
the O
design O
of O
compounds O
with O
leishmanicidal O
properties O
and O
encourage O
the O
development O
of O
drug O
formulation O
and O
new O
compounds O
for O
further O
studies O
in O
vivo O
. O

Vibrational O
assignments O
have O
provided O
the O
frequency O
of O
the O
Cu B
- I
C I
stretching O
mode O
, O
nu O
3 O
, O
in O
the O
ground O
and O
all O
three O
excited O
states O
, O
along O
with O
both O
bending O
modes O
, O
nu O
4 O
and O
nu O
5 O
, O
in O
the O
A O
( O
1 O
) O
Sigma O
( O
+ O
) O
and O
B O
( O
1 O
) O
Pi O
states O
, O
and O
the O
Cu B
- I
C I
= I
C I
bending O
mode O
, O
nu O
5 O
, O
in O
the O
ground O
state O
. O

In O
an O
attempt O
to O
overcome O
these O
problems O
, O
LiNi0 B
. I
62Co0 I
. I
14Mn0 I
. I
24O2 I
cathode O
material O
with O
pillar O
layers O
in O
which O
Ni B
( I
2 I
+ I
) I
ions O
were O
resided O
in O
Li B
slabs O
near O
the O
surface O
having O
a O
thickness O
of O
~ O
10 O
nm O
was O
prepared O
using O
a O
polyvinylpyrrolidone B
( O
PVP B
) O
functionalized O
Mn B
precursor O
coating O
on O
Ni0 B
. I
7Co0 I
. I
15Mn0 I
. I
15 I
( I
OH I
) I
2 I
. O

In O
fact O
, O
the O
baseline O
proportion O
of O
hypodiploid O
cells O
and O
the O
mitochondrial O
potential O
and O
mass O
were O
higher O
in O
adults O
, O
whereas O
8 B
- I
hydroxy I
- I
2 I
' I
- I
deoxyguanosine I
( O
8 B
- I
oxo I
- I
dGuo I
) O
levels O
, O
the O
proportion O
of O
necrotic O
cells O
, O
and O
the O
extent O
of O
autophagy O
were O
higher O
early O
in O
life O
. O

Adult O
mice O
were O
more O
responsive O
to O
CS O
by O
increasing O
the O
proportion O
of O
necrotic O
cells O
and O
of O
cells O
in O
S O
/ O
G2 O
phase O
, O
whereas O
young O
mice O
maintained O
a O
high O
extent O
of O
autophagy O
, O
exhibited O
a O
greater O
increase O
of O
lipid O
peroxidation O
products O
and O
8 B
- I
oxo I
- I
dGuo I
levels O
, O
and O
had O
a O
higher O
frequency O
of O
micronucleated O
cells O
. O

Furthermore O
, O
the O
authors O
investigated O
the O
influence O
of O
Mg B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Na B
( I
+ I
) I
, O
and O
Cl B
( I
- I
) I
on O
Ni B
toxicity O
to O
F O
. O
heteroclitus O
. O

Furthermore O
, O
the O
authors O
investigated O
the O
influence O
of O
Mg B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Na B
( I
+ I
) I
, O
and O
Cl B
( I
- I
) I
on O
Ni B
toxicity O
to O
F O
. O
heteroclitus O
. O

Freshwater O
with O
up O
to O
120 O
mg O
/ O
L O
Ca B
( I
2 I
+ I
) I
as O
CaSO4 B
, O
250 O
mg O
/ O
L O
Mg B
( I
2 I
+ I
) I
as O
MgSO4 B
, O
or O
250 O
mg O
/ O
L O
Na B
( I
+ I
) I
as O
NaHCO3 B
did O
not O
provide O
protection O
against O
Ni B
toxicity O
. O

Freshwater O
with O
up O
to O
120 O
mg O
/ O
L O
Ca B
( I
2 I
+ I
) I
as O
CaSO4 B
, O
250 O
mg O
/ O
L O
Mg B
( I
2 I
+ I
) I
as O
MgSO4 B
, O
or O
250 O
mg O
/ O
L O
Na B
( I
+ I
) I
as O
NaHCO3 B
did O
not O
provide O
protection O
against O
Ni B
toxicity O
. O

Both O
poly B
( I
sulfobetaine I
methacrylate I
) I
( O
pSBMA B
) O
and O
poly B
( I
carboxybetaine I
methacrylate I
) I
( O
pCBMA B
) O
have O
been O
studied O
as O
matrices O
for O
the O
embedding O
of O
silver B
. O

Both O
poly B
( I
sulfobetaine I
methacrylate I
) I
( O
pSBMA B
) O
and O
poly B
( I
carboxybetaine I
methacrylate I
) I
( O
pCBMA B
) O
have O
been O
studied O
as O
matrices O
for O
the O
embedding O
of O
silver B
. O

benzimidazol I
- I
2 I
( I
10H I
) I
- I
one I
13 O
, O
as O
well O
as O
the O
in O
vitro O
evaluation O
of O
their O
inhibitory O
activity O
on O
human O
platelet O
aggregation O
induced O
in O
platelet O
- O
rich O
plasma O
by O
ADP B
, O
collagen O
or O
the O
Ca B
( I
2 I
+ I
) I
ionophore O
A23187 B
were O
here O
described O
. O

The O
design O
, O
synthesis O
, O
biological O
evaluation O
, O
and O
in O
vivo O
studies O
of O
difluoromethyl B
ketones I
as O
GABAB O
agonists O
that O
are O
not O
structurally O
analogous O
to O
known O
GABAB O
agonists O
, O
such O
as O
baclofen B
or O
3 B
- I
aminopropyl I
phosphinic I
acid I
, O
are O
presented O
. O

In O
the O
present O
study O
we O
have O
investigated O
the O
effects O
of O
( B
- I
) I
- I
cannabidiol I
, O
a O
non O
- O
psychoactive O
component O
of O
cannabis O
for O
its O
actions O
on O
bronchial O
smooth O
muscle O
in O
vitro O
and O
in O
vivo O
. O

In O
addition O
, O
contractile O
responses O
of O
bronchial O
smooth O
muscle O
from O
ovalbumin O
- O
sensitized O
guinea O
- O
pigs O
were O
investigated O
in O
the O
absence O
or O
presence O
of O
( B
- I
) I
- I
cannabidiol I
. O

Furthermore O
, O
the O
effect O
of O
( B
- I
) I
- I
cannabidiol I
against O
ovalbumin O
- O
induced O
airway O
obstruction O
was O
investigated O
in O
vivo O
in O
ovalbumin O
- O
sensitized O
guinea O
- O
pigs O
. O

( B
- I
) I
- I
Cannabidiol I
did O
not O
influence O
the O
bronchial O
smooth O
muscle O
contraction O
induced O
by O
carbachol B
, O
histamine B
or O
neurokinin O
A O
. O

In O
contrast O
, O
( B
- I
) I
- I
cannabidiol I
inhibited O
anandamide B
- O
and O
virodhamine B
- O
induced O
responses O
of O
isolated O
bronchi O
. O

A O
fatty B
acid I
amide I
hydrolase O
inhibitor O
, O
phenylmethanesulfony B
fluoride I
reversed O
the O
inhibitory O
effect O
of O
( B
- I
) I
- I
cannabidiol I
on O
anandamide B
- O
induced O
contractions O
. O

In O
addition O
, O
( B
- I
) I
- I
cannabidiol I
inhibited O
the O
contractile O
response O
of O
bronchi O
obtained O
from O
allergic O
guinea O
- O
pigs O
induced O
by O
ovalbumin O
. O

In O
vivo O
, O
( B
- I
) I
- I
cannabidiol I
reduced O
ovalbumin O
- O
induced O
airway O
obstruction O
. O

Therefore O
, O
to O
reveal O
the O
existence O
of O
more O
permanent O
alterations O
of O
DNA O
structure O
after O
genotoxic O
stress O
, O
the O
RTG O
- O
2 O
rainbow O
trout O
cell O
line O
was O
exposed O
for O
3days O
to O
benzo B
[ I
a I
] I
pyrene I
( O
B B
[ I
a I
] I
P I
, O
0 O
. O
1 O
- O
10 O
mu O
M O
) O
and O
ethyl B
methanesulfonate I
( O
EMS B
, O
0 O
. O
1 O
- O
1mM O
) O
followed O
by O
3days O
of O
recovery O
period O
. O

Therefore O
, O
to O
reveal O
the O
existence O
of O
more O
permanent O
alterations O
of O
DNA O
structure O
after O
genotoxic O
stress O
, O
the O
RTG O
- O
2 O
rainbow O
trout O
cell O
line O
was O
exposed O
for O
3days O
to O
benzo B
[ I
a I
] I
pyrene I
( O
B B
[ I
a I
] I
P I
, O
0 O
. O
1 O
- O
10 O
mu O
M O
) O
and O
ethyl B
methanesulfonate I
( O
EMS B
, O
0 O
. O
1 O
- O
1mM O
) O
followed O
by O
3days O
of O
recovery O
period O
. O

Significant O
induction O
in O
DNA O
damage O
measured O
by O
the O
Comet O
assay O
was O
noticed O
after O
B B
[ I
a I
] I
P I
treatment O
at O
all O
concentrations O
but O
values O
returned O
to O
the O
control O
level O
after O
recovery O
. O

The O
approach O
employs O
ozone O
to O
produce O
fully O
oxidized O
alpha B
- I
Fe2O3 I
or O
a O
milder O
oxidant O
, O
H2O2 B
, O
to O
generate O
the O
Fe B
( I
2 I
+ I
) I
/ O
Fe B
( I
3 I
+ I
) I
spinel O
, O
Fe3O4 B
. O

The O
approach O
employs O
ozone O
to O
produce O
fully O
oxidized O
alpha B
- I
Fe2O3 I
or O
a O
milder O
oxidant O
, O
H2O2 B
, O
to O
generate O
the O
Fe B
( I
2 I
+ I
) I
/ O
Fe B
( I
3 I
+ I
) I
spinel O
, O
Fe3O4 B
. O

Human O
cytochrome O
P450 O
( O
P450 O
) O
2A13 O
was O
found O
to O
interact O
with O
several O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
to O
produce O
Type O
I O
binding O
spectra O
, O
including O
acenaphthene B
, O
acenaphthylene B
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
fluoranthene B
- I
2 I
, I
3 I
- I
diol I
, O
and O
1 B
- I
nitropyrene I
. O

P450 O
1B1 O
is O
well O
- O
known O
to O
oxidize O
many O
carcinogenic O
PAHs B
, O
and O
we O
found O
that O
several O
PAHs B
( O
i O
. O
e O
. O
, O
7 B
, I
12 I
- I
dimethylbenz I
[ I
a I
] I
anthracene I
, O
7 B
, I
12 I
- I
dimethylbenz I
[ I
a I
] I
anthracene I
- I
5 I
, I
6 I
- I
diol I
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
fluoranthene B
- I
2 I
, I
3 I
- I
diol I
, O
5 B
- I
methylchrysene I
, O
benz B
[ I
a I
] I
pyrene I
- I
4 I
, I
5 I
- I

Metabolic O
activation O
of O
PAHs B
and O
aryl B
- I
and I
heterocyclic I
amines I
to O
genotoxic O
products O
was O
examined O
in O
Salmonella O
typhimurium O
NM2009 O
, O
and O
we O
found O
that O
P450 O
2A13 O
and O
2A6 O
( O
as O
well O
as O
P450 O
1B1 O
) O
were O
able O
to O
activate O
several O
of O
these O
procarcinogens O
. O

These O
results O
suggest O
that O
P450 O
2A O
enzymes O
, O
as O
well O
as O
P450 O
Family O
1 O
enzymes O
including O
P450 O
1B1 O
, O
are O
major O
enzymes O
involved O
in O
activating O
PAHs B
and O
aryl B
- I
and I
heterocyclic I
amines I
, O
as O
well O
as O
tobacco O
- O
related O
nitrosamines B
. O

Herein O
we O
discuss O
a O
novel O
class O
of O
bioactive O
lipid O
mediators O
, O
which O
are O
enzymatically O
biosynthesized O
in O
vivo O
from O
omega B
- I
3 I
eicosapentaenoic I
acid I
( O
EPA B
) O
and O
docosahexaenoic B
acid I
( O
DHA B
) O
, O
termed O
resolvins B
. O

A O
one O
- O
pot O
domino O
synthesis O
and O
discovery O
of O
highly O
functionalized O
dihydrobenzo B
[ I
b I
] I
thiophenes I
as O
AChE O
inhibitors O
. O

Electron O
spin O
resonance O
spectrometry O
showed O
that O
OxLDL O
- O
induced O
superoxide B
( O
O2 B
( I
. I
- I
) I
) O
production O
in O
the O
MR O
fractions O
was O
substantially O
reduced O
by O
statins B
. O

Furthermore O
, O
O2 B
( I
. I
- I
) I
production O
in O
situ O
was O
3 O
- O
fold O
higher O
in O
the O
coronary O
arteries O
from O
hypercholesterolemic O
mice O
than O
in O
those O
from O
normal O
mice O
, O
and O
such O
increase O
was O
inhibited O
by O
statins B
. O

The O
results O
indicated O
that O
genistin B
( O
5 O
- O
80 O
mu O
mol O
/ O
L O
) O
inhibited O
the O
contraction O
of O
IJS O
in O
a O
dose O
- O
dependent O
manner O
and O
inhibited O
the O
increased O
- O
contractility O
of O
IJS O
induced O
by O
acetylcholine B
( O
ACh B
) O
, O
histamine B
, O
high O
Ca B
( I
2 I
+ I
) I
, O
and O
erythromycin B
, O
respectively O
. O

No O
further O
inhibitory O
effects O
of O
genistin B
were O
observed O
in O
the O
presence O
of O
verapamil B
or O
in O
Ca B
( I
2 I
+ I
) I
- O
free O
condition O
, O
indicating O
genistin B
- O
induced O
inhibitory O
effects O
are O
Ca B
( I
2 I
+ I
) I
- O
dependent O
. O

No O
further O
inhibitory O
effects O
of O
genistin B
were O
observed O
in O
the O
presence O
of O
verapamil B
or O
in O
Ca B
( I
2 I
+ I
) I
- O
free O
condition O
, O
indicating O
genistin B
- O
induced O
inhibitory O
effects O
are O
Ca B
( I
2 I
+ I
) I
- O
dependent O
. O

Genistin B
decreased O
myosin O
light O
chain O
kinase O
( O
MLCK O
) O
protein O
contents O
and O
MLCK O
mRNA O
expression O
in O
IJS O
, O
and O
inhibited O
both O
phosphorylation O
and O
Mg B
( I
2 I
+ I
) I
- O
ATPase O
activity O
of O
purified O
myosin O
, O
implicating O
that O
the O
decrease O
of O
MLCK O
contents O
and O
inhibition O
of O
MLCK O
activity O
are O
involved O
in O
the O
genistin B
- O
induced O
inhibitory O
effects O
. O

The O
rigid O
E O
- O
geometry O
of O
the O
exocyclic O
double O
bond O
allowed O
a O
more O
efficient O
binding O
conformation O
compared O
to O
more O
flexible O
and O
less O
active O
2 B
- I
( I
1 I
- I
benzofuran I
- I
3 I
- I
yl I
) I
- I
N I
- I
methylacetamide I
isomers O
and O
4 B
- I
N I
- I
methylcarboxamidomet I
analogues O
. O

Definition O
of O
formulation O
design O
space O
, O
in O
vitro O
bioactivity O
and O
in O
vivo O
biodistribution O
for O
hydrophilic O
drug O
loaded O
PLGA B
/ O
PEO B
- I
PPO I
- I
PEO I
nanoparticles O
using O
OFAT O
experiments O
. O

Modified O
nanoprecipitation O
method O
was O
used O
for O
improved O
incorporation O
of O
hydrophilic O
drug O
( O
irinotecan B
hydrochloride I
) O
into O
the O
PLGA B
/ O
PEO B
- I
PPO I
- I
PEO I
blended O
and O
blended O
/ O
adsorbed O
nanoparticles O
. O

One O
factor O
at O
a O
time O
( O
OFAT O
) O
variation O
experiments O
were O
conducted O
in O
order O
to O
determine O
key O
formulation O
factors O
( O
concentration O
and O
volume O
of O
drug O
solution O
, O
evaporation O
rate O
and O
PLGA B
/ O
PEO B
- I
PPO I
- I
PEO I
ratio O
) O
influencing O
nanoparticle O
properties O
( O
particle O
size O
and O
size O
distribution O
, O
encapsulation O
efficiency O
, O
drug O
content O
, O
zeta O
potential O
, O
drug O
dissolution O
rate O
, O
as O
well O
as O
protein O
binding O
capacity O
) O
. O

The O
mean O
particle O
size O
, O
mainly O
dependent O
upon O
PLGA B
/ O
PEO B
- I
PPO I
- I
PEO I
ratio O
, O
was O
in O
the O
range O
of O
112 O
- O
125nm O
, O
with O
narrow O
unimodal O
distribution O
( O
PDI O
~ O
0 O
. O
1 O
) O
. O

Encapsulation O
efficiency O
( O
32 O
- O
63 O
% O
) O
was O
impacted O
by O
evaporation O
rate O
and O
PLGA B
/ O
PEO B
- I
PPO I
- I
PEO I
ratio O
. O

Zeta O
potential O
values O
indicated O
that O
presence O
of O
PEO B
- I
PPO I
- I
PEO I
in O
the O
formulations O
shielded O
the O
high O
surface O
negative O
charge O
of O
PLGA B
. O

PEO B
- I
PPO I
- I
PEO I
surface O
coverage O
of O
PLGA B
/ O
PEO B
- I
PPO I
- I
PEO I
blended O
as O
well O
as O
blended O
/ O
adsorbed O
nanoparticles O
depended O
upon O
amount O
of O
used O
PEO B
- I
PPO I
- I
PEO I
during O
preparation O
procedure O
and O
was O
related O
to O
the O
protein O
resistant O
characteristics O
of O
nanoparticles O
. O

PEO B
- I
PPO I
- I
PEO I
surface O
coverage O
of O
PLGA B
/ O
PEO B
- I
PPO I
- I
PEO I
blended O
as O
well O
as O
blended O
/ O
adsorbed O
nanoparticles O
depended O
upon O
amount O
of O
used O
PEO B
- I
PPO I
- I
PEO I
during O
preparation O
procedure O
and O
was O
related O
to O
the O
protein O
resistant O
characteristics O
of O
nanoparticles O
. O

PEO B
- I
PPO I
- I
PEO I
surface O
coverage O
of O
PLGA B
/ O
PEO B
- I
PPO I
- I
PEO I
blended O
as O
well O
as O
blended O
/ O
adsorbed O
nanoparticles O
depended O
upon O
amount O
of O
used O
PEO B
- I
PPO I
- I
PEO I
during O
preparation O
procedure O
and O
was O
related O
to O
the O
protein O
resistant O
characteristics O
of O
nanoparticles O
. O

The O
pleiotropic O
effects O
of O
vitamin B
A I
are O
exerted O
mainly O
by O
one O
active O
metabolite O
, O
all B
- I
trans I
retinoic I
acid I
( O
atRA B
) O
, O
which O
regulates O
the O
expression O
of O
a O
battery O
of O
target O
genes O
through O
several O
families O
of O
nuclear O
receptors O
( O
RARs O
, O
RXRs O
and O
PPAR O
beta O
/ O
delta O
) O
, O
polymorphic O
retinoic B
acid I
( O
RA O
) O
response O
elements O
and O
multiple O
coregulators O
. O

Moreover O
; O
it O
was O
found O
that O
some O
of O
the O
tested O
compounds O
bearing O
imidazole B
- I
2 I
- I
yl I
moiety O
on O
the O
C11 O
- O
position O
of O
dihydropyridine B
ring O
exhibited O
superior O
antiproliferative O
activity O
in O
comparison O
to O
cis B
- I
platin I
especially O
in O
Jurkat O
cell O
line O
( O
compounds O
29 O
, O
31 O
, O
and O
33 O
) O
. O

Transient O
network O
hydrogels O
cross O
- O
linked O
through O
histidine B
- O
divalent O
cation O
coordination O
bonds O
were O
studied O
by O
conventional O
rheologic O
methods O
using O
histidine B
- O
modified O
star O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
polymers O
. O

This O
approach O
allows O
several O
transient O
radiolytic O
species O
to O
be O
followed O
in O
parallel O
, O
particularly O
the O
solvated O
electron O
, O
BrOH B
( I
- I
* I
) I
, O
Br2 B
( I
- I
* I
) I
, O
and O
Br3 B
( I
- I
) I
. O

This O
approach O
allows O
several O
transient O
radiolytic O
species O
to O
be O
followed O
in O
parallel O
, O
particularly O
the O
solvated O
electron O
, O
BrOH B
( I
- I
* I
) I
, O
Br2 B
( I
- I
* I
) I
, O
and O
Br3 B
( I
- I
) I
. O

The O
kinetics O
measured O
within O
4 O
ns O
at O
260 O
and O
370 O
nm O
clearly O
exhibit O
that O
the O
decay O
of O
Br2 B
( I
* I
- I
) I
is O
correlated O
with O
the O
formation O
of O
Br3 B
( I
- I
) I
. O

In O
highly O
concentrated O
Br B
( I
- I
) I
solutions O
, O
the O
OH B
( I
* I
) I
radical O
is O
fully O
replaced O
by O
Br2 B
( I
* I
- I
) I
, O
and O
the O
spur O
kinetics O
of O
OH B
( I
* I
) I
radical O
in O
pure O
water O
is O
comparable O
with O
that O
of O
Br2 B
( I
- I
* I
) I
. O

In O
highly O
concentrated O
Br B
( I
- I
) I
solutions O
, O
the O
OH B
( I
* I
) I
radical O
is O
fully O
replaced O
by O
Br2 B
( I
* I
- I
) I
, O
and O
the O
spur O
kinetics O
of O
OH B
( I
* I
) I
radical O
in O
pure O
water O
is O
comparable O
with O
that O
of O
Br2 B
( I
- I
* I
) I
. O

Moreover O
, O
they O
point O
out O
that O
oxidation O
of O
Br B
( I
- I
) I
occurs O
within O
the O
electron O
pulse O
both O
by O
direct O
energy O
absorption O
and O
by O
scavenging O
of O
the O
water O
radical O
cation O
, O
H2O B
( I
* I
+ I
) I
. O

A O
popular O
analytical O
application O
is O
fluorescence O
quenching O
by O
Hg B
( I
2 I
+ I
) I
, O
where O
d O
( O
10 O
) O
- O
d O
( O
10 O
) O
metallophilic O
interaction O
has O
often O
been O
proposed O
for O
associating O
Hg B
( I
2 I
+ I
) I
with O
nanoclusters O
. O

A O
popular O
analytical O
application O
is O
fluorescence O
quenching O
by O
Hg B
( I
2 I
+ I
) I
, O
where O
d O
( O
10 O
) O
- O
d O
( O
10 O
) O
metallophilic O
interaction O
has O
often O
been O
proposed O
for O
associating O
Hg B
( I
2 I
+ I
) I
with O
nanoclusters O
. O

However O
, O
it O
cannot O
explain O
the O
lack O
of O
response O
to O
other O
d O
( O
10 O
) O
ions O
such O
as O
Zn B
( I
2 I
+ I
) I
and O
Cd B
( I
2 I
+ I
) I
. O

However O
, O
it O
cannot O
explain O
the O
lack O
of O
response O
to O
other O
d O
( O
10 O
) O
ions O
such O
as O
Zn B
( I
2 I
+ I
) I
and O
Cd B
( I
2 I
+ I
) I
. O

In O
our O
effort O
to O
elucidate O
the O
quenching O
mechanism O
, O
we O
studied O
a O
total O
of O
eight O
AgNCs O
prepared O
by O
different O
hairpin O
DNA O
sequences O
; O
they O
showed O
different O
sensitivity O
to O
Hg B
( I
2 I
+ I
) I
, O
and O
DNA O
with O
a O
larger O
cytosine B
loop O
size O
produced O
more O
sensitive O
AgNCs O
. O

In O
all O
the O
cases O
, O
samples O
strongly O
quenched O
by O
Hg B
( I
2 I
+ I
) I
were O
also O
more O
easily O
photobleached O
. O

Strong O
fluorescence O
quenching O
was O
also O
observed O
with O
high O
redox O
potential O
metal O
ions O
such O
as O
Ag B
( I
+ I
) I
, O
Au B
( I
3 I
+ I
) I
, O
Cu B
( I
2 I
+ I
) I
and O
Hg B
( I
2 I
+ I
) I
, O
but O
not O
with O
low O
redox O
potential O
ions O
. O

Strong O
fluorescence O
quenching O
was O
also O
observed O
with O
high O
redox O
potential O
metal O
ions O
such O
as O
Ag B
( I
+ I
) I
, O
Au B
( I
3 I
+ I
) I
, O
Cu B
( I
2 I
+ I
) I
and O
Hg B
( I
2 I
+ I
) I
, O
but O
not O
with O
low O
redox O
potential O
ions O
. O

Strong O
fluorescence O
quenching O
was O
also O
observed O
with O
high O
redox O
potential O
metal O
ions O
such O
as O
Ag B
( I
+ I
) I
, O
Au B
( I
3 I
+ I
) I
, O
Cu B
( I
2 I
+ I
) I
and O
Hg B
( I
2 I
+ I
) I
, O
but O
not O
with O
low O
redox O
potential O
ions O
. O

The O
photochemistry O
of O
[ B
CpRu I
( I
CO I
) I
2 I
] I
2 I
in O
P B
( I
OMe I
) I
3 I
/ O
CH2Cl2 B
solution O
has O
been O
studied O
using O
picosecond O
time O
- O
resolved O
infrared O
( O
TRIR O
) O
spectroscopy O
. O

The O
DFT O
results O
predict O
a O
bent O
CO B
ligand O
in O
CpRu B
( I
CO I
) I
2P I
( I
OMe I
) I
3 I
( I
* I
) I
, O
whereas O
approximately O
linear O
Fe B
- I
C I
- I
O I
bond O
angles O
are O
predicted O
for O
CpFe B
( I
CO I
) I
2P I
( I
OMe I
) I
3 I
( I
* I
) I
. O

Both O
enantiomers O
of O
dihydro B
- I
beta I
- I
ionol I
and O
beta B
- I
ionol I
, O
contained O
in O
the O
aromatic O
components O
of O
Osmanthus O
flower O
and O
of O
Hakuto O
peach O
, O
were O
obtained O
with O
high O
optical O
purity O
by O
lipase O
- O
catalyzed O
kinetic O
resolution O
of O
the O
racemates O
. O

The O
absolute O
configuration O
and O
the O
enantiomer O
ratios O
of O
dihydro B
- I
beta I
- I
ionol I
in O
the O
aromatic O
components O
of O
Osmanthus O
flower O
and O
of O
Hakuto O
peach O
were O
determined O
. O

A O
new O
asymmetric O
[ O
2 O
+ O
2 O
+ O
2 O
] O
cycloaddition O
of O
diynes B
to O
sulfonimines B
under O
rhodium B
catalysis O
that O
provides O
the O
corresponding O
enantioenriched O
1 B
, I
2 I
- I
dihydropyridines I
in O
good O
yields O
is O
described O
. O

NMR O
and O
X O
- O
ray O
results O
provide O
strong O
supporting O
evidence O
for O
a O
structural O
model O
in O
which O
phosphorylated B
serine I
repeats O
( O
pSX O
) O
4 O
complex O
with O
divalent O
cations O
Ca B
( I
2 I
+ I
) I
and O
Mg B
( I
2 I
+ I
) I
to O
form O
rigid O
nanocrystalline O
beta O
- O
sheet O
structures O
in O
caddisfly O
silk O
. O

NMR O
and O
X O
- O
ray O
results O
provide O
strong O
supporting O
evidence O
for O
a O
structural O
model O
in O
which O
phosphorylated B
serine I
repeats O
( O
pSX O
) O
4 O
complex O
with O
divalent O
cations O
Ca B
( I
2 I
+ I
) I
and O
Mg B
( I
2 I
+ I
) I
to O
form O
rigid O
nanocrystalline O
beta O
- O
sheet O
structures O
in O
caddisfly O
silk O
. O

In O
this O
study O
, O
we O
determined O
the O
ability O
of O
seven O
dietary O
C B
- I
18 I
fatty I
acids I
to O
cause O
cytotoxicity O
and O
induce O
apoptosis O
in O
various O
types O
of O
human O
prostate O
cancer O
cells O
. O

The O
spatial O
conformation O
cis O
, O
trans O
, O
cis O
of O
jacaric B
and I
punicic I
acid I
was O
shown O
to O
play O
a O
key O
role O
in O
the O
increased O
potency O
and O
efficacy O
of O
these O
two O
fatty B
acids I
in O
comparison O
to O
the O
five O
other O
C B
- I
18 I
fatty I
acids I
tested O
. O

Three O
- O
dimensional O
conformational O
analysis O
using O
the O
PubChem O
Database O
( O
http O
: O
/ O
/ O
pubchem O
. O
ncbi O
. O
nlm O
. O
nih O
. O
gov O
) O
showed O
that O
the O
cytotoxic O
potency O
of O
the O
C B
- I
18 I
fatty I
acids I
was O
related O
to O
their O
degree O
of O
conformational O
similarity O
to O
our O
cytotoxic O
reference O
compound O
, O
punicic B
acid I
, O
based O
on O
optimized O
shape O
( O
ST O
) O
and O
feature O
( O
CT O
) O
similarity O
scores O
, O
with O
jacaric B
acid I
being O
most O
' O
biosimilar O
' O
( O
ST O
( O
ST O
- O
opt O
) O
= O
0 O
. O
81 O
; O
CT O
( O
CT O
- O
opt O
) O
= O

Tumor O
delivery O
of O
Photofrin B
( O
R O
) O
by O
PLL B
- I
g I
- I
PEG I
for O
photodynamic O
therapy O
. O

To O
enhance O
localization O
of O
Photofrin B
to O
tumors O
, O
we O
have O
formulated O
Photofrin B
with O
the O
tumor O
- O
localizing O
graft O
copolymer O
poly B
( I
ethylene I
glycol I
) I
- I
grafted I
poly I
( I
l I
- I
lysine I
) I
, O
PLL B
- I
g I
- I
PEG I
. O

We O
demonstrate O
that O
Photofrin B
preferentially O
interacts O
with O
PLL B
- I
g I
- I
PEG I
through O
both O
ionic O
and O
hydrophobic O
interactions O
. O

The O
serum O
competitive O
study O
showed O
that O
the O
highly O
PEG B
- I
grafted I
PLL I
is O
better O
for O
preventing O
serum O
binding O
to O
the O
Photofrin B
/ O
PLL B
- I
g I
- I
PEG I
complex O
. O

In O
tumor O
- O
bearing O
mice O
, O
formulation O
of O
Photofrin B
with O
PLL B
- I
g I
- I
PEG I
enhanced O
tumor O
localization O
of O
Photofrin B
as O
twice O
as O
Photofrin B
alone O
and O
concomitantly O
suppressed O
the O
photosensitivity O
reaction O
drastically O
. O

The O
leading O
cyclic B
polyamine I
disulfide I
was O
shown O
to O
be O
the O
spermine B
tetra I
- I
amine I
disulfide I
( O
TetraN B
- I
3 I
, I
4 I
, I
3 I
) O
. O

By O
contrast O
, O
our O
original O
cyclic B
tetra I
- I
amine I
disulfide I
remains O
the O
most O
efficient O
agent O
for O
the O
transfection O
of O
lung O
epithelial O
cells O
in O
vivo O
following O
intra O
- O
nasal O
administration O
. O

The O
first O
series O
of O
compounds O
investigated O
, O
beta B
- I
lactam I
phosphate I
esters I
7a O
, O
8a O
and O
9a O
, O
exhibited O
potent O
antiproliferative O
activity O
and O
caused O
microtubule O
disruption O
in O
human O
breast O
carcinoma O
- O
derived O
MCF O
- O
7 O
cells O
. O

Synthesis O
, O
evaluation O
and O
absolute O
configuration O
assignment O
of O
novel O
dihydropyrimidin B
- I
2 I
- I
ones I
as O
picomolar O
sodium B
iodide I
symporter O
inhibitors O
. O

A O
small O
library O
of O
dihydropyrimidin B
- I
2 I
- I
ones I
( O
DHPMs B
) O
was O
synthesized O
and O
evaluated O
for O
their O
potency O
to O
block O
iodide B
entrapment O
in O
rat O
thyroid O
cells O
. O

Cereal O
- O
based O
food O
products O
( O
n O
= O
174 O
) O
were O
analysed O
for O
the O
occurrence O
of O
deoxynivalenol B
, O
3 B
- I
acetyldeoxynivalenol I
, O
15 B
- I
acetyldeoxynivalenol I
, O
zearalenone B
, O
alpha B
- I
zearalenol I
, O
beta B
- I
zearalenol I
, O
T B
- I
2 I
- I
toxin I
, O
HT B
- I
2 I
- I
toxin I
, O
and O
their O
respective O
masked O
forms O
, O
including O
, O
deoxynivalenol B
- I
3 I
- I
glucoside I
, O
zearalenone B
- I
4 I
- I
glucoside I
, O
alpha B
- I

Cereal O
- O
based O
food O
products O
( O
n O
= O
174 O
) O
were O
analysed O
for O
the O
occurrence O
of O
deoxynivalenol B
, O
3 B
- I
acetyldeoxynivalenol I
, O
15 B
- I
acetyldeoxynivalenol I
, O
zearalenone B
, O
alpha B
- I
zearalenol I
, O
beta B
- I
zearalenol I
, O
T B
- I
2 I
- I
toxin I
, O
HT B
- I
2 I
- I
toxin I
, O
and O
their O
respective O
masked O
forms O
, O
including O
, O
deoxynivalenol B
- I
3 I
- I
glucoside I
, O
zearalenone B
- I
4 I
- I
glucoside I
, O
alpha B
- I

Cereal O
- O
based O
food O
products O
( O
n O
= O
174 O
) O
were O
analysed O
for O
the O
occurrence O
of O
deoxynivalenol B
, O
3 B
- I
acetyldeoxynivalenol I
, O
15 B
- I
acetyldeoxynivalenol I
, O
zearalenone B
, O
alpha B
- I
zearalenol I
, O
beta B
- I
zearalenol I
, O
T B
- I
2 I
- I
toxin I
, O
HT B
- I
2 I
- I
toxin I
, O
and O
their O
respective O
masked O
forms O
, O
including O
, O
deoxynivalenol B
- I
3 I
- I
glucoside I
, O
zearalenone B
- I
4 I
- I
glucoside I
, O
alpha B
- I

Cereal O
- O
based O
food O
products O
( O
n O
= O
174 O
) O
were O
analysed O
for O
the O
occurrence O
of O
deoxynivalenol B
, O
3 B
- I
acetyldeoxynivalenol I
, O
15 B
- I
acetyldeoxynivalenol I
, O
zearalenone B
, O
alpha B
- I
zearalenol I
, O
beta B
- I
zearalenol I
, O
T B
- I
2 I
- I
toxin I
, O
HT B
- I
2 I
- I
toxin I
, O
and O
their O
respective O
masked O
forms O
, O
including O
, O
deoxynivalenol B
- I
3 I
- I
glucoside I
, O
zearalenone B
- I
4 I
- I
glucoside I
, O
alpha B
- I

zearalenol I
- I
4 I
- I
glucoside I
, O
beta B
- I
zearalenol I
- I
4 I
- I
glucoside I
and O
zearalenone B
- I
4 I
- I
sulfate I
. O

Polyethylene B
oxide I
( O
PEO B
) O
is O
used O
as O
a O
carrier O
polymer O
in O
a O
chemically O
cross O
- O
linking O
poly B
( I
ethylene I
glycol I
) I
- O
high O
molecular O
weight O
heparin O
( O
PEG B
- O
HMWH O
) O
hydrogel O
. O

( B
+ I
) I
- I
Laburnamine I
, O
a O
Natural O
Selective O
Ligand O
and O
Partial O
Agonist O
for O
the O
alpha O
4 O
beta O
2 O
Nicotinic O
Receptor O
Subtype O
. O

( B
+ I
) I
- I
Laburnamine I
( O
1 O
) O
, O
a O
rare O
alkaloid O
extracted O
from O
Laburnum O
anagyroides O
seeds O
( O
~ O
4 O
mg O
from O
1 O
kg O
) O
, O
was O
shown O
to O
bind O
with O
high O
affinity O
( O
Ki O
, O
293 O
nM O
) O
to O
the O
alpha O
4 O
beta O
2 O
nicotinic O
receptor O
subtype O
, O
which O
is O
, O
respectively O
, O
126 O
and O
136 O
times O
higher O
than O
to O
the O
alpha O
3 O
beta O
4 O
( O
Ki O
37 O
mu O
M O
) O
and O
alpha O
7 O
subtypes O
( O
Ki O
40 O
mu O
M O
) O
. O

Two O
new O
tri B
- I
nor I
- I
eudesmanolides I
from O
Inula O
racemosa O
. O

Two O
new O
tri B
- I
nor I
- I
eudesmane I
- O
type O
sesquiterpenoids B
were O
isolated O
from O
the O
roots O
of O
Inula O
racemosa O
, O
and O
their O
structures O
were O
elucidated O
as O
8 B
- I
oxo I
- I
tri I
- I
nor I
- I
eudesm I
- I
6 I
- I
en I
- I
5 I
alpha I
- I
ol I
( O
1 O
) O
and O
tri B
- I
nor I
- I
eudesm I
- I
5 I
- I
en I
- I
7 I
beta I
, I
8 I
beta I
- I
diol I
( O
2 O
) O
. O

Thioacetamide B
( O
TA O
) O
has O
long O
been O
known O
as O
a O
hepatotoxicant O
whose O
bioactivation O
requires O
S B
- O
oxidation O
to O
thioacetamide B
S I
- I
oxide I
( O
TASO B
) O
and O
then O
to O
the O
very O
reactive O
S B
, I
S I
- I
dioxide I
( O
TASO2 B
) O
. O

3 B
- I
Hydroxyazetidine I
carboxylic I
acids I
: O
non O
- O
proteinogenic O
amino B
acids I
for O
medicinal O
chemists O
. O

The O
formation O
from O
D B
- I
glucose I
of O
both O
enantiomers O
of O
2 B
, I
4 I
- I
dideoxy I
- I
2 I
, I
4 I
- I
iminoribonic I
acid I
is O
the O
first O
chemical O
synthesis O
of O
unprotected O
3 B
- I
hydroxyazetidine I
carboxylic I
acids I
. O

Despite O
the O
apparent O
stability O
, O
organometallic B
complexes O
of O
methylthiolate B
and O
phenylthiolate B
with O
the O
gold O
- O
adatom O
( O
RS B
- I
Au I
- I
SR I
, O
with O
R O
- O
the O
hydrocarbon B
group O
) O
undergo O
a O
stoichiometric O
exchange O
reaction O
, O
forming O
hybridized O
CH3S B
- I
Au I
- I
SPh I
complexes O
. O

Despite O
the O
apparent O
stability O
, O
organometallic B
complexes O
of O
methylthiolate B
and O
phenylthiolate B
with O
the O
gold O
- O
adatom O
( O
RS B
- I
Au I
- I
SR I
, O
with O
R O
- O
the O
hydrocarbon B
group O
) O
undergo O
a O
stoichiometric O
exchange O
reaction O
, O
forming O
hybridized O
CH3S B
- I
Au I
- I
SPh I
complexes O
. O

Green O
luminescent O
, O
monodisperse O
, O
smooth O
, O
porous O
and O
hollow O
spheres O
were O
simply O
prepared O
by O
Cu B
( I
2 I
+ I
) I
and O
temperature O
mediated O
oxidative O
coupling O
assembly O
of O
green O
tea O
polyphenols B
in O
water O
. O

Here O
we O
synthesized O
a O
number O
of O
new O
derivatives O
of O
3 B
- I
methyl I
- I
benzyl I
- I
PP I
( O
3 B
- I
MB I
- I
PP I
, O
or O
1 O
) O
. O

The O
present O
study O
demonstrated O
that O
human O
multidrug O
resistance O
- O
associated O
protein O
3 O
vesicles O
accepted O
conjugated O
3 B
beta I
- I
hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
acids I
along O
with O
common O
bile B
acids I
such O
as O
glycocholic B
acid I
and O
taurolithocholic B
acid I
3 I
- I
sulfate I
. O

Detailed O
comparisons O
between O
the O
available O
experimental O
and O
computed O
AEA O
data O
at O
the O
B3LYP O
/ O
6 O
- O
311 O
+ O
G O
* O
level O
identified O
the O
electronic O
ground O
state O
of O
( O
5 O
) O
Delta O
for O
FeS B
, O
( O
4 O
) O
Delta O
for O
FeS B
( I
- I
) I
, O
( O
5 O
) O
B2 O
for O
FeS2 B
, O
( O
6 O
) O
A1 O
for O
FeS2 B
( I
- I
) I
, O
( O
1 O
) O
A1 O
for O
Fe2 B
S2 I
, O
( O
8 O
) O
A O
' O
for O
Fe2 B
S2 I
( I
- I
) I
, O
( O
5 O
) O
A O
' O
' O
for O
Fe3 B
S4 I
, O
( O
6 O
) O
A O
' O
' O
for O
Fe3 B
S4 I
( I
- I
) I
, O
( O

Detailed O
comparisons O
between O
the O
available O
experimental O
and O
computed O
AEA O
data O
at O
the O
B3LYP O
/ O
6 O
- O
311 O
+ O
G O
* O
level O
identified O
the O
electronic O
ground O
state O
of O
( O
5 O
) O
Delta O
for O
FeS B
, O
( O
4 O
) O
Delta O
for O
FeS B
( I
- I
) I
, O
( O
5 O
) O
B2 O
for O
FeS2 B
, O
( O
6 O
) O
A1 O
for O
FeS2 B
( I
- I
) I
, O
( O
1 O
) O
A1 O
for O
Fe2 B
S2 I
, O
( O
8 O
) O
A O
' O
for O
Fe2 B
S2 I
( I
- I
) I
, O
( O
5 O
) O
A O
' O
' O
for O
Fe3 B
S4 I
, O
( O
6 O
) O
A O
' O
' O
for O
Fe3 B
S4 I
( I
- I
) I
, O
( O

1 O
) O
A1 O
for O
Fe4 B
S4 I
, O
and O
( O
1 O
) O
A2 O
for O
Fe4 B
S4 I
( I
- I
) I
. O

In O
addition O
, O
Fe2 B
S2 I
, O
Fe3 B
S4 I
, O
Fe3 B
S4 I
( I
- I
) I
, O
Fe4 B
S4 I
, O
and O
Fe4 B
S4 I
( I
- I
) I
are O
antiferromagnetic O
at O
the O
B3LYP O
/ O
6 O
- O
311 O
+ O
G O
* O
level O
. O

In O
addition O
, O
Fe2 B
S2 I
, O
Fe3 B
S4 I
, O
Fe3 B
S4 I
( I
- I
) I
, O
Fe4 B
S4 I
, O
and O
Fe4 B
S4 I
( I
- I
) I
are O
antiferromagnetic O
at O
the O
B3LYP O
/ O
6 O
- O
311 O
+ O
G O
* O
level O
. O

We O
show O
that O
the O
salts O
when O
ordered O
by O
heat O
effects O
produced O
by O
mixing O
of O
NaF B
and O
NaBr B
with O
3 B
, I
3 I
- I
, I
6 I
, I
9 I
- I
, I
or I
6 I
, I
12 I
- I
ionene I
fluorides I
and I
bromides I
follow O
the O
opposite O
ordering O
than O
in O
the O
case O
when O
the O
same O
alkali B
halide I
salts O
are O
mixed O
with O
more O
hydrophobic O
12 B
, I
12 I
- I
ionene I
salts O
. O

Sonochemical O
synthesis O
and O
characterization O
of O
nano O
- O
sized O
lead B
( I
II I
) I
3D O
coordination O
polymer O
: O
Precursor O
for O
the O
synthesis O
of O
lead B
( I
II I
) I
oxybromide I
nanoparticles O
. O

The O
O2 B
( I
- I
) I
. I
- O
production O
efficiency O
of O
1 O
- O
( B
I I
( I
- I
) I
) I
10 I
was O
confirmed O
by O
using O
an O
O2 B
( I
- I
) I
. I
- O
reactive O
bis B
( I
2 I
, I
4 I
- I
dinitrobenzenesulfon I
) I
tetrafluorofluoresce I
probe O
and O
correlated O
to O
the O
photoinduced O
electron O
- O
transfer O
event O
going O
from O
iodide B
anions O
to O
( B
3 I
) I
C60 I
* I
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
leading O
to O
C60 B
( I
- I
) I
. I
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
. O

The O
O2 B
( I
- I
) I
. I
- O
production O
efficiency O
of O
1 O
- O
( B
I I
( I
- I
) I
) I
10 I
was O
confirmed O
by O
using O
an O
O2 B
( I
- I
) I
. I
- O
reactive O
bis B
( I
2 I
, I
4 I
- I
dinitrobenzenesulfon I
) I
tetrafluorofluoresce I
probe O
and O
correlated O
to O
the O
photoinduced O
electron O
- O
transfer O
event O
going O
from O
iodide B
anions O
to O
( B
3 I
) I
C60 I
* I
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
leading O
to O
C60 B
( I
- I
) I
. I
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
. O

Synthesis O
using O
microwave O
irradiation O
and O
antibacterial O
evaluation O
of O
new O
N B
, I
O I
- I
acetals I
and O
N B
, I
S I
- I
acetals I
derived O
from O
2 B
- I
amino I
- I
1 I
, I
4 I
- I
naphthoquinones I
. O

Synthesis O
using O
microwave O
irradiation O
and O
antibacterial O
evaluation O
of O
new O
N B
, I
O I
- I
acetals I
and O
N B
, I
S I
- I
acetals I
derived O
from O
2 B
- I
amino I
- I
1 I
, I
4 I
- I
naphthoquinones I
. O

This O
paper O
describes O
a O
novel O
series O
of O
N B
, I
O I
- I
acetals I
and O
N B
, I
S I
- I
acetals I
( O
7a O
- O
o O
) O
derived O
from O
2 B
- I
amino I
- I
1 I
, I
4 I
- I
naphthoquinones I
that O
were O
synthesized O
and O
evaluated O
as O
potential O
antimicrobial O
agents O
. O

This O
paper O
describes O
a O
novel O
series O
of O
N B
, I
O I
- I
acetals I
and O
N B
, I
S I
- I
acetals I
( O
7a O
- O
o O
) O
derived O
from O
2 B
- I
amino I
- I
1 I
, I
4 I
- I
naphthoquinones I
that O
were O
synthesized O
and O
evaluated O
as O
potential O
antimicrobial O
agents O
. O

Three O
of O
our O
biologically O
active O
2 B
- I
amino I
- I
1 I
, I
4 I
- I
naphthoquinone I
N B
, I
O I
- I
acetals I
and O
N B
, I
S I
- I
acetals I
tested O
against O
hospital O
bacterial O
strains O
were O
identified O
as O
potential O
lead O
compounds O
. O

Three O
of O
our O
biologically O
active O
2 B
- I
amino I
- I
1 I
, I
4 I
- I
naphthoquinone I
N B
, I
O I
- I
acetals I
and O
N B
, I
S I
- I
acetals I
tested O
against O
hospital O
bacterial O
strains O
were O
identified O
as O
potential O
lead O
compounds O
. O

Using O
LC O
- O
NSI O
- O
HRMS O
/ O
MS O
- O
PRM O
, O
O B
( I
6 I
) I
- I
methyl I
- I
G I
, O
7 B
- I
POB I
- I
G I
, O
and O
O B
( I
2 I
) I
- I
POB I
- I
dT I
were O
positively O
identified O
in O
ALDH O
- O
positive O
cell O
DNA O
. O

Two O
mitochondriotropic O
, O
4 B
- I
O I
- I
triphenylphosphonium I
derivatives O
of O
quercetin B
( O
QTA B
- I
3BTPI I
and O
Q B
- I
3BTPI I
) O
were O
compared O
to O
quercetin B
for O
protection O
against O
glyceryl B
trinitrate I
- O
induced O
tolerance O
and O
endothelial O
dysfunction O
of O
isolated O
rat O
aorta O
rings O
. O

Physicochemical O
Properties O
and O
Supernucleophilicity O
of O
Oxime B
- O
Functionalized O
Surfactants O
: O
Hydrolytic O
Catalysts O
toward O
Dephosphorylation O
of O
Di B
- I
and I
Triphosphate I
Esters I
. O

Aggregation O
and O
kinetic O
studies O
have O
been O
performed O
to O
understand O
the O
hydrolytic O
potencies O
of O
the O
series O
of O
oxime B
- O
functionalized O
surfactants O
, O
viz O
. O
, O
3 B
- I
hydroxyiminomethyl I
- I
1 I
- I
alkylpyridinium I
bromide I
( O
alkyl B
= O
CnH2n B
+ I
1 I
, O
n O
= O
10 O
, O
12 O
, O
14 O
, O
16 O
, O
18 O
) O
in O
the O
cleavage O
of O
phosphate B
esters I
, O
p B
- I
nitrophenyl I
diphenyl I
phosphate I
( O
PNPDPP B
) O
and O
bis B
( I
2 I
, I
4 I
- I
dinitrophenyl I
) I
phosphate I
( O

Functionalized O
oxime B
- O
based O
surfactants O
were O
proved O
to O
be O
supernucleophiles O
to O
attack O
on O
the O
P B
= I
O I
center O
of O
tri B
- I
and I
diphosphate I
esters I
. O

We O
studied O
the O
equilibrium O
conformations O
of O
a O
zinc B
porphyrin I
tweezer O
composed O
of O
two O
carboxylphenyl B
- O
functionalized O
zinc B
tetraphenyl I
porphyrin I
subunits O
connected O
by O
a O
1 B
, I
4 I
- I
butyndiol I
spacer O
, O
which O
was O
suspended O
inside O
the O
amphiphilic O
regions O
of O
1 B
, I
2 I
- I
distearoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
( O
DSPC B
) O
liposomes O
. O

TSS O
- O
SPIONs O
were O
developed O
by O
chelation O
between O
thiolated O
chitosan O
- O
thioglycolic B
acid I
( O
chitosan O
- O
TGA B
) O
hydrogel O
and O
iron B
ions O
( O
Fe B
( I
2 I
+ I
) I
/ O
Fe B
( I
3 I
+ I
) I
) O
. O

TSS O
- O
SPIONs O
were O
developed O
by O
chelation O
between O
thiolated O
chitosan O
- O
thioglycolic B
acid I
( O
chitosan O
- O
TGA B
) O
hydrogel O
and O
iron B
ions O
( O
Fe B
( I
2 I
+ I
) I
/ O
Fe B
( I
3 I
+ I
) I
) O
. O

1 B
- I
Methylimidazolium I
hydrogen I
sulfate I
catalyzed O
convenient O
synthesis O
of O
2 B
, I
5 I
- I
dimethyl I
- I
N I
- I
substituted I
pyrroles I
under O
ultrasonic O
irradiation O
. O

Ionic O
liquid O
[ B
HMIM I
] I
HSO4 I
was O
found O
to O
be O
an O
efficient O
catalyst O
for O
the O
synthesis O
of O
N B
- I
substituted I
pyrroles I
through O
the O
reaction O
of O
2 B
, I
5 I
- I
hexanedione I
with O
amines B
under O
ultrasonic O
irradiation O
at O
room O
temperature O
. O

Furthermore O
, O
CK O
induced O
activation O
of O
nuclear O
erythroid O
2 O
- O
related O
factor O
2 O
( O
Nrf2 O
) O
- O
mediated O
antioxidant O
enzymes O
such O
as O
gamma B
- I
glutamylcysteine I
synthetase O
( O
gamma O
- O
GCS O
) O
, O
heme B
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
, O
NAD B
( I
P I
) I
H I
quinone B
oxidoreductase O
1 O
( O
NQO1 O
) O
, O
and O
glutathione B
- O
S B
- O
transferase O
( O
GST O
) O
in O
HepG2 O
cells O
. O

Other O
migrants O
such O
as O
dipropylene B
glycol I
methyl I
ether I
or O
tributyl B
- I
o I
- I
acetylcitrate I
, O
both O
coming O
from O
the O
coating O
were O
also O
found O
, O
but O
none O
of O
them O
have O
potential O
adverse O
effects O
. O

Nicotine B
, O
varenicline B
, O
and O
cytisine B
were O
administered O
alone O
, O
in O
combination O
with O
each O
other O
, O
and O
in O
combination O
with O
mecamylamine B
and O
dihydro B
- I
beta I
- I
erythroidine I
( O
DH B
beta I
E I
) O
. O

GTLE O
reduces O
AlCl3 B
neurotoxicity O
probably O
via O
antioxidative O
effects O
and O
improves O
mitochondrial O
and O
cholinergic O
synaptic O
functions O
through O
the O
actions O
of O
( B
- I
) I
- I
epigallocatechin I
gallate I
and O
( B
- I
) I
- I
epicatechin I
, O
compounds O
most O
abundantly O
found O
in O
GTLE O
. O

Here O
, O
we O
show O
the O
formation O
of O
a O
living O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
layer O
that O
can O
be O
patterned O
with O
visible O
light O
on O
plastic O
surfaces O
. O

Here O
we O
use O
vibrational O
sum O
frequency O
spectroscopy O
( O
SF O
) O
to O
study O
the O
origin O
of O
the O
opposite O
Delta O
V O
signs O
of O
Langmuir O
films O
of O
CH3 B
( I
CH2 I
) I
20COCH2CH3 I
( O
ethyl B
ether I
, O
EE O
) O
and O
CH3 B
( I
CH2 I
) I
20COCH2CF3 I
( O
fluorinated B
ethyl I
ether I
, O
FEE B
) O
. O

Here O
we O
use O
vibrational O
sum O
frequency O
spectroscopy O
( O
SF O
) O
to O
study O
the O
origin O
of O
the O
opposite O
Delta O
V O
signs O
of O
Langmuir O
films O
of O
CH3 B
( I
CH2 I
) I
20COCH2CH3 I
( O
ethyl B
ether I
, O
EE O
) O
and O
CH3 B
( I
CH2 I
) I
20COCH2CF3 I
( O
fluorinated B
ethyl I
ether I
, O
FEE B
) O
. O

Optimisation O
of O
synthesis O
of O
oligosaccharides O
derived O
from O
lactulose B
( O
fructosyl B
- I
galacto I
- I
oligosaccharides I
) O
with O
beta O
- O
galactosidases O
of O
different O
origin O
. O

Batch O
synthesis O
of O
fructosyl B
- I
galacto I
- I
oligosaccharides I
from O
lactulose B
was O
performed O
with O
commercial O
beta O
- O
galactosidase O
preparations O
from O
Aspergillus O
oryzae O
, O
Kluyveromyces O
lactis O
and O
Bacillus O
circulans O
. O

Optimization O
of O
fructosyl B
- I
galacto I
- I
oligosaccharides I
synthesis O
was O
carried O
out O
using O
response O
surface O
methodology O
, O
considering O
temperature O
and O
initial O
sugar B
concentration O
as O
variables O
and O
yield O
and O
specific O
productivity O
as O
response O
parameters O
. O

Maximum O
yield O
of O
0 O
. O
41 O
g O
g O
( O
- O
1 O
) O
fructosyl B
- I
galacto I
- I
oligosaccharides I
was O
obtained O
at O
70 O
degrees O
C O
and O
60 O
% O
w O
/ O
w O
lactulose B
concentration O
, O
while O
maximum O
specific O
productivity O
of O
1 O
. O
2 O
g O
h O
( O
- O
1 O
) O
mg O
( O
- O
1 O
) O
was O
obtained O
at O
70 O
degrees O
C O
and O
40 O
% O
w O
/ O
w O
lactulose B
concentration O
. O

In O
their O
free O
form O
, O
cis B
- I
antheraxanthin I
degraded O
30 O
- O
fold O
faster O
while O
cis B
- I
violaxanthin I
instantaneously O
disappeared O
because O
of O
the O
isomerisation O
of O
its O
5 B
, I
6 I
- I
epoxy I
groups O
into O
5 B
, I
8 I
- I
epoxy I
. O

In O
their O
free O
form O
, O
cis B
- I
antheraxanthin I
degraded O
30 O
- O
fold O
faster O
while O
cis B
- I
violaxanthin I
instantaneously O
disappeared O
because O
of O
the O
isomerisation O
of O
its O
5 B
, I
6 I
- I
epoxy I
groups O
into O
5 B
, I
8 I
- I
epoxy I
. O

The O
key O
step O
was O
the O
elimination O
of O
HBr B
in O
a O
vicinal B
dibromo I
D I
- I
homosteroid I
by O
treatment O
with O
1 B
, I
4 I
- I
diazabicyclo I
[ I
2 I
. I
2 I
. I
2 I
] I
octane I
( O
DABCO B
) O
. O

Little O
is O
known O
in O
terms O
of O
multi O
- O
matrix O
cytochrome O
P450 O
activity O
induction O
under O
repeated O
oral O
exposure O
to O
planar O
halogenated B
and I
polycyclic I
aromatic I
hydrocarbons I
( O
PHH O
, O
PAH B
) O
. O

In O
the O
present O
study O
, O
60 O
rats O
were O
daily O
exposed O
, O
during O
28days O
, O
to O
oral O
ingestion O
of O
a O
mixture O
consisting O
of O
phenanthrene B
, O
pyrene B
and O
benzo B
( I
a I
) I
pyrene I
at O
0 O
, O
6 O
or O
600 O
mu O
g O
/ O
day O
. O

Synthesis O
and O
evaluation O
of O
7 B
, I
8 I
- I
dehydrorutaecarpine I
derivatives O
as O
potential O
multifunctional O
agents O
for O
the O
treatment O
of O
Alzheimer O
' O
s O
disease O
. O

A O
series O
of O
7 B
, I
8 I
- I
dehydrorutaecarpine I
derivatives O
were O
synthesized O
and O
characterized O
as O
potential O
multifunctional O
agents O
for O
treatment O
of O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
. O

Synthesis O
of O
phenyleneethynylene B
- O
doped O
poly B
( I
pphenylenebutadiynyl I
) I
s I
for O
live O
cell O
imaging O
. O

The O
high O
purity O
, O
molecular O
weight O
and O
correct O
compositions O
of O
each O
new O
polypeptide O
have O
been O
confirmed O
via O
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
, O
sodium B
dodecyl I
sulfate I
polyacrylamide I
gel I
electrophoresis O
( O
SDS B
- O
PAGE O
) O
, O
matrix O
- O
assisted O
laser O
desorption O
/ O
ionization O
mass O
spectrometry O
( O
MALDI O
- O
MS O
) O
, O
and O
amino B
acid I
analysis O
. O

Tris B
( I
hydroxymethyl I
phosphine I
) I
cross O
- O
linked O
RLP O
hydrogels O
were O
able O
to O
maintain O
their O
mechanical O
integrity O
as O
well O
as O
the O
viability O
of O
encapsulated O
primary O
human O
mesenchymal O
stem O
cells O
( O
MSCs O
) O
. O

Also O
blocking O
of O
CbpD O
using O
N B
- I
acetyl I
- I
glucosamine I
yielded O
a O
lower O
adhesion O
force O
( O
- O
4 O
. O
3 O
nN O
) O
with O
hyphae O
. O

An O
amphiphilic O
diblock O
copolymer O
poly B
( I
acrylamidoethylamine I
) I
90 I
- I
block I
- I
poly I
( I
dl I
- I
lactide I
) I
40 I
( O
PAEA90 B
- I
b I
- I
PDLLA40 I
) O
was O
synthesized O
, O
self O
- O
assembled O
in O
aqueous O
solution O
, O
and O
shell O
cross O
- O
linked O
using O
a O
hydrolyzable O
cross O
- O
linker O
to O
afford O
deg O
- O
cSCKs O
with O
an O
average O
core O
diameter O
of O
45 O
+ O
/ O
- O
7 O
nm O
. O

NAD B
( I
P I
) I
H I
: O
Quinone B
Oxidoreductase O
1 O
Inducer O
Activity O
of O
Some O
Saudi O
Arabian O
Medicinal O
Plants O
. O

One O
such O
multifunctional O
cytoprotective O
enzyme O
is O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
. O

In O
this O
study O
, O
we O
prepared O
extracts O
of O
27 O
Saudi O
Arabian O
medicinal O
plants O
which O
belong O
to O
18 O
different O
plant O
families O
and O
tested O
their O
ability O
to O
induce O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
in O
murine O
hepatoma O
cells O
grown O
in O
microtiter O
plate O
wells O
. O

In O
addition O
to O
the O
Brassicaceae O
, O
a O
known O
source O
of O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
inducer O
activity O
, O
we O
found O
substantial O
inducer O
activity O
in O
extracts O
from O
the O
Apiaceae O
, O
Apocynaceae O
, O
and O
the O
Asteraceae O
families O
. O

Thus O
, O
the O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
inducer O
activity O
of O
extracts O
of O
some O
Saudi O
Arabian O
medicinal O
plants O
indicates O
the O
presence O
of O
specific O
phytochemicals O
which O
have O
the O
potential O
to O
protect O
against O
chronic O
degenerative O
diseases O
. O

The O
protective O
effects O
of O
omega B
- I
3 I
fatty I
acids I
on O
doxorubicin B
- O
induced O
hepatotoxicity O
and O
nephrotoxicity O
in O
rats O
. O

This O
study O
aims O
to O
evaluate O
the O
protective O
effects O
of O
omega B
- I
3 I
fatty I
acids I
( O
FAs B
) O
on O
doxorubicin B
( O
DOX B
) O
- O
induced O
hepatotoxicity O
and O
nephrotoxicity O
in O
rats O
. O

Epigallocatechin B
- I
3 I
- I
Gallate I
Inhibits O
Collagen O
Production O
of O
Nasal O
Polyp O
- O
Derived O
Fibroblasts O
. O

The O
meso B
- I
tetra I
( I
2 I
, I
6 I
- I
dichloro I
- I
3 I
- I
sulfonatophenyl I
) I
porphyrinate I
of O
manganese B
( I
III I
) I
chloride I
[ B
Mn I
- I
( I
TDCPPS I
) I
Cl I
] I
biomimetic O
catalyst O
immobilized O
on O
spacer O
- O
functionalized O
kaolinite B
clay O
mineral O
was O
employed O
in O
the O
oxidative O
coupling O
reaction O
of O
a O
dissolved O
humic O
acid O
( O
HA O
) O
suprastructure O
with O
either O
chemical O
( O
H2O2 B
) O
or O
UV O
- O
light O
oxidation O
. O

Biological O
activity O
of O
Pd B
( I
II I
) I
complexes O
with O
mono B
- I
and I
disubstituted I
pyridines I
- O
Experimental O
and O
theoretical O
studies O
. O

Activity O
of O
six O
PdCl2 B
( I
X2Py I
) I
2 I
complexes O
( O
Py B
= O
pyridine B
, O
and O
X O
= O
CH3 B
or O
Cl B
) O
was O
measured O
by O
MTT B
test O
using O
MCF7 O
, O
CCRF O
- O
SB O
, O
PC3 O
and O
human O
B O
- O
lymphoblastoid O
cell O
lines O
. O

We O
found O
that O
the O
effect O
of O
PdCl2 B
( I
XnPy I
) I
2 I
was O
cell O
- O
specific O
and O
time O
- O
dependent O
. O

Obtained O
results O
were O
discussed O
and O
compared O
with O
the O
activation O
parameters O
calculated O
for O
the O
hydrolysis O
of O
PdCl2 B
( I
XnPy I
) I
2 I
, O
indicating O
a O
correlation O
between O
viability O
of O
MCF7 O
and O
CCRF O
- O
SB O
cells O
and O
rates O
of O
hydrolysis O
of O
the O
Pd B
( I
II I
) I
complexes O
. O

In O
vitro O
study O
demonstrated O
that O
the O
addition O
of O
0 O
. O
5 O
mM O
Fe B
( I
2 I
+ I
) I
and O
0 O
. O
1 O
mM O
ascorbate B
caused O
increase O
in O
the O
production O
of O
MDA B
level O
in O
placental O
tissue O
with O
PE O
than O
normal O
placentas O
, O
and O
vitamin B
E I
( O
100 O
micro O
M O
) O
caused O
lower O
inhibition O
of O
in O
vitro O
lipid O
peroxidation O
in O
placental O
tissue O
with O
PE O
when O
compared O
with O
normal O
tissue O
. O

Ca B
( I
2 I
+ I
) I
- O
dependent O
suicidal O
erythrocyte O
death O
following O
zearalenone B
exposure O
. O

The O
most O
important O
stimulator O
of O
eryptosis O
is O
an O
increase O
in O
cytosolic O
Ca B
( I
2 I
+ I
) I
activity O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
) O
. O

The O
most O
important O
stimulator O
of O
eryptosis O
is O
an O
increase O
in O
cytosolic O
Ca B
( I
2 I
+ I
) I
activity O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
) O
. O

Erythrocyte O
volume O
was O
estimated O
from O
forward O
scatter O
, O
phosphatidylserine O
exposure O
at O
the O
erythrocyte O
surface O
from O
annexin O
- O
V O
binding O
, O
hemolysis O
from O
hemoglobin O
release O
, O
and O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
from O
Fluo3 B
fluorescence O
. O

A O
48 O
- O
h O
exposure O
to O
zearalenone B
( O
> O
= O
25 O
mu O
M O
) O
was O
followed O
by O
a O
significant O
increase O
in O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
and O
annexin O
- O
V O
binding O
, O
and O
a O
significant O
decrease O
in O
forward O
scatter O
. O

The O
effect O
on O
annexin O
- O
V O
binding O
was O
significantly O
blunted O
in O
the O
nominal O
absence O
of O
extracellular O
Ca B
( I
2 I
+ I
) I
. O

Zearalenone B
stimulates O
the O
suicidal O
erythrocyte O
death O
, O
an O
effect O
at O
least O
partially O
due O
to O
stimulation O
of O
Ca B
( I
2 I
+ I
) I
entry O
. O

We O
examined O
this O
hypothesis O
by O
using O
alginate O
and O
poly B
( I
acrylic I
acid I
) I
( O
PAA B
) O
modified O
with O
a O
controlled O
number O
of O
methacrylic B
groups O
as O
model O
inflexible O
and O
flexible O
cross O
- O
linkers O
, O
respectively O
. O

7 B
- I
hydroxymitragynine I
( O
7 B
- I
OH I
- I
MG I
) O
, O
and O
several O
synthetic O
analogues O
of O
these O
natural O
products O
display O
centrally O
mediated O
( O
supraspinal O
and O
spinal O
) O
antinociceptive O
( O
analgesic O
) O
activity O
in O
various O
pain O
models O
. O

A O
novel O
series O
of O
compounds O
were O
synthesized O
by O
cyclic O
condensation O
reaction O
of O
substituted O
isothiocyanate B
( O
2a O
- O
c O
) O
with O
2 B
- I
thiophenecarboxylic I
acid I
hydrazide I
( O
1 O
) O
in O
the O
presence O
of O
ethyl B
alcohol I
, O
to O
obtain O
intermediate O
thiosemicarbazides B
( O
3a O
- O
c O
) O
, O
which O
were O
further O
treated O
with O
sodium B
hydroxide I
in O
the O
presence O
of O
ethanol B
to O
obtain O
triazole B
derivatives O
( O
4a O
- O
c O
) O
. O

Furthermore O
, O
we O
observed O
that O
AVM B
- O
induced O
expression O
of O
P O
- O
gp O
was O
due O
to O
elevation O
of O
intracellular O
calcium B
concentration O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
) O
. O

These O
results O
are O
supported O
by O
our O
observations O
that O
verapamil B
, O
a O
Ca B
( I
2 I
+ I
) I
channel O
blocker O
, O
and O
niflumic B
acid I
, O
a O
chloride B
channel O
antagonist O
, O
significantly O
attenuated O
AVM B
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
elevation O
, O
thereby O
reducing O
P O
- O
gp O
expression O
. O

These O
results O
are O
supported O
by O
our O
observations O
that O
verapamil B
, O
a O
Ca B
( I
2 I
+ I
) I
channel O
blocker O
, O
and O
niflumic B
acid I
, O
a O
chloride B
channel O
antagonist O
, O
significantly O
attenuated O
AVM B
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
elevation O
, O
thereby O
reducing O
P O
- O
gp O
expression O
. O

Inhibition O
of O
P O
- O
gp O
with O
anti O
- O
P O
- O
gp O
antibody O
or O
cyclosporine B
A I
( O
a O
P O
- O
gp O
inhibitor O
) O
reduced O
the O
AVM B
- O
induced O
elevation O
of O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
, O
implying O
that O
P O
- O
gp O
and O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
regulate O
each O
other O
. O

Inhibition O
of O
P O
- O
gp O
with O
anti O
- O
P O
- O
gp O
antibody O
or O
cyclosporine B
A I
( O
a O
P O
- O
gp O
inhibitor O
) O
reduced O
the O
AVM B
- O
induced O
elevation O
of O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
, O
implying O
that O
P O
- O
gp O
and O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
regulate O
each O
other O
. O

One O
of O
them O
that O
resulted O
from O
the O
oxidation O
of O
2 B
- I
oxo I
- I
prasugrel I
by O
human O
liver O
microsomes O
in O
the O
presence O
of O
ethanolamine B
and O
CPDH B
was O
isolated O
and O
completely O
characterized O
by O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
spectroscopy O
in O
addition O
to O
MS O
and O
MS O
( O
2 O
) O
spectrometry O
. O

The O
influence O
of O
lattice O
strain O
on O
the O
oxygen B
exchange O
kinetics O
and O
diffusion O
in O
oxides B
was O
investigated O
on O
( O
100 O
) O
epitaxial O
La1 B
- I
xSrxCoO3 I
- I
delta I
( O
LSC B
) O
thin O
films O
grown O
by O
pulsed O
laser O
deposition O
. O

We O
tested O
associations O
of O
circulating O
vitamin B
D I
metabolite O
concentrations O
with O
subclinical O
atherosclerosis O
among O
1 O
, O
193 O
participants O
with O
type O
1 O
diabetes O
in O
the O
DCCT O
/ O
EDIC O
study O
. O
RESEARCH O
DESIGN O
AND O
METHODSWe O
measured O
plasma O
concentrations O
of O
25 B
- I
hydroxyvitamin I
D I
[ O
25 B
( I
OH I
) I
D I
] O
, O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
, O
and O
24 B
, I
25 I
- I
dihydroxyvitamin I
D I
by O
mass O
spectrometry O
at O
the O
end O
of O
the O
DCCT O
. O

Silicone O
sheets O
are O
first O
plasma O
treated O
and O
then O
functionalized O
by O
grafting O
sequentially O
under O
stretching O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
chains O
and O
biotin B
or O
arginine B
- O
glycine B
- O
aspartic B
acid I
( O
RGD O
) O
peptides O
. O

Nickel B
( I
II I
) I
Dithiocarbamate I
Complexes O
Containing O
Sulforhodamine B
B I
as O
Fluorescent O
Probes O
for O
Selective O
Detection O
of O
Nitrogen B
Dioxide I
. O

The O
previously O
developed O
probe O
was O
found O
to O
display O
the O
greatest O
activity O
in O
the O
inhibition O
of O
NMDA B
- O
induced O
Ca B
( I
2 I
+ I
) I
influx O
by O
calcium B
imaging O
experiments O
on O
HEK293 O
cells O
transfected O
with O
the O
cDNA O
encoding O
for O
GluN1 O
- O
1A O
and O
GluN2B O
. O

Intra O
- O
dorsal O
hippocampus O
( O
DH O
) O
injections O
of O
8 B
- I
hydroxy I
- I
2 I
- I
( I
di I
- I
n I
- I
propylamino I
) I
tetralin I
( O
8 B
- I
OH I
- I
DPAT I
) O
, O
a O
serotonin B
- O
1A O
( O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
- O
1A O
) O
receptor O
agonist O
, O
were O
previously O
shown O
to O
inhibit O
the O
expression O
of O
contextual O
fear O
when O
administered O
six O
hours O
after O
conditioning O
. O

Although O
intra O
- O
DH O
injections O
of O
8 B
- I
OH I
- I
DPAT I
did O
not O
produce O
behavioral O
changes O
, O
muscimol O
reduced O
both O
FPS O
and O
the O
freezing O
response O
. O

Lipid O
profile O
indicated O
that O
administration O
of O
canola O
and O
fish O
oil O
can O
increase O
the O
content O
of O
omega B
- I
3 I
fatty I
acids I
in O
rat O
testis O
. O

Additional O
experiments O
involving O
the O
incubation O
of O
liver O
microsomes O
with O
individual O
monohydroxy B
- O
tetrabrominated O
metabolites O
in O
place O
of O
BDE B
- I
47 I
demonstrated O
that O
2 B
, I
4 I
- I
dibromophenol I
was O
a O
product O
of O
BDE B
- I
47 I
and O
several O
primary O
metabolites O
, O
but O
the O
dihydroxy B
- O
tetrabrominated O
metabolite O
was O
not O
formed O
by O
sequential O
hydroxylation O
of O
any O
of O
the O
monohydroxy B
- O
tetrabrominated O
metabolites O
tested O
. O

In O
addition O
, O
major O
metabolites O
were O
identified O
and O
measurements O
of O
OH B
- I
PAHs I
( O
1 B
- I
naphthol I
, O
9 B
- I
phenantrol I
, O
9 B
- I
fluorenol I
, O
1 B
- I
pyrenol I
, O
1OH B
- I
BaP I
and O
3OH B
- I
BaP I
) O
and O
alkylphenols B
( O
4 B
- I
n I
- I
nonylphenol I
( O
4 B
- I
n I
- I
NP I
) O
and O
4 B
- I
tertoctylphenol I
( O
4 B
- I
tert I
- I
OP I
) O
) O
in O
the O
same O
fish O
bile O
extracts O
were O
taken O
by O
gas O
chromatography O
- O
mass O
spectrometry O
in O
electron O

In O
addition O
, O
major O
metabolites O
were O
identified O
and O
measurements O
of O
OH B
- I
PAHs I
( O
1 B
- I
naphthol I
, O
9 B
- I
phenantrol I
, O
9 B
- I
fluorenol I
, O
1 B
- I
pyrenol I
, O
1OH B
- I
BaP I
and O
3OH B
- I
BaP I
) O
and O
alkylphenols B
( O
4 B
- I
n I
- I
nonylphenol I
( O
4 B
- I
n I
- I
NP I
) O
and O
4 B
- I
tertoctylphenol I
( O
4 B
- I
tert I
- I
OP I
) O
) O
in O
the O
same O
fish O
bile O
extracts O
were O
taken O
by O
gas O
chromatography O
- O
mass O
spectrometry O
in O
electron O

In O
addition O
, O
major O
metabolites O
were O
identified O
and O
measurements O
of O
OH B
- I
PAHs I
( O
1 B
- I
naphthol I
, O
9 B
- I
phenantrol I
, O
9 B
- I
fluorenol I
, O
1 B
- I
pyrenol I
, O
1OH B
- I
BaP I
and O
3OH B
- I
BaP I
) O
and O
alkylphenols B
( O
4 B
- I
n I
- I
nonylphenol I
( O
4 B
- I
n I
- I
NP I
) O
and O
4 B
- I
tertoctylphenol I
( O
4 B
- I
tert I
- I
OP I
) O
) O
in O
the O
same O
fish O
bile O
extracts O
were O
taken O
by O
gas O
chromatography O
- O
mass O
spectrometry O
in O
electron O

The O
highest O
biliary O
concentrations O
of O
1 B
- I
pyrenol I
, O
9 B
- I
fluorenol I
and O
4 B
- I
n I
- I
NP I
were O
found O
in O
fish O
from O
Barcelona O
and O
from O
the O
Mar O
Menor O
coastal O
lagoon O
. O

The O
contribution O
of O
1 B
- I
pyrenol I
, O
4 B
- I
n I
- I
NP I
and O
4 B
- I
tert I
- I
OP I
to O
the O
total O
estrogenic O
potency O
measured O
in O
male O
fish O
bile O
was O
found O
to O
be O
negligible O
, O
indicating O
the O
presence O
of O
other O
estrogenic O
compounds O
in O
red O
mullet O
bile O
. O

The O
contribution O
of O
1 B
- I
pyrenol I
, O
4 B
- I
n I
- I
NP I
and O
4 B
- I
tert I
- I
OP I
to O
the O
total O
estrogenic O
potency O
measured O
in O
male O
fish O
bile O
was O
found O
to O
be O
negligible O
, O
indicating O
the O
presence O
of O
other O
estrogenic O
compounds O
in O
red O
mullet O
bile O
. O

Two O
new O
tryptophan B
derivatives O
, O
N B
- I
sulfonyl I
- I
L I
- I
tryptophan I
( O
tryptorheedei B
A I
) O
( O
1 O
) O
and O
3 B
- I
( I
N I
- I
sulfonylindolyl I
) I
- I
D I
- I
lactic I
acid I
( O
tryptorheedei B
B I
) O
( O
2 O
) O
together O
with O
the O
known O
5 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
2 I
- I
hydroxyphenylacetic I
acid I
( O
3 O
) O
, O
1 B
- I
O I
- I
methylglucopyranosid I
, O
entadamide B
A I
, O
homogentisic B
acid I
and O
3 B
- I
O I

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
effects O
of O
2 B
, I
4 I
- I
D I
, O
an O
herbicide O
used O
worldwide O
also O
known O
as O
endocrine O
disruptor O
, O
in O
Sertoli O
cell O
( O
SC O
) O
metabolism O
. O

Immature O
rat O
SCs O
were O
maintained O
50h O
under O
basal O
conditions O
or O
exposed O
to O
2 B
, I
4 I
- I
D I
( O
100nM O
, O
10 O
mu O
M O
and O
1mM O
) O
. O

SCs O
exposed O
to O
10 O
mu O
M O
and O
1mM O
of O
2 B
, I
4 I
- I
D I
presented O
lower O
intracellular O
glucose B
and O
lactate B
content O
. O

Exposure O
to O
10 O
mu O
M O
of O
2 B
, I
4 I
- I
D I
induced O
a O
significant O
decrease O
in O
glucose B
transporter O
- O
3 O
mRNA O
levels O
and O
phosphofructokinase O
- O
1 O
mRNA O
levels O
decreased O
in O
cells O
exposed O
to O
100nM O
and O
10 O
mu O
M O
of O
2 B
, I
4 I
- I
D I
. O

Exposure O
to O
10 O
mu O
M O
of O
2 B
, I
4 I
- I
D I
induced O
a O
significant O
decrease O
in O
glucose B
transporter O
- O
3 O
mRNA O
levels O
and O
phosphofructokinase O
- O
1 O
mRNA O
levels O
decreased O
in O
cells O
exposed O
to O
100nM O
and O
10 O
mu O
M O
of O
2 B
, I
4 I
- I
D I
. O

Exposure O
to O
100nM O
and O
10 O
mu O
M O
also O
induced O
a O
decrease O
in O
lactate B
dehydrogenase O
( O
LDH O
) O
mRNA O
levels O
while O
the O
LDH O
protein O
levels O
were O
only O
decreased O
in O
cells O
exposed O
to O
1mM O
of O
2 B
, I
4 I
- I
D I
. O

Exposure O
to O
2 B
, I
4 I
- I
D I
altered O
glucose B
uptake O
and O
metabolization O
in O
SCs O
, O
as O
well O
as O
lactate B
metabolism O
and O
export O
that O
may O
result O
in O
impaired O
spermatogenesis O
. O

Carotenoid O
/ O
lipid O
hydro B
peroxide I
( O
LOOH O
) O
concentration O
was O
evaluated O
using O
two O
different O
methods O
: O
LOOH O
+ O
Fe B
( I
2 I
+ I
) I
reaction O
connected O
with O
a O
colored O
complex O
of O
ammonium B
thiocyanate I
determined O
with O
the O
help O
of O
a O
spectrophotometer O
, O
and O
LOOH O
determined O
with O
the O
help O
of O
a O
chemiluminometer O
. O

Selection O
against O
Ni B
( I
2 I
+ I
) I
- O
nitrilotriacetic B
acid I
( O
NTA B
) O
enriched O
for O
sequences O
containing O
histidine B
and O
BpyAla B
. O

Two O
peptides O
containing O
BpyAla B
were O
synthesized O
and O
found O
to O
bind O
Ni B
( I
2 I
+ I
) I
with O
low O
micromolar O
dissociation O
constants O
. O

Further O
examination O
showed O
that O
manganese B
but O
not O
zinc B
ethylene I
bis I
- I
dithiocarbamate I
is O
the O
active O
component O
for O
the O
positive O
modulation O
effects O
. O

However O
, O
the O
iron B
( O
Fe B
( I
3 I
+ I
) I
) O
alone O
, O
organic O
ligands O
alone O
or O
the O
mixture O
of O
iron B
with O
the O
organic O
ligand O
did O
not O
show O
any O
potentiation O
effect O
, O
suggesting O
as O
the O
active O
ingredient O
is O
a O
specific O
complex O
rather O
than O
two O
separate O
additive O
or O
synergistic O
components O
. O

Among O
the O
synthesized O
analogs O
, O
( B
Z I
) I
- I
Goniothalamin I
appeared O
to O
be O
the O
most O
active O
in O
cytotoxicity O
( O
IC50 O
= O
12 O
mu O
M O
) O
. O

Enzymatically O
catalyzed O
polycondensation O
of O
p B
- I
xylylenediamine I
and O
diethyl B
sebacate I
resulted O
in O
oligo B
( I
p I
- I
xylylene I
sebacamide I
) I
with O
high O
melting O
temperatures O
( O
223 O
- O
230 O
degrees O
C O
) O
and O
the O
enzymatic O
polycondensation O
of O
dimethyl B
terephthalate I
and O
1 B
, I
8 I
- I
diaminooctane I
leads O
to O
oligo B
( I
octamethylene I
terephthalamide I
) I
with O
two O
melting O
temperatures O
at O
186 O
and O
218 O
degrees O
C O
. O

Enzymatically O
catalyzed O
polycondensation O
of O
p B
- I
xylylenediamine I
and O
diethyl B
sebacate I
resulted O
in O
oligo B
( I
p I
- I
xylylene I
sebacamide I
) I
with O
high O
melting O
temperatures O
( O
223 O
- O
230 O
degrees O
C O
) O
and O
the O
enzymatic O
polycondensation O
of O
dimethyl B
terephthalate I
and O
1 B
, I
8 I
- I
diaminooctane I
leads O
to O
oligo B
( I
octamethylene I
terephthalamide I
) I
with O
two O
melting O
temperatures O
at O
186 O
and O
218 O
degrees O
C O
. O

For O
the O
first O
time O
, O
stable O
overcharge O
protection O
for O
hundreds O
of O
cycles O
was O
demonstrated O
in O
several O
cell O
chemistries O
, O
including O
LiNi1 B
/ O
3Co1 B
/ O
3Mn1 B
/ O
3O2 B
, O
LiFePO4 B
, O
and O
spinel O
Li1 B
. I
05Mn1 I
. I
95O4 I
half O
- O
cells O
. O

Abstract O
Objective O
: O
Lyophilized O
microparticles O
composed O
of O
budesonide B
( O
BDS B
) O
, O
hydroxypropyl B
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
, O
and O
hydroxypropylmethylc O
( O
HPMC O
) O
or O
sodium B
carboxymethylcellulo O
( O
CMC O
- O
Na B
) O
were O
developed O
for O
intranasal O
delivery O
and O
their O
characteristics O
were O
evaluated O
. O

Abstract O
Objective O
: O
Lyophilized O
microparticles O
composed O
of O
budesonide B
( O
BDS B
) O
, O
hydroxypropyl B
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
, O
and O
hydroxypropylmethylc O
( O
HPMC O
) O
or O
sodium B
carboxymethylcellulo O
( O
CMC O
- O
Na B
) O
were O
developed O
for O
intranasal O
delivery O
and O
their O
characteristics O
were O
evaluated O
. O

The O
coupling O
of O
O B
- I
pivaloyl I
benzhydroxamic I
acids I
with O
donor O
/ O
acceptor O
diazo B
compounds O
provides O
isoindolones B
in O
high O
yield O
. O

Novel O
quinolone B
substituted O
thiazolidin B
- I
4 I
- I
ones I
as O
anti O
- O
inflammatory O
, O
anticancer O
agents O
: O
Design O
, O
synthesis O
and O
biological O
screening O
. O

A O
library O
of O
quinolone B
substituted O
thiazolidin B
- I
4 I
- I
ones I
was O
docked O
into O
the O
active O
site O
of O
NF O
- O
kappa O
B O
and O
the O
top O
- O
ranked O
31 O
compounds O
were O
synthesized O
and O
evaluated O
for O
anti O
- O
inflammatory O
and O
anticancer O
activity O
. O

Ion O
Distributions O
at O
the O
Water O
/ O
1 B
, I
2 I
- I
Dichloroethane I
Interface O
: O
Potential O
of O
Mean O
Force O
Approach O
to O
Analyzing O
X O
- O
ray O
Reflectivity O
and O
Interfacial O
Tension O
Measurements O
. O

The O
aqueous O
phase O
contains O
alkali B
- I
metal I
chlorides I
, O
including O
LiCl B
, O
NaCl B
, O
RbCl B
, O
or O
CsCl B
, O
and O
the O
organic O
phase O
is O
a O
1 B
, I
2 I
- I
dichloroethane I
solution O
of O
bis B
( I
triphenylphosphor I
anylidene I
) I
ammonium I
tetrakis I
( I
pentafluorophenyl I
) I
borate I
( O
BTPPATPFB B
) O
. O

The O
widely O
used O
hypnosedative O
- O
anxiolytic O
agent O
R B
, I
S I
- I
lorazepam I
is O
cleared O
predominantly O
by O
conjugation O
with O
glucuronic B
acid I
in O
humans O
, O
but O
the O
enantioselective O
glucuronidation O
of O
lorazepam B
has O
received O
little O
attention O
. O

Poly B
( I
vinyl I
alcohol I
) I
Physical O
Hydrogel O
Nanoparticles O
, O
Not O
Polymer O
Solutions O
, O
Exert O
Inhibition O
of O
Nitric B
Oxide I
Synthesis O
in O
Cultured O
Macrophages O
. O

In O
this O
work O
, O
we O
investigate O
assembly O
of O
HNP O
based O
on O
a O
polymer O
with O
decades O
of O
prominence O
in O
the O
biomedical O
field O
, O
poly B
( I
vinyl I
alcohol I
) I
, O
PVA B
. O

Au B
NPs O
were O
prepared O
by O
reduction O
of O
Au B
( I
3 I
+ I
) I
compound O
onto O
HCl B
- O
refreshed O
Ti B
in O
the O
presence O
of O
thiol B
- O
functionalized O
small O
peptides O
. O

This O
study O
investigated O
the O
effect O
of O
in O
vitro O
gastrointestinal O
digestion O
on O
the O
stability O
and O
composition O
of O
flavan B
- I
3 I
- I
ols I
from O
red O
grape O
skin O
and O
seed O
extracts O
( O
raw O
and O
purified O
, O
which O
are O
high O
in O
proanthocyanidins B
( O
PAs B
) O
) O
. O

Batsch O
, O
pulp O
extract O
on O
Ang B
II I
- O
induced O
intracellular O
Ca B
( I
2 I
+ I
) I
mobilization O
, O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
and O
signal O
transduction O
events O
in O
cultured O
vascular O
smooth O
muscle O
cells O
( O
VSMCs O
) O
was O
investigated O
. O

Pretreatment O
of O
peach O
ethyl B
acetate I
extract O
inhibited O
Ang B
II I
- O
induced O
intracellular O
Ca B
( I
2 I
+ I
) I
elevation O
in O
VSMCs O
. O

These O
results O
suggest O
that O
peach O
ethyl B
acetate I
extract O
may O
have O
clinical O
potential O
for O
preventing O
cardiovascular O
diseases O
by O
interfering O
with O
Ang B
II I
- O
induced O
intracellular O
Ca B
( I
2 I
+ I
) I
elevation O
, O
the O
generation O
of O
ROS O
, O
and O
then O
blocking O
signal O
transduction O
events O
. O

Also O
, O
the O
relative O
increase O
in O
omega B
- I
3 I
fatty I
acids I
and O
alpha B
- I
tocopherol I
, O
from O
winter O
to O
summer O
, O
was O
greater O
in O
JG O
milk O
. O

The O
oxidation O
of O
chlorophyll B
a I
( O
chl B
a I
) O
catalysed O
by O
peroxidase O
( O
POD O
) O
from O
mesocarp O
of O
the O
olive O
fruit O
( O
Olea O
europaea O
L O
. O
, O
cv O
Hojiblanca O
) O
in O
the O
presence O
of O
H2O2 B
and O
2 B
, I
4 I
- I
dichlorophenol I
( O
2 B
, I
4 I
- I
DCP I
) O
, O
is O
characterised O
via O
the O
individualised O
quantification O
of O
the O
products O
of O
the O
enzymatic O
reaction O
using O
a O
new O
methodology O
of O
HPLC O
- O
UV O
spectrometry O
. O

The O
oxidation O
of O
chlorophyll B
a I
( O
chl B
a I
) O
catalysed O
by O
peroxidase O
( O
POD O
) O
from O
mesocarp O
of O
the O
olive O
fruit O
( O
Olea O
europaea O
L O
. O
, O
cv O
Hojiblanca O
) O
in O
the O
presence O
of O
H2O2 B
and O
2 B
, I
4 I
- I
dichlorophenol I
( O
2 B
, I
4 I
- I
DCP I
) O
, O
is O
characterised O
via O
the O
individualised O
quantification O
of O
the O
products O
of O
the O
enzymatic O
reaction O
using O
a O
new O
methodology O
of O
HPLC O
- O
UV O
spectrometry O
. O

Their O
origins O
have O
been O
linked O
to O
POD O
activity O
in O
the O
presence O
of O
2 B
, I
4 I
- I
DCP I
. O

Likewise O
, O
a O
study O
of O
the O
effect O
of O
the O
concentration O
of O
the O
various O
cosubstrates O
on O
the O
POD O
reaction O
rate O
demonstrated O
that O
the O
correct O
establishment O
of O
the O
relative O
concentrations O
of O
the O
same O
( O
[ O
H2O2 B
] O
/ O
[ O
2 B
, I
4 I
- I
DCP I
] O
/ O
[ O
Chl B
] O
= O
1 O
: O
3 O
: O
0 O
. O
02 O
) O
is O
crucial O
to O
explaining O
inhibition O
effects O
by O
substrates O
and O
carrying O
out O
optimum O
measurements O
. O

A O
potent O
11 O
- O
mer O
peptide O
TSG B
- I
8 I
- I
1 I
, O
WWSYVRRWRSR O
- O
amide B
, O
was O
developed O
, O
which O
exhibited O
antimicrobial O
activity O
against O
E O
. O
coli O
and O
S O
. O
aureus O
while O
very O
little O
hemolytic O
activity O
in O
human O
erythrocytes O
was O
observed O
at O
high O
dose O
level O
. O

Bioinspired O
design O
and O
macroscopic O
assembly O
of O
poly B
( I
vinyl I
alcohol I
) I
- O
coated O
graphene B
into O
kilometers O
- O
long O
fibers O
. O

Here O
, O
we O
prepared O
sandwich O
- O
like O
building O
blocks O
of O
poly B
( I
vinyl I
alcohol I
) I
( O
PVA B
) O
- O
coated O
graphene B
, O
and O
achieved O
high O
- O
nanofiller O
- O
content O
kilometers O
- O
long O
fibers O
by O
continuous O
wet O
- O
spinning O
assembly O
technology O
. O

Ultrasonic O
synthesis O
, O
characterization O
of O
beta B
- I
aminoketones I
by O
bismuth B
( I
III I
) I
triflate I
and O
determination O
of O
antigenotoxic O
properties O
. O

Hydrogen B
peroxide I
( O
H2O2 B
) O
production O
, O
lipid O
peroxidation O
( O
LPO O
) O
, O
protein O
carbonyl B
content O
and O
activities O
of O
uridine B
5 I
' I
- I
diphospho I
- O
glucuronyltransferas O
( O
UDPGT O
) O
and O
P450 O
were O
significantly O
increased O
. O

A O
preactivation O
step O
followed O
, O
mediated O
by O
6 B
, I
6 I
' I
dithionicotinamide I
, O
thiol B
groups O
were O
modified O
by O
disulfide B
bonds O
formation O
. O

Finally O
, O
amphiphilic O
random O
polypeptides O
containing O
10 O
% O
and O
20 O
% O
alpha B
- I
d I
- I
mannose I
in O
addition O
to O
glucose B
containing O
a O
hydrophobic O
alkyl B
chain O
at O
its O
6 O
position O
were O
synthesized O
by O
our O
methodology O
, O
and O
these O
polymers O
were O
also O
found O
to O
assemble O
into O
spherical O
nanostructures O
. O

6 B
- I
DHSG I
was O
metabolised O
by O
GSH B
to O
form O
a O
GSH B
conjugate O
( O
GS B
- I
6 I
- I
DHSG I
) O
in O
RAW O
264 O
. O
7 O
cells O
, O
via O
a O
potential O
mechanism O
involving O
the O
catalytic O
activity O
of O
glutathione B
- O
S B
- O
transferase O
( O
GST O
) O
. O

GS B
- I
6 I
- I
DHSG I
showed O
reduced O
biological O
activities O
compared O
with O
6 B
- I
DHSG I
in O
multiple O
biological O
assays O
. O

Impact O
of O
( B
+ I
) I
- I
catechin I
and O
gallic B
acid I
on O
sensory O
perception O
and O
volatility O
of O
isoamyl B
acetate I
, O
ethyl B
isobutyrate I
, O
ethyl B
butyrate I
and O
ethyl B
octanoate I
was O
investigated O
in O
model O
solutions O
, O
by O
means O
of O
triangle O
tests O
, O
detection O
threshold O
determination O
and O
HS O
- O
GC O
- O
MS O
analyses O
. O

The O
development O
of O
t B
- I
2 I
- I
heptenal I
and O
1 B
- I
octen I
- I
3 I
- I
ol I
increased O
greatly O
in O
chlorophyll B
sensitised O
O O
/ O
W O
emulsions O
with O
an O
increase O
in O
beta B
- I
carotene I
concentration O
, O
implying O
that O
more O
singlet O
oxygen B
oxidation O
occurred O
due O
to O
the O
higher O
levels O
of O
remaining O
chlorophylls B
. O

However O
, O
the O
content O
of O
t B
- I
2 I
- I
heptenal I
and O
1 B
- I
octen I
- I
3 I
- I
ol I
in O
the O
riboflavin B
sensitised O
O O
/ O
W O
emulsions O
was O
not O
significantly O
correlated O
with O
the O
beta B
- I
carotene I
concentration O
, O
which O
indicates O
that O
beta B
- I
carotene I
in O
the O
lipid O
particles O
effectively O
quenched O
singlet O
oxygen B
. O

These O
analogs O
followed O
SAR O
trends O
similar O
to O
those O
previously O
reported O
for O
3 B
- I
cycloalkyl I
substituted I
indoles I
. O

Exposures O
of O
75 O
and O
150 O
mu O
M O
Cu B
( I
2 I
+ I
) I
caused O
toxicity O
symptoms O
( O
chlorosis O
, O
necrosis O
and O
rolling O
in O
leaves O
) O
, O
sharp O
increases O
in O
malondialdehyde B
( O
MDA B
) O
, O
hydrogen B
peroxide I
( O
H2O2 B
) O
contents O
and O
lipoxygenase O
( O
LOX O
) O
activity O
with O
concomitant O
reductions O
of O
chlorophyll O
( O
Chl O
) O
and O
relative O
water O
content O
( O
RWC O
) O
. O

Studies O
on O
antioxidant O
enzymes O
showed O
that O
SA O
further O
enhanced O
the O
activities O
of O
superoxide B
dismutase O
, O
ascorbate B
peroxidase O
, O
glutathione B
reductase O
and O
glutathione B
peroxidase O
, O
and O
also O
elevated O
the O
depressed O
activities O
of O
catalase O
, O
dehydroascorbate B
reductase O
and O
glutathione B
S B
- O
transferase O
particularly O
at O
150 O
mu O
M O
Cu B
( I
2 I
+ I
) I
stress O
. O

Six O
compounds O
were O
isolated O
and O
identified O
from O
this O
plant O
: O
three O
phenolic B
compounds O
( O
kampferol B
, O
kampferol B
- I
3 I
- I
glucoside I
and O
kampferol B
- I
3 I
- I
galactoside I
) O
in O
addition O
to O
three O
steroidal O
compounds O
( O
1 B
- I
ethoxypentacosane I
, O
heptacosan B
- I
1 I
- I
ol I
and O
beta B
- I
sitosterol I
) O
. O

Six O
compounds O
were O
isolated O
and O
identified O
from O
this O
plant O
: O
three O
phenolic B
compounds O
( O
kampferol B
, O
kampferol B
- I
3 I
- I
glucoside I
and O
kampferol B
- I
3 I
- I
galactoside I
) O
in O
addition O
to O
three O
steroidal O
compounds O
( O
1 B
- I
ethoxypentacosane I
, O
heptacosan B
- I
1 I
- I
ol I
and O
beta B
- I
sitosterol I
) O
. O

Six O
compounds O
were O
isolated O
and O
identified O
from O
this O
plant O
: O
three O
phenolic B
compounds O
( O
kampferol B
, O
kampferol B
- I
3 I
- I
glucoside I
and O
kampferol B
- I
3 I
- I
galactoside I
) O
in O
addition O
to O
three O
steroidal O
compounds O
( O
1 B
- I
ethoxypentacosane I
, O
heptacosan B
- I
1 I
- I
ol I
and O
beta B
- I
sitosterol I
) O
. O

Three O
compounds O
( O
heptacosan B
- I
1 I
- I
ol I
, O
beta B
- I
sitosterol I
and O
kampferol B
- I
3 I
- I
galactoside I
) O
were O
found O
to O
be O
responsible O
for O
the O
anti O
- O
UC O
activity O
of O
E O
. O
granuleta O
extract O
. O

Three O
compounds O
( O
heptacosan B
- I
1 I
- I
ol I
, O
beta B
- I
sitosterol I
and O
kampferol B
- I
3 I
- I
galactoside I
) O
were O
found O
to O
be O
responsible O
for O
the O
anti O
- O
UC O
activity O
of O
E O
. O
granuleta O
extract O
. O

Solvent O
effect O
studies O
revealed O
that O
in O
good O
solvents O
such O
as O
n B
- I
hexane I
, O
benzene B
, O
and O
1 B
, I
4 I
- I
dioxane I
, O
the O
profile O
of O
the O
fluorescence O
emission O
of O
the O
compound O
is O
characterized O
by O
pyrene B
monomer O
emission O
, O
but O
in O
poor O
solvent O
such O
as O
water O
, O
the O
emission O
is O
dominated O
by O
pyrene O
excimer O
emission O
. O

Spin O
- O
cast O
films O
of O
dyes O
( O
donor O
- O
pi O
- O
donor O
, O
donor O
- O
pi O
- O
acceptor O
, O
and O
acceptor O
- O
pi O
- O
acceptor O
type O
, O
where O
the O
donor O
is O
Ph2N B
- O
, O
the O
acceptor O
is O
2 B
- I
benzothiazoyl I
, O
and O
the O
pi O
- O
linker O
is O
9 B
, I
9 I
- I
diethylfluorene I
) O
blended O
with O
nonconjugated O
bisphthalimides B
were O
prepared O
. O

Synthesis O
and O
antitumor O
activity O
of O
1 B
, I
3 I
, I
4 I
- I
oxadiazole I
possessing O
1 B
, I
4 I
- I
benzodioxan I
moiety O
as O
a O
novel O
class O
of O
potent O
methionine B
aminopeptidase O
type O
II O
inhibitors O
. O

A O
series O
of O
1 B
, I
3 I
, I
4 I
- I
oxadiazole I
derivatives O
containing O
1 B
, I
4 I
- I
benzodioxan I
moiety O
( O
7a O
- O
7q O
) O
have O
been O
designed O
, O
synthesized O
and O
evaluated O
for O
their O
antitumor O
activity O
. O

Furthermore O
, O
we O
showed O
that O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
( O
NQO1 O
) O
may O
participate O
in O
this O
stimulation O
. O

One O
mechanism O
by O
which O
chronic O
MeHg B
may O
exert O
its O
neurotoxicity O
is O
via O
sustained O
disruption O
of O
intracellular O
calcium B
homeostasis O
, O
with O
a O
consequent O
increase O
of O
intracellular O
Ca B
( I
2 I
+ I
) I
ions O
in O
vulnerable O
neurons O
. O

To O
evaluate O
the O
role O
of O
calcium B
antagonism O
in O
MeHg B
toxicity O
in O
vivo O
, O
adult O
BALB O
/ O
c O
mice O
were O
exposed O
chronically O
to O
0 O
or O
15ppm O
of O
Hg B
( O
as O
MeHg B
) O
via O
drinking O
water O
and O
to O
nimodipine B
, O
a O
dihydropryidine B
, O
L O
- O
type O
Ca B
( I
2 I
+ I
) I
channel O
blocker O
with O
action O
in O
the O
CNS O
. O

Copper B
( I
II I
) I
complexes O
[ B
Cu I
( I
Fc I
- I
aa I
) I
( I
cur I
) I
] I
( O
1 O
- O
3 O
) O
of O
curcumin B
( O
Hcur B
) O
and O
N B
- I
ferrocenylmethyl I
- I
l I
- I
amino I
acids I
( O
Fc B
- I
aa I
) O
, O
viz O
. O
, O
ferrocenylmethyl B
- I
l I
- I
tyrosine I
( O
Fc B
- I
TyrH I
) O
, O
ferrocenylmethyl B
- I
l I
- I
tryptophan I
( O
Fc B
- I
TrpH I
) O
and O
ferrocenylmethyl B
- I
l I
- I
methionine I

Copper B
( I
II I
) I
complexes O
[ B
Cu I
( I
Fc I
- I
aa I
) I
( I
cur I
) I
] I
( O
1 O
- O
3 O
) O
of O
curcumin B
( O
Hcur B
) O
and O
N B
- I
ferrocenylmethyl I
- I
l I
- I
amino I
acids I
( O
Fc B
- I
aa I
) O
, O
viz O
. O
, O
ferrocenylmethyl B
- I
l I
- I
tyrosine I
( O
Fc B
- I
TyrH I
) O
, O
ferrocenylmethyl B
- I
l I
- I
tryptophan I
( O
Fc B
- I
TrpH I
) O
and O
ferrocenylmethyl B
- I
l I
- I
methionine I

In O
this O
paper O
, O
ultrastable O
aqueous O
foam O
stabilized O
by O
a O
kind O
of O
flexible O
connecting O
bipolar O
- O
headed O
surfactant O
alkyl B
polyoxyethylene I
sulfate I
( O
AE3S B
) O
with O
coexisting O
Mg B
( I
2 I
+ I
) I
was O
reported O
. O

Detailed O
molecular O
behaviors O
of O
AE3S B
in O
foam O
film O
with O
coexisting O
divalent O
cationic O
Ca B
( I
2 I
+ I
) I
or O
Mg B
( I
2 I
+ I
) I
were O
investigated O
by O
molecular O
dynamic O
simulation O
, O
comparing O
with O
the O
traditional O
surfactant O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
, O
to O
find O
out O
how O
the O
microcharacter O
and O
array O
behavior O
of O
molecules O
in O
the O
foam O
film O
determined O
by O
molecular O
interaction O
effect O
the O
foam O
stability O
. O

Detailed O
molecular O
behaviors O
of O
AE3S B
in O
foam O
film O
with O
coexisting O
divalent O
cationic O
Ca B
( I
2 I
+ I
) I
or O
Mg B
( I
2 I
+ I
) I
were O
investigated O
by O
molecular O
dynamic O
simulation O
, O
comparing O
with O
the O
traditional O
surfactant O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
, O
to O
find O
out O
how O
the O
microcharacter O
and O
array O
behavior O
of O
molecules O
in O
the O
foam O
film O
determined O
by O
molecular O
interaction O
effect O
the O
foam O
stability O
. O

Duroquinone B
( O
derivative O
of O
1 B
, I
4 I
- I
benzoquinone I
) O
is O
a O
xenobiotic O
compound O
widespread O
in O
the O
environment O
. O

The O
fraction O
of O
proximal O
renal O
cells O
with O
elevated O
8 B
- I
oxodeoxyguanosine I
( O
8 B
- I
OH I
- I
dG I
) O
was O
only O
increased O
at O
the O
high O
dose O
and O
did O
not O
differ O
by O
sex O
. O

Based O
on O
highly O
selective O
and O
irreversible O
Hg B
( I
2 I
+ I
) I
- O
promoted O
desulfurization O
reaction O
, O
a O
new O
and O
simple O
phenanthroimidazole B
- O
type O
sensor O
was O
prepared O
and O
exhibited O
high O
selectivity O
towards O
Hg B
( I
2 I
+ I
) I
ion O
over O
other O
metal O
ions O
, O
accompanied O
by O
transformation O
of O
a O
weakly O
fluorescent O
thioamide B
moiety O
( O
colorless O
) O
to O
a O
highly O
fluorescent O
amide B
one O
( O
blue O
) O
, O
with O
a O
136 O
- O
fold O
increase O
in O
fluorescent O
intensity O
in O
aqueous O
solution O
with O
a O
pH O
span O
2 O
. O
57 O
- O
9 O
. O
12 O
. O

Based O
on O
highly O
selective O
and O
irreversible O
Hg B
( I
2 I
+ I
) I
- O
promoted O
desulfurization O
reaction O
, O
a O
new O
and O
simple O
phenanthroimidazole B
- O
type O
sensor O
was O
prepared O
and O
exhibited O
high O
selectivity O
towards O
Hg B
( I
2 I
+ I
) I
ion O
over O
other O
metal O
ions O
, O
accompanied O
by O
transformation O
of O
a O
weakly O
fluorescent O
thioamide B
moiety O
( O
colorless O
) O
to O
a O
highly O
fluorescent O
amide B
one O
( O
blue O
) O
, O
with O
a O
136 O
- O
fold O
increase O
in O
fluorescent O
intensity O
in O
aqueous O
solution O
with O
a O
pH O
span O
2 O
. O
57 O
- O
9 O
. O
12 O
. O

Melatonin B
and O
its O
analogue O
5 B
- I
MCA I
- I
NAT I
potentiate O
adrenergic O
receptor O
- O
mediated O
ocular O
hypotensive O
effects O
in O
rabbits O
: O
Significance O
for O
combination O
therapy O
in O
glaucoma O
. O

We O
have O
investigated O
the O
effect O
of O
melatonin B
and O
its O
analogue O
5 B
- I
methoxycarbonylamino I
- I
N I
- I
acetyltryptamine I
, O
5 B
- I
MCA I
- I
NAT I
, O
on O
beta O
2 O
/ O
alpha O
2A O
- O
adrenergic O
receptor O
mRNA O
as O
well O
as O
protein O
expression O
in O
cultured O
rabbit O
non O
- O
pigmented O
ciliary O
epithelial O
cells O
. O

IOP O
experiments O
showed O
that O
the O
administration O
of O
timolol B
in O
rabbits O
pre O
- O
treated O
with O
melatonin B
or O
5 B
- I
MCA I
- I
NAT I
evoked O
an O
additional O
IOP O
reduction O
of O
14 O
. O
02 O
+ O
/ O
- O
5 O
. O
8 O
% O
or O
16 O
. O
75 O
+ O
/ O
- O
5 O
. O
48 O
% O
( O
p O
< O
0 O
. O
01 O
) O
in O
comparison O
with O
rabbits O
treated O
with O
timolol B
alone O
for O
24 O
hours O
. O

Concerning O
brimonidine B
hypotensive O
action O
, O
an O
additional O
IOP O
reduction O
of O
29 O
. O
26 O
+ O
/ O
- O
5 O
. O
21 O
% O
or O
39 O
. O
07 O
+ O
/ O
- O
5 O
. O
81 O
% O
( O
p O
< O
0 O
. O
001 O
) O
was O
observed O
in O
rabbits O
pretreated O
with O
melatonin B
or O
5 B
- I
MCA I
- I
NAT I
when O
compared O
with O
animals O
treated O
with O
brimonidine B
alone O
for O
24 O
hours O
. O

Additionally O
, O
a O
sustained O
potentiating O
effect O
of O
a O
single O
dose O
of O
5 B
- I
MCA I
- I
NAT I
was O
seen O
in O
rabbits O
treated O
with O
brimonidine B
once O
daily O
for O
up O
four O
days O
( O
extra O
IOP O
decrease O
of O
15 O
. O
57 O
+ O
/ O
- O
5 O
. O
15 O
% O
, O
p O
< O
0 O
. O
05 O
, O
compared O
to O
brimonidine B
alone O
) O
. O

Similarly O
, O
the O
specific O
pharmacological O
FAK O
inhibitor O
PF B
- I
573 I
, I
228 I
as O
well O
as O
specific O
inhibitors O
of O
p38 O
MAPK O
and O
Src O
also O
fully O
inhibited O
collagen O
I O
- O
induced O
proliferation O
, O
whereas O
partial O
inhibition O
was O
observed O
by O
inhibition O
of O
PI3 O
- O
kinase O
and O
MEK O
. O

Genistein O
- O
Modified O
Poly B
( I
ethylene I
oxide I
) I
/ O
Poly B
( I
d I
, I
l I
- I
lactic I
acid I
) I
Electrospun O
Mats O
with O
Improved O
Antioxidant O
and O
Anti O
- O
inflammatory O
Properties O
. O

Based O
on O
the O
guidance O
afforded O
by O
the O
ternary O
phase O
diagram O
of O
poly B
( I
d I
, I
l I
- I
lactic I
acid I
) I
( O
PDLLA B
) O
, O
poly B
( I
ethylene I
oxide I
) I
( O
PEO B
) O
, O
and O
genistein B
blends O
, O
certain O
selective O
compositions O
were O
electrospun O
. O

In O
this O
review O
, O
an O
overview O
of O
proposed O
reaction O
mechanisms O
for O
the O
MTO O
process O
is O
given O
, O
focusing O
on O
the O
archetypal O
MTO O
catalysts O
, O
H B
- I
ZSM I
- I
5 I
and O
H B
- I
SAPO I
- I
34 I
. O

In O
this O
review O
, O
an O
overview O
of O
proposed O
reaction O
mechanisms O
for O
the O
MTO O
process O
is O
given O
, O
focusing O
on O
the O
archetypal O
MTO O
catalysts O
, O
H B
- I
ZSM I
- I
5 I
and O
H B
- I
SAPO I
- I
34 I
. O

The O
novel O
recreational O
drug O
3 B
, I
4 I
- I
methylenedioxypyrova I
( O
MDPV B
) O
is O
a O
potent O
psychomotor O
stimulant O
: O
Self O
- O
administration O
and O
locomotor O
activity O
in O
rats O
. O

Recreational O
use O
of O
the O
cathinone O
derivative O
3 B
, I
4 I
- I
methylenedioxypyrova I
( O
MDPV B
; O
" O
bath O
salts O
" O
) O
has O
increased O
worldwide O
in O
past O
years O
, O
accompanied O
by O
accounts O
of O
health O
and O
legal O
problems O
in O
the O
popular O
media O
and O
efforts O
to O
criminalize O
possession O
in O
numerous O
jurisdictions O
. O

The O
reaction O
kinetics O
between O
CO2 B
and O
trihexyl B
( I
tetradecyl I
) I
phosphonium I
( O
[ B
P66614 I
] I
) O
- O
based O
ionic O
liquids O
( O
ILs O
) O
with O
prolinate B
( O
[ B
Pro I
] I
) O
, O
2 B
- I
cyanopyrrolide I
( O
[ B
2 I
- I
CNpyr I
] I
) O
, O
and O
3 B
- I
( I
trifluoromethyl I
) I
pyrazolide I
( O
[ B
3 I
- I
CF3pyra I
] I
) O
anions O
are O
studied O
at O
temperatures O
from O
22 O
- O
60 O
degrees O
C O
. O

The O
reaction O
kinetics O
between O
CO2 B
and O
trihexyl B
( I
tetradecyl I
) I
phosphonium I
( O
[ B
P66614 I
] I
) O
- O
based O
ionic O
liquids O
( O
ILs O
) O
with O
prolinate B
( O
[ B
Pro I
] I
) O
, O
2 B
- I
cyanopyrrolide I
( O
[ B
2 I
- I
CNpyr I
] I
) O
, O
and O
3 B
- I
( I
trifluoromethyl I
) I
pyrazolide I
( O
[ B
3 I
- I
CF3pyra I
] I
) O
anions O
are O
studied O
at O
temperatures O
from O
22 O
- O
60 O
degrees O
C O
. O

The O
reaction O
kinetics O
between O
CO2 B
and O
trihexyl B
( I
tetradecyl I
) I
phosphonium I
( O
[ B
P66614 I
] I
) O
- O
based O
ionic O
liquids O
( O
ILs O
) O
with O
prolinate B
( O
[ B
Pro I
] I
) O
, O
2 B
- I
cyanopyrrolide I
( O
[ B
2 I
- I
CNpyr I
] I
) O
, O
and O
3 B
- I
( I
trifluoromethyl I
) I
pyrazolide I
( O
[ B
3 I
- I
CF3pyra I
] I
) O
anions O
are O
studied O
at O
temperatures O
from O
22 O
- O
60 O
degrees O
C O
. O

Concentrations O
of O
trans B
elaidic I
acid I
( O
t9 B
- I
C18 I
: I
1 I
) O
from O
hydrogenated O
oils O
in O
all O
samples O
were O
< O
0 O
. O
2g O
/ O
100g O
food O
. O

Inhibitory O
action O
of O
salicylideneamino B
- I
2 I
- I
thiophenol I
on O
NF O
- O
kappa O
B O
signaling O
cascade O
and O
cyclooxygenase O
- O
2 O
in O
HNE B
- O
treated O
endothelial O
cells O
. O

In O
the O
present O
study O
, O
the O
anti O
- O
inflammatory O
effect O
of O
salicylideneamino B
- I
2 I
- I
thiophenol I
( O
SAL B
- I
2 I
) O
, O
a O
derivative O
of O
salicylate B
, O
on O
a O
potent O
oxidant O
4 B
- I
hydroxynonenal I
( O
HNE B
) O
- O
induced O
oxidative O
stress O
was O
investigated O
using O
rat O
prostate O
endothelial O
( O
YPEN O
- O
1 O
) O
cells O
. O

In O
order O
to O
identify O
the O
candidate O
target O
proteins O
covalently O
modified O
by O
15d B
- I
PGJ2 I
in O
human O
aortic O
endothelial O
cell O
( O
EC O
) O
, O
EC O
were O
treated O
with O
biotinylated B
- I
15d I
- I
PGJ2 I
, O
the O
modified O
proteins O
extracted O
by O
Neutravidin O
affinity O
- O
purification O
and O
the O
proteins O
identified O
by O
LTQ O
Orbitrap O
mass O
spectrometer O
. O

MATERIALS O
AND O
METHODS O
: O
Acetone B
extract O
and O
its O
sub O
- O
fractions O
of O
Acacia O
ferruginea O
stem O
bark O
were O
subjected O
to O
assess O
their O
antioxidant O
potential O
using O
various O
in O
vitro O
systems O
such O
as O
DPPH B
( I
* I
) I
, O
ABTS B
( I
* I
+ I
) I
scavenging O
, O
FRAP O
and O
phosphomolybdenum B
reduction O
activities O
. O

The O
phytochemical O
investigations O
showed O
the O
presence O
of O
cyclopeptid B
alkaloids I
, O
flavonoids B
( O
e O
. O
g O
. O
, O
( B
- I
) I
- I
epicatechin I
, O
quercetin B
, O
kaempferol B
, O
kaempferol B
- I
3 I
- I
O I
- I
beta I
- I
d I
- I
( I
6 I
' I
' I
- I
E I
- I
p I
- I
coumaryl I
) I
- I
glucopyranoside I
) I
, O
tannins B
, O
sterols B
, O
terpenes B
, O
saponins B
, O
anthraquinones B
. O

A O
well O
- O
defined O
amphiphilic O
polypeptide O
, O
poly B
( I
glutamic I
acid I
) I
22 I
- I
block I
- I
poly I
( I
alanine I
) I
8 I
( O
PGlu22 B
- I
b I
- I
PAla8 I
) O
, O
which O
plays O
the O
roles O
of O
both O
soluble O
( O
functional O
) O
additive O
and O
insoluble O
( O
structural O
) O
matrix O
, O
is O
employed O
to O
mediate O
the O
mineralization O
of O
CaCO3 B
at O
the O
air O
/ O
water O
interface O
. O

The O
observations O
from O
SEM O
and O
TEM O
suggest O
that O
PGlu22 B
- I
b I
- I
PAla8 I
initiates O
the O
amorphous O
precursor O
phase O
and O
heterogeneous O
nucleation O
of O
CaCO3 B
at O
the O
air O
/ O
water O
interface O
, O
while O
temporarily O
stabilizes O
the O
gelatinous O
precursors O
as O
a O
process O
- O
directing O
agent O
; O
nevertheless O
, O
the O
initial O
concentration O
of O
Ca B
( I
2 I
+ I
) I
controls O
the O
procedure O
of O
crystallization O
and O
the O
final O
morphology O
of O
CaCO3 B
particles O
. O

The O
observations O
from O
SEM O
and O
TEM O
suggest O
that O
PGlu22 B
- I
b I
- I
PAla8 I
initiates O
the O
amorphous O
precursor O
phase O
and O
heterogeneous O
nucleation O
of O
CaCO3 B
at O
the O
air O
/ O
water O
interface O
, O
while O
temporarily O
stabilizes O
the O
gelatinous O
precursors O
as O
a O
process O
- O
directing O
agent O
; O
nevertheless O
, O
the O
initial O
concentration O
of O
Ca B
( I
2 I
+ I
) I
controls O
the O
procedure O
of O
crystallization O
and O
the O
final O
morphology O
of O
CaCO3 B
particles O
. O

A O
solid O
phase O
extraction O
method O
for O
enrichment O
- O
separation O
and O
the O
determination O
of O
cobalt B
( O
Co B
( I
2 I
+ I
) I
) O
, O
copper B
( O
Cu B
( I
2 I
+ I
) I
) O
, O
nickel B
( O
Ni B
( I
2 I
+ I
) I
) O
, O
zinc B
( O
Zn B
( I
2 I
+ I
) I
) O
and O
lead O
( O
Pb B
( I
2 I
+ I
) I
) O
ions O
in O
real O
samples O
has O
been O
proposed O
. O

A O
solid O
phase O
extraction O
method O
for O
enrichment O
- O
separation O
and O
the O
determination O
of O
cobalt B
( O
Co B
( I
2 I
+ I
) I
) O
, O
copper B
( O
Cu B
( I
2 I
+ I
) I
) O
, O
nickel B
( O
Ni B
( I
2 I
+ I
) I
) O
, O
zinc B
( O
Zn B
( I
2 I
+ I
) I
) O
and O
lead O
( O
Pb B
( I
2 I
+ I
) I
) O
ions O
in O
real O
samples O
has O
been O
proposed O
. O

A O
solid O
phase O
extraction O
method O
for O
enrichment O
- O
separation O
and O
the O
determination O
of O
cobalt B
( O
Co B
( I
2 I
+ I
) I
) O
, O
copper B
( O
Cu B
( I
2 I
+ I
) I
) O
, O
nickel B
( O
Ni B
( I
2 I
+ I
) I
) O
, O
zinc B
( O
Zn B
( I
2 I
+ I
) I
) O
and O
lead O
( O
Pb B
( I
2 I
+ I
) I
) O
ions O
in O
real O
samples O
has O
been O
proposed O
. O

A O
solid O
phase O
extraction O
method O
for O
enrichment O
- O
separation O
and O
the O
determination O
of O
cobalt B
( O
Co B
( I
2 I
+ I
) I
) O
, O
copper B
( O
Cu B
( I
2 I
+ I
) I
) O
, O
nickel B
( O
Ni B
( I
2 I
+ I
) I
) O
, O
zinc B
( O
Zn B
( I
2 I
+ I
) I
) O
and O
lead O
( O
Pb B
( I
2 I
+ I
) I
) O
ions O
in O
real O
samples O
has O
been O
proposed O
. O

A O
solid O
phase O
extraction O
method O
for O
enrichment O
- O
separation O
and O
the O
determination O
of O
cobalt B
( O
Co B
( I
2 I
+ I
) I
) O
, O
copper B
( O
Cu B
( I
2 I
+ I
) I
) O
, O
nickel B
( O
Ni B
( I
2 I
+ I
) I
) O
, O
zinc B
( O
Zn B
( I
2 I
+ I
) I
) O
and O
lead O
( O
Pb B
( I
2 I
+ I
) I
) O
ions O
in O
real O
samples O
has O
been O
proposed O
. O

Metabolomics O
of O
brain O
homogenate O
and O
cerebrospinal O
fluid O
revealed O
a O
significant O
up O
- O
regulation O
of O
L B
- I
carnitine I
, O
acetyl B
- I
L I
- I
carnitine I
, O
pantothenic B
acid I
, O
2 B
' I
- I
deoxycytidine I
diphosphate I
( O
dCDP B
) O
, O
anandamide B
, O
N B
- I
acetylglucosaminylam I
and O
a O
down O
- O
regulation O
of O
stearoyl B
- I
L I
- I
carnitine I
in O
Tg O
- O
2D6 O
mice O
compared O
with O
WT O
mice O
. O

Metabolomics O
of O
brain O
homogenate O
and O
cerebrospinal O
fluid O
revealed O
a O
significant O
up O
- O
regulation O
of O
L B
- I
carnitine I
, O
acetyl B
- I
L I
- I
carnitine I
, O
pantothenic B
acid I
, O
2 B
' I
- I
deoxycytidine I
diphosphate I
( O
dCDP B
) O
, O
anandamide B
, O
N B
- I
acetylglucosaminylam I
and O
a O
down O
- O
regulation O
of O
stearoyl B
- I
L I
- I
carnitine I
in O
Tg O
- O
2D6 O
mice O
compared O
with O
WT O
mice O
. O

Metabolomics O
of O
brain O
homogenate O
and O
cerebrospinal O
fluid O
revealed O
a O
significant O
up O
- O
regulation O
of O
L B
- I
carnitine I
, O
acetyl B
- I
L I
- I
carnitine I
, O
pantothenic B
acid I
, O
2 B
' I
- I
deoxycytidine I
diphosphate I
( O
dCDP B
) O
, O
anandamide B
, O
N B
- I
acetylglucosaminylam I
and O
a O
down O
- O
regulation O
of O
stearoyl B
- I
L I
- I
carnitine I
in O
Tg O
- O
2D6 O
mice O
compared O
with O
WT O
mice O
. O

We O
apply O
highly O
porous O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
microparticles O
and O
functionalize O
them O
introducing O
both O
sugar B
ligands O
for O
specific O
bacteria O
targeting O
and O
cationic O
moieties O
for O
electrostatic O
loading O
of O
superparamagnetic O
iron B
oxide I
nanoparticles O
. O

These O
react O
with O
additional O
R3SiX B
to O
generate O
Ar B
' I
BiX2 I
complexes O
and O
R3SiOC6H3tBu2 B
- I
2 I
, I
6 I
. O

Replacing O
the O
piperidine B
ring O
by O
a O
N B
- I
di I
- I
isobutyl I
residue O
( O
SCT B
- I
66 I
) O
prevents O
interactions O
with O
TRPV1 O
and O
simultaneously O
increases O
the O
potency O
and O
efficiency O
of O
GABAA O
receptor O
modulation O
. O

Compounds O
were O
evaluated O
using O
both O
two O
electrode O
voltage O
clamp O
recordings O
from O
Xenopus O
laevis O
oocytes O
and O
imaging O
of O
mammalian O
BHK O
cells O
loaded O
with O
Ca B
( I
2 I
+ I
) I
- O
sensitive O
dyes O
. O

The O
antiproliferative O
factor O
( O
APF O
) O
involved O
in O
interstitial O
cystitis O
is O
a O
glycosylated O
nonapeptide B
( O
TVPAAVVVA O
) O
containing O
a O
sialylated O
core O
alpha B
- I
O I
- I
disaccharide I
linked O
to O
the O
N B
- O
terminal O
threonine B
. O

This O
study O
evaluated O
the O
in O
vitro O
cytotoxicity O
of O
poly B
( I
propylene I
fumarate I
) I
( O
PPF B
) O
. O

Milk O
- O
Derived O
Peptides O
, O
Val B
- I
Pro I
- I
Pro I
and O
Ile B
- I
Pro I
- I
Pro I
, O
Attenuate O
Atherosclerosis O
Development O
in O
Apolipoprotein O
E O
- O
Deficient O
Mice O
: O
A O
Preliminary O
Study O
. O

Milk O
- O
Derived O
Peptides O
, O
Val B
- I
Pro I
- I
Pro I
and O
Ile B
- I
Pro I
- I
Pro I
, O
Attenuate O
Atherosclerosis O
Development O
in O
Apolipoprotein O
E O
- O
Deficient O
Mice O
: O
A O
Preliminary O
Study O
. O

Abstract O
Milk O
- O
derived O
peptides O
, O
Val B
- I
Pro I
- I
Pro I
( O
VPP O
) O
and O
Ile B
- I
Pro I
- I
Pro I
( O
IPP O
) O
, O
have O
angiotensin O
I O
- O
converting O
enzyme O
inhibitory O
activities O
and O
blood O
pressure O
- O
lowering O
effects O
. O

Abstract O
Milk O
- O
derived O
peptides O
, O
Val B
- I
Pro I
- I
Pro I
( O
VPP O
) O
and O
Ile B
- I
Pro I
- I
Pro I
( O
IPP O
) O
, O
have O
angiotensin O
I O
- O
converting O
enzyme O
inhibitory O
activities O
and O
blood O
pressure O
- O
lowering O
effects O
. O

Among O
the O
formulations O
investigated O
, O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
- O
poly B
( I
ethylene I
glycol I
) I
- O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
triblock O
copolymer O
systems O
provided O
the O
longest O
sustained O
drug O
delivery O
, O
probably O
due O
to O
their O
rigid O
gel O
structures O
and O
/ O
or O
polymer O
- O
to O
- O
cidofovir B
interactions O
. O

Aminoalkenes B
are O
catalytically O
cyclized O
in O
the O
presence O
of O
cyclopentadienylbis B
( I
oxazolinyl I
) I
borato I
group O
4 O
complexes O
{ B
PhB I
( I
C5H4 I
) I
( I
Ox I
( I
R I
) I
) I
2 I
} I
M I
( I
NMe2 I
) I
2 I
( O
M O
= O
Ti B
, O
Zr B
, O
Hf B
; O
Ox B
( I
R I
) I
= O
4 B
, I
4 I
- I
dimethyl I
- I
2 I
- I
oxazoline I
, O
4S B
- I
isopropyl I
- I
5 I
, I
5 I
- I
dimethyl I
- I
2 I
- I
oxazoline I
, O
4S B
- I

Asymmetric O
hydroamination O
/ O
cyclization O
of O
N B
- I
deutero I
- I
aminoalkenes I
provides O
products O
with O
higher O
optical O
purities O
than O
obtained O
with O
N B
- I
proteo I
- I
aminoalkenes I
. O

Asymmetric O
hydroamination O
/ O
cyclization O
of O
N B
- I
deutero I
- I
aminoalkenes I
provides O
products O
with O
higher O
optical O
purities O
than O
obtained O
with O
N B
- I
proteo I
- I
aminoalkenes I
. O

The O
pharmacokinetics O
of O
the O
25 B
- I
OCH3 I
- I
PPD I
epimers O
and O
active O
metabolites O
in O
rat O
plasma O
after O
a O
single O
intravenous O
( O
i O
. O
v O
. O
) O
administration O
were O
studied O
by O
a O
rapid O
, O
selective O
and O
sensitive O
UPLC O
- O
MS O
/ O
MS O
method O
. O

These O
concepts O
are O
then O
used O
to O
analyze O
the O
electronic O
structure O
changes O
occurring O
in O
the O
reaction O
of O
C B
- I
H I
bond O
oxidation O
by O
Fe B
( I
IV I
) I
oxo I
species O
. O

The O
analysis O
reveals O
that O
the O
energy O
separation O
and O
the O
overlap O
between O
the O
electron O
donating O
orbitals O
and O
electron O
accepting O
orbitals O
of O
the O
Fe B
( I
IV I
) I
oxo I
complexes O
dictate O
the O
reaction O
stereochemistry O
, O
and O
that O
the O
manner O
in O
which O
the O
exchange O
interaction O
changes O
depends O
on O
the O
identity O
of O
these O
orbitals O
. O

The O
electronic O
reorganization O
of O
the O
Fe B
( I
IV I
) I
oxo I
species O
during O
the O
reaction O
is O
thoroughly O
analyzed O
and O
it O
is O
shown O
that O
the O
Fe B
( I
IV I
) I
oxo I
reactant O
develops O
oxyl B
radical O
character O
, O
which O
interacts O
effectively O
with O
the O
sigma O
CH B
orbital O
of O
the O
alkane B
. O

The O
electronic O
reorganization O
of O
the O
Fe B
( I
IV I
) I
oxo I
species O
during O
the O
reaction O
is O
thoroughly O
analyzed O
and O
it O
is O
shown O
that O
the O
Fe B
( I
IV I
) I
oxo I
reactant O
develops O
oxyl B
radical O
character O
, O
which O
interacts O
effectively O
with O
the O
sigma O
CH B
orbital O
of O
the O
alkane B
. O

The O
aim O
of O
the O
present O
study O
was O
to O
develop O
a O
( B
68 I
) I
Ga I
labeled I
bis I
- I
DOTA I
derivative O
of O
benzylidene B
- I
bis I
- I
indole I
and O
compare O
the O
in O
vivo O
stability O
and O
biodistribution O
with O
that O
of O
the O
previously O
reported O
bis B
- I
DTPA I
derivate O
for O
in O
vivo O
imaging O
of O
necrosis O
using O
PET O
. O

This O
work O
describes O
a O
technique O
for O
forming O
high O
- O
density O
arrays O
and O
patterns O
of O
membrane O
- O
bound O
proteins O
through O
binding O
to O
a O
curvature O
- O
organized O
compositional O
pattern O
of O
metal O
- O
chelating O
lipids O
( O
Cu B
( I
2 I
+ I
) I
- O
DOIDA O
or O
Cu B
( I
2 I
+ I
) I
- O
DSIDA O
) O
. O

This O
work O
describes O
a O
technique O
for O
forming O
high O
- O
density O
arrays O
and O
patterns O
of O
membrane O
- O
bound O
proteins O
through O
binding O
to O
a O
curvature O
- O
organized O
compositional O
pattern O
of O
metal O
- O
chelating O
lipids O
( O
Cu B
( I
2 I
+ I
) I
- O
DOIDA O
or O
Cu B
( I
2 I
+ I
) I
- O
DSIDA O
) O
. O

This O
curvature O
pattern O
sorts O
Cu B
( I
2 I
+ I
) I
- O
DOIDA O
to O
the O
200 O
nm O
hemispherical O
lattice O
sites O
of O
a O
600 O
nm O
X O
600 O
nm O
unit O
cell O
in O
Ld O
- O
Lo O
phase O
separated O
lipid O
multibilayers O
. O

In O
comparison O
, O
the O
negative O
pixel O
pattern O
is O
created O
by O
sorting O
Cu B
( I
2 I
+ I
) I
- O
DSIDA O
in O
Ld O
- O
L O
beta O
' O
phase O
separated O
lipid O
multibilayers O
to O
the O
flat O
grid O
between O
the O
lattice O
sites O
followed O
by O
binding O
to O
His O
- O
GFP O
. O

Vibrational O
Perturbations O
of O
W B
( I
CO I
) I
6 I
Trapped O
in O
a O
Molecular O
Lattice O
Probed O
by O
Linear O
and O
Non O
Linear O
Spectroscopy O
. O

W B
( I
CO I
) I
6 I
is O
found O
to O
be O
trapped O
in O
two O
main O
families O
of O
sites O
differing O
by O
their O
symmetries O
( O
called O
hereafter O
Oh O
and O
D2h O
) O
. O

In O
addition O
, O
pretreatment O
with O
Z B
- I
Val I
- I
Ala I
- I
Asp I
- I
fluoromethylketone I
( O
Z B
- I
VAD I
- I
fmk I
) O
, O
a O
broad O
spectrum O
of O
caspase O
inhibitor O
, O
could O
not O
rescue O
apoptotic O
cells O
from O
ClpP O
toxicity O
. O

In O
contrast O
, O
LXA4 B
from O
different O
sources O
neither O
increased O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
and O
extracellular O
- O
signal O
- O
regulated O
kinase O
( O
ERK O
) O
phosphorylation O
, O
nor O
did O
it O
induce O
a O
decrease O
in O
cAMP B
levels O
or O
a O
translocation O
of O
beta O
- O
arrestin O
. O

These O
compounds O
resulted O
from O
our O
efforts O
to O
merge O
the O
pharmacophores O
of O
selective O
factor O
Xa O
inhibitor O
rivaroxaban B
with O
a O
mimic O
of O
the O
Arg B
- I
Gly I
- I
Asp I
( O
RGD O
) O
sequence O
of O
fibrinogen O
to O
obtain O
designed O
multiple O
ligands O
with O
potential O
antithrombotic O
activity O
. O

